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Design and characterization of tissue engineered substitutes rely on robust 
monitoring techniques that provide information regarding viability and function when 
exposed to various environmental conditions. In vitro studies permit the direct monitoring 
of cellular and construct changes because these substitutes remain accessible.  However, 
upon in vivo implantation, changes in cell viability and function are often detected using 
indirect or invasive methods that make assessing temporal changes challenging.  Thus, 
the development of non-invasive monitoring modalities may facilitate improved tissue 
substitute design and, ultimately, clinical outcome.   
Nuclear magnetic resonance (NMR) spectroscopy and imaging are valuable tools 
to non-invasively monitor tissue substitutes in vitro and in vivo.  However, due to 
sensitivity issues, monitoring the physiologic status of cells in substitutes after 
implantation by NMR is challenging.  This limitation was overcome in this thesis by 
developing a method that non-invasively monitors the dissolved oxygen (DO) 
concentrations within tissue engineered constructs, since DO levels are known to effect 
cell viability and function.  In these studies, a pancreatic substitute that consisted of a 
mouse insulinoma cell line sequestered in an alginate bead was used to develop the 
methodology.  Specifically, the oxygenation within pancreatic substitutes was assessed 
via the incorporation of perfluorocarbon (PFC) emulsions into the construct; 19F NMR 
was then used to measure T1 relaxation rates, which inversely correlate to DO 
concentrations.  This technique was developed by designing and building an NMR-
compatible perfusion system capable of maintaining user-defined DO concentrations.  
 xiv
The completed system enabled the investigation of a pancreatic substitute composed of 
βTC-tet cells (a mouse insulinoma cell line) encapsulated into alginate beads . 
One of the first challenges addressed in this thesis was the acquisition of DO and 
cell density gradients within the alginate beads.  Although these profiles could be attained 
by using 19F NMR chemical shift imaging, the magnet used in this thesis did not have the 
necessary gradients to perform such imaging.  In addition, the long acquisition times 
associated with chemical shift imaging would be problematic upon moving to in vivo 
studies.  This caveat was addressed by the development of a mathematical model.  The 
model simulated changes in DO and cell density profiles based on Fickian diffusion 
equations, spatial limitations of alginate beads, oxygen consumption, and the growth and 
death characteristics of βTC-tet cells.  Based on the model, correlations between the 
experimentally measurable average intrabead DO (AIDO) concentration and the cell 
number, cell density profiles and DO concentration gradients were established. 
With these correlations established, the volume-averaged DO concentrations 
could be acquired by 19F NMR and used to monitor the pancreatic substitute.  The 
AIDO/mathematical model system was validated by exposing encapsulated βTC-tet cells 
to a range of DO concentrations (0.20 to 0.04 mM) within the NMR-compatible 
perfusion system.  During this validation, the metabolic and bioenergetic states of the 
cells were assessed by DO sensors bracketing the bioreactor and 31P NMR, respectively.  
In addition, AIDO measurements were acquired using 19F NMR and an established 
calibration curve.  Comparing the simulated and experimental data revealed that the 
AIDO/mathematical model system indeed could track the status of encapsulated cells, as 
long as the DO concentration immediately external to the beads is known.  Measuring the 
 xv
surrounding DO concentration is trivial in an in vitro setting, as DO sensors can be used, 
but this is not easily performed in vivo.  Therefore, a dual-PFC system was developed 
that enabled simultaneous DO concentration acquisition from two bead populations.  This 
capability was demonstrated using two populations of cell-free beads that were implanted 
into the peritoneal cavity of mice.  The first set of beads contained the PFC 
perfluorotributylamine (PFTBA), along with a coating of poly-l-lysine (PLL), an 
inflammatory response initiator.  The second set of beads had perfluoro-15-crown-5-ether 
(PFCE) sequestered in alginate-only beads.  The close proximity of the chemical shifts of 
these two PFCs allowed simultaneous T1 relaxation rate measurements, and thus 
simultaneous DO concentration measurements.  Due to the induced fibrotic response by 
the PLL in the PFTBA beads, a lower DO concentration was indeed measured by the 
PFTBA compared to that measured by PFCE.  These results provided validation that the 
dual-PFC system could be utilized in vivo. 
The ability to monitor a pancreatic substitute by the AIDO/mathematical model 
system was then investigated under two simulated in vivo conditions.  The first study was 
designed to mimic the changes in DO concentrations that often occur in vivo – either due 
to natural fluctuations at the site of implantation or an induced inflammatory response.  
During this study, AIDO measurements and the mathematical model were used in 
combination to estimate the cell density within alginate beads, while the external DO 
levels were changed.  In the second study, the ability to measure cell death during a 
mimicked cytokine attack was assessed.  Specifically, AIDO-estimated cell densities 
were acquired upon the addition of puromycin (an antibiotic that disrupts mRNA 
translation, thereby killing the cell).  During both of the above studies, AIDO-estimated 
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cell densities were compared to estimates based on overall oxygen consumption rate 
measurements.  It was concluded that the AIDO measurement was indeed capable of 
tracking a pancreatic substitute and could possibly aide in distinguishing between various 
modes of implant failure. 
In the final portion of this thesis, the effect of PFC emulsions on encapsulated 
cells was investigated both experimentally and through mathematical modeling.  In this 
experiment, βTC-tet cells were encapsulated in alginate beads that contained 0%, 5%, or 
10% v/v PFTBA emulsion, and cell viability and stimulated insulin secretion were 
measured over a 16 day period.  It was found that the presence of PFTBA had no effect 
on either cell viability or insulin secretion.  Indeed, simulations by the mathematical 
model did not show any effect on cell viability during the first 8 days and only a slight 
increase in viability thereafter when PFC emulsions were incorporated.  Lastly, the 
mathematical model was used to simulate the effect of PFCs on cell viability under 
additional environments.  Specifically, the ability of PFCs to buffer the DO concentration 
within alginate beads upon transient reductions in the DO levels external to the beads was 
studied.  It was found that PFCs are able to maintain higher AIDO concentrations within 
beads during short hypoxic episodes; however, these differences had only a small effect 
on the number of viable cells that could be sustained in the beads. 
In conclusion, this thesis has established the ability to track pancreatic substitutes 
using DO concentration measurements acquired from sequestered PFC emulsions and a 
mathematical model.  Future studies could expand this methodology to in vivo 








Insulin dependent diabetes comprises approximately 10% of the currently 18 
million cases of diabetes in the United States and current health care costs are estimated 
to be over $130 billion.  Despite being a treated disease, diabetics typically live 15 years 
less than the national average [1], primarily due to the long-term complications 
associated with the disease (e.g. retinopathy, neuropathy, nephropathy).  Fortunately, 
research has shown that the long-term complications can be mitigated when blood 
glucose levels are kept under tighter (more physiologic) regulation [2].  Minimizing 
blood glucose concentration excursions currently requires the use of multiple insulin 
injections or the use of insulin pumps, and do not entirely eliminate the complications.   
Promising new therapies, such as islet transplantation, provide better physiologic control 
of blood sugar and avoid the need for painful traditional bolus insulin injections or insulin 
pumps.  This procedure, which was discovered in 1973, has recently attracted more 
attention with the introduction of an improved implantation and immunesuppression 
regimen developed in 2000 [3].  However, the implantation of islets is greatly limited by 
the scarce supply and the immunosuppressant regimen needed to prevent rejection.  
Therefore, an alternative treatment that provides tight physiologic control and alleviates 
cell source issues would greatly benefit insulin-dependent diabetics. 
The engineering of living tissues, or tissue engineering, to secrete insulin is a 
promising alternative. Research in this field primarily focuses on creating biologically-
based tissue substitutes that repair, augment, or replace the function of diseased or 
malfunctioning tissue in the body [4].  One type of tissue substitute is created by 
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sequestering genetically modified cell lines – a continuous source of cells – that have the 
desired functional properties into a three-dimensional construct.  The construct matrix 
provides mechanical support, allowing cells to remain viable and functioning.  The 
encapsulation of insulin-secreting cells into a biocompatible material may become a 
viable treatment option for diabetics.  Despite significant progress, the especially 
complex nature of cell-based therapies and the considerable characterization needed prior 
to use have precluded the development of such a pancreatic substitute. 
Characterization, design and functional improvements of tissue substitutes are 
routinely accomplished through in vitro and in vivo testing.  In such testing, parameters 
that can affect viability and function of sequestered cells are meticulously evaluated and 
monitored to determine consequences.  Numerous tools are available to researchers for 
this in vitro characterization and assessment of constructs, as the substitute is readily 
available and duplicates for destructive assays can be made.  Nevertheless, upon 
transitioning to in vivo characterization, tools available for assessing the tissue substitute 
are limited.  Typically, researchers must rely on monitoring constructs indirectly – in the 
example of a pancreatic substitute, blood glucose levels could be monitored – or at the 
end of an animal study when the implant is extracted.  Such measurements are important 
in determining the functional quality of a substitute; however, discerning the mechanism 
for failure is difficult using such methods.  The dissolved oxygen (DO) concentration 
cannot currently be measured by direct or indirect methods, yet is known to have a direct 
impact on both cell viability and function [5-9].  This impact has been demonstrated in 
numerous cell lines [5, 8, 10-18], especially in pancreatic substitutes, as insulin secretion 
is compromised in low oxygen environments.  In addition, the effect of DO 
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concentrations on viability and function is not always proportional, as cellular function is 
often diminished at higher DO concentrations than those which would cause cellular 
apoptosis and death [8].  Thus, monitoring the DO concentration is equally as critical in 
evaluating a construct as determining the number of viable cells.   
The overall objective of this thesis was to establish a method to monitor and track 
cells and the cellular environment within a tissue engineered substitute in vitro and in 
vivo.  This was accomplished via 31P NMR spectroscopy and through the incorporation of 
perfluorocarbon (PFC) emulsions for the monitoring of DO concentration by 19F NMR 
spectroscopy.  The first aim of this thesis was to develop a method that tracked the state 
of cells and of the cellular environment within alginate constructs during perfusion 
studies in which the perfusing medium DO concentrations were changed over time or 
cells were exposed to a cytotoxic antibiotic.  Due to challenges in acquiring DO 
concentration gradient information within beads, a second aim was to develop a 
mathematical model that would calculate gradients from experimentally acquired volume 
averaged DO concentrations; thus, significantly enhancing the robustness of tracking the 
alginate beads.  Lastly, since the PFC emulsions used in the study may affect cell 
viability and function, a third aim was to characterize, experimentally and via modeling, 
the effect of several PFC emulsion concentrations on the encapsulated βTC-tet cells.  The 
thesis chapters are organized by the order in which they were published (CHAPTERS 3 
and 4) and by the order in which they were performed (CHAPTERS 5 and 6). 
Previous studies have shown that the DO concentration can be monitored using 
19F NMR when PFC emulsions are employed.  Specifically, the inverse of the T1 
relaxation time of specific perfluorinated chemical groups directly correlate with the DO 
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concentration surrounding the emulsion [19, 20].  Given that 19F is the second most 
sensitive nucleus after 1H and that there is no significant amount of 19F normally present 
in tissues, 19F NMR spectroscopy is particularly suitable for monitoring constructs in 
NMR-compatible bioreactors and in vivo.  Additional background material is provided in 
CHAPTER 2 of this thesis. 
An encapsulated cell system was utilized to establish the methodology described 
in this thesis.  The pancreatic substitute consisted of βTC-tet cells (a mouse insulinoma 
cell line) encapsulated into alginate beads.  Despite extensive characterization by our 
group, this substitute presented many challenges within this thesis, as the use of 
continuous cell lines causes substantial remodeling within the construct [21, 22].  This 
redistribution of cells creates a continuously changing DO concentration profile and 
would therefore require one, two, or three dimensional chemical shift imaging of the 
construct, to reconstruct such profiles.  However, if intra-construct oxygen profiles are to 
be acquired using 19F chemical shift imaging, long acquisition times would be required, 
which are a caveat to in vivo applications due to the lengthy anesthesia times required of 
experimental animals.  In contrast, collecting signal from the entire tissue construct is a 
more rapid process; thus, a quantitative mathematical model was created that describes 
the cellular remodeling and changes in DO concentration profiles when proliferative cells 
are encapsulated in hydrogel beads (CHAPTER 3).  The model uses parameters based on 
a permissive material, which does not directly influence cell growth and in which 
remodeling of the cell distribution occurs only from interplay between DO concentrations 
and spatial constraints.  Simulated changes of the oxygen and cellular profiles with time 
are first presented and the latter is compared with previously obtained experimental 
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results, offering a preliminary validation.  The model was then used in a reverse fashion 
to decipher cell and oxygen distributions from measurements of the average intrabead 
DO concentration – the same measurement that would be acquired by 19F NMR averaged 
over a pancreatic substitute. 
The use of a mathematical model and 19F NMR to monitor alginate encapsulated 
cells first required the development of several technologies.  The system required: (1) the 
design and construction of an in vitro perfusion circuit and bioreactor, (2) the selection of 
a suitable PFC that could be made into an emulsion, and (3) the generation of a 
calibration curve relating the inverse T1 relaxations of the PFC emulsion to the DO 
concentration.   
In brief, the computer controlled NMR-compatible perfusion bioreactor and 
circuit was designed and built (fully described in section 4.3.2 of the thesis and illustrated 
in Figure 4.1) according to the following criteria: (1) the system had to fit on a cart so 
that it could be brought in and out of an NMR room, i.e. maximum portability; (2) 
constant temperature (37°C) had to be sustained for the media entering the bioreactor; (3) 
media oxygenation had to remain constant going into the bioreactor and be capable of 
being changed at will by the operator to desired concentrations; (4) the system had to be 
capable of sustaining nutrient concentrations; (5) the system had to be capable of 
delivering alternative test media to the bioreactor when desired, and (6) the system had to 
remain aseptic.   
Several PFC emulsions have been reported in the literature for use as an oxygen 
sensor [19, 20, 23-29].  In this thesis, the PFC perfluorotributylamine (PFTBA), was 
chosen since it is reportedly non-toxic [30, 31] and the T1 relaxation is highly sensitive to 
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changes in surrounding DO concentrations [20].  Using the NMR-compatible perfusion 
system, a calibration curve was created for alginate encapsulated PFTBA emulsion 
(CHAPTER 4), allowing the assessment of DO concentrations within pancreatic 
substitutes.  APPENDIX I of the thesis provides additional characterization studies of the 
PFTBA emulsion – e.g., distribution within alginate beads, leak from the beads, effect on 
βTC-tet cells at low concentrations, and the rate at which T1 relaxations change in 
response to changes in DO concentrations. 
 With the capacity to assess intrabead DO concentrations, we next investigated the 
ability to track a pancreatic substitute by combining experimental measurements with 
mathematical modeling of the construct.  Encapsulated βTC-tet cells were propagated in 
the above described NMR-compatible perfusion bioreactor and subjected to DO 
concentration step changes over the course of 50 hours.  The overall cellular metabolic 
activity was monitored by the oxygen consumption rate (OCR) of the culture and by the 
level of intracellular nucleotide triphosphates (NTP), measured by 31P NMR 
spectroscopy.  The cellular oxygenation state was monitored by measuring the average 
intrabead DO concentration (AIDO) as a function of time by 19F NMR.  To test the 
validity of the model, the mathematical model was then used to predict the viable cell 
number and cellular oxygenation state when subjected to the same external DO 
concentrations measured experimentally.  In the mathematical calculations, the model 
inputs were the intrinsic parameters for βTC-tet cells in alginate beads (CHAPTER 3) 
and the measured external DO concentration during the experiment.  The model output 
was the time-dependent cell and DO distributions, from which the total viable cell 
number and a volume-average intrabead DO were calculated and compared against 
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experimental results.  It was found that the mechanistic model of the encapsulated system 
was in general agreement with the experimentally acquired data, thus providing model 
validation.   
 Upon the implantation of tissue substitutes, such as the artificial pancreas 
described above, two types of immune reactions may compromise the function and 
viability of the implant due to biocompatibility issues.  A non-specific host response can 
cause a dense fibrotic layer to form around the construct, severely limiting the transport 
of oxygen to the cells and, as mentioned previously, causing malfunction or death of the 
implant.  In the second type of response, cytokines are released at the site of implantation, 
causing cell death within the substitute. To determine the utility of the mathematical 
model/19F NMR system in distinguishing between these in vivo scenarios, these two 
conditions were mimicked in vitro (CHAPTER 5).  First, the ability of the mathematical 
model and 19F NMR to track cell growth in alginate beads that were cultured for one 
week prior to being placed in the NMR-compatible perfusion system and then subjected 
to DO concentration step changes is evaluated.  This initial study is designed to 
reproduce monitoring that may occur during in vivo experiments, where parameters 
influencing cell function and viability are not continuously monitored and the DO 
concentration can vary widely from day to day.  The second study monitors cell death as 
would occur via a cytotoxic immune response.  Specifically, the AIDO and medium DO 
concentration are used to assess the cell density within alginate beads after the addition of 
puromycin, a toxic antibiotic. 
Since the goal of the system developed in this thesis is to monitor constructs in 
vivo, the ability to measure the DO concentrations in an animal model was demonstrated 
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in CHAPTER 4.  It should be noted that several investigators have demonstrated the 
ability to measure DO concentrations from PFC-loaded alginate beads in vivo [24, 32].  
However, the mathematical model developed in this thesis requires a measurement of 
both the AIDO and the external DO concentrations; therefore, in CHAPTER 4, a novel 
dual PFC system is used to simultaneously monitor the DO concentrations in two distinct 
bead populations implanted in the peritoneal cavity of mice.  Specifically, the method 
involved placing PFTBA and a second PFC emulsion, perfluoro-15-crown-5-ether 
(PFCE), whose chemical shifts are only separated by 9 ppm, into two types of beads, 
allowing for simultaneous T1 relaxation measurements.  The beads containing the PFTBA 
emulsion were coated with PLL, while no additional coating was placed on beads 
containing PFCE.  The beads coated with PLL elicited a strong inflammatory response, 
thus causing a statistically lower DO concentration measurement within these beads. 
Lastly, the use of PFC emulsions in tissue engineered constructs and the culturing 
of cells has gained considerable interest among researchers recently [33-42].  As 
mentioned above, the DO concentrations within tissue engineered constructs, combined 
with the inherently low solubility of oxygen in water, often limit the number of cells that 
can be supported within a substitute.  Hence, any method that can enhance the solubility 
of oxygen or increase its effective diffusivity into a construct is desirable.  PFC 
emulsions accomplish both of these objectives, as the solubility of oxygen is 15-20 fold 
higher in PFC emulsions than water [35] and the effective diffusivity is also increased by 
their presence [38].  However, since these emulsions are in constant equilibrium with the 
surrounding aqueous phase, which is determined by the partition coefficient, it would 
seem that the benefit is only transient and that, at steady-state, the only benefit would be 
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due to the increased diffusivity of oxygen.  To explore this issue in greater detail, the 
mathematical model developed in CHAPTER 3 was augmented to account for the 
presence of PFC emulsion (CHAPTER 6).  The model was first used to simulate the 
proliferation of βTC-tet cells encapsulated in alginate under incubator-type conditions 
with and without PFC emulsion.  To provide validation, these simulations were compared 
to experimentally acquired data of the same system.  Finally, the model was used to 
simulate the effect of having the PFC emulsion under changing DO concentrations, as is 
often observed upon implantation of constructs and due to naturally occurring 
fluctuations [24, 43]. 
Utilization of the combined mathematical model and 19F NMR system to monitor 
the DO concentration within a pancreatic substitute and to assess cell viability and 
function are discussed further in CHAPTER 7.  Direction for future research based on 
this method is also given.   
Finally, I had the opportunity to participate in the two year NSF-sponsored 
IGERT Technological Innovation Generating Economic Results (TI:GER) program that 
spanned across Georgia Institute of Technology and Emory University.  The program 
brought together Ph.D. candidates and M.B.A. students from Georgia Tech with two J.D. 
students from Emory University to learn about commercializing research.  During the 
two years, my team developed a commercialization and business plan around a 
technology aimed at assessing the quality of islets destined for implantation.  In 
APPENDIX II, the executive summary from the business plan is given, as well as a 








2.1  Diabetes 
Diabetes is now one of the fastest growing diseases and leading cause of both 
morbidity and mortality worldwide.  In the United States alone, 18 million people are 
afflicted with either Type 1 or Type 2 diabetes.  The disease is characterized by the 
inability to maintain normal blood glucose levels, which causes major secondary health 
complications.  Type 1 diabetes, which accounts for approximately two million of those 
affected, is an autoimmune disease that has been growing at a rate of 7.2% each year (i.e. 
130,000 new cases per year).  In this disease, the immune system attacks and kills all the 
insulin-producing β cells within the pancreas and without the ability to produce insulin, 
blood glucose levels cannot be sustained in the physiological range.  Such an inability to 
regulate blood glucose levels causes major complications, and even death [44].  
Currently, there is no cure for diabetes, only various treatment options.   
 
2.2  Current and Future Therapies 
The most common treatments for Type 1 diabetes are multiple daily injections of 
insulin and insulin pumps.  Monitoring blood glucose levels combined with daily insulin 
injections provides patients with a near normal life.  Still, bolus insulin injections fail to 
provide the minute-to-minute maintenance of normoglycemia that a pancreas or 
pancreatic substitute provides and long-term complications therefore arise.  Some of 
these complications of include: nephropathy, retinopathy, problems with circulation, and 
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neuropathy.  A study performed in the early 1990s showed that most of these 
complications are mitigated with tighter glucose control [2].  Thus, researchers have 
focused efforts on developing cell-based pancreatic substitutes capable of providing more 
physiologic control.  One such procedure, the implantation of naked islets – cell clusters 
in the pancreas that produce insulin and control blood sugar – has shown promising 
results as a pancreatic substitute.  However, several major limitations of implanting naked 
islets or whole pancreases currently exist, such as the need for chronic 
immunosuppressive drug therapy and islet donor availability (islets must be harvested 
from cadavers [45]).  Therefore, such therapies are usually reserved for patients that are 
incapable of controlling blood glucose with exogenous insulin and have end-stage renal 
disease.  Issues of donor availability could be minimized by the use of xenogeneic islets, 
but the ability to keep the animals disease free is a daunting task with many 
complications.  
 
2.3  Tissue Engineered Pancreatic Substitutes 
An alternative to islet or whole pancreas transplantation is the use of a tissue 
engineered pancreatic substitute.  The field of tissue engineering is devoted to designing 
and creating biological substitutes that replace or repair a function in the body.  In the 
realm of diabetes, this translates to the engineering of a pancreatic substitute, which 
typically consists of insulin secreting cells encapsulated in a biomaterial.  The use of 
biocompatible materials for cell encapsulation circumvents the need for heavy 
immunosuppressive drugs by acting as a barrier, giving the sequestered cells partial 
immunoprotection.  Since vital cell nutrients like glucose and oxygen, as well as insulin 
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are much smaller molecules than most immune response elements, the biomaterial does 
not impose a permeability barrier to these molecules, thus allowing the encapsulated cells 
to sense the surrounding glucose levels and respond with insulin secretion accordingly 
[46-48]. 
Lim and Sun developed one of the most widely used encapsulation techniques in 
1980 [48], involving the encapsulation of cells in a three-layered biomaterial.  By 
dispensing droplets of the alginate-cell suspension into calcium chloride, the previously 
uncross-linked alginate solution gels.  This cross-linking of the alginate solution 
sequesters the cells in a spherical alginate bead.  To give the construct greater mechanical 
strength, and to establish a semi-permeable coating, a layer of poly-l-lysine is used to 
cover the alginate bead [49, 50].  A final layer of alginate is then formed around the bead 
to maintain biocompatibility. 
Alginate is a polymer found abundantly in nature and is composed of mannuronic 
acid and guluronic acid (Figure 2.1).  Through manipulation of the ratio of mannuronic 
acid to guluronic acid, the sequential order of the residues, and the molecular weight, the 
overall physical characteristics and properties of alginate gels can be changed.  For 
example, alginates containing larger amounts of mannuronic acid are softer, have faster 
degradation times, and are less porous when compared to alginate beads containing larger 
amounts of guluronic acid residues [46, 47, 51]. The effects of alginate composition have 
also been linked to growth characteristics of encapsulated cells, as well as the overall 
metabolic and secretory attributes of the cells.  These studies demonstrated that high 
guluronic acid content transiently hinders metabolic and secretory activity of βTC3 cells, 
a mouse insulinoma cell line, due to growth inhibition.  Conversely, a larger amount of 
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mannuronic acid allows an increase in the overall metabolic and secretory activity 
because of rapid cellular growth within the construct [51].  Given the ability of cells to 
grow uninhibited within the high-mannuronic acid alginates, these alginates are often 




























2.4  Insulin-secreting Cells 
There have been several cell sources studied for their use as pancreatic 
substitutes.  In general, sources included harvested islet cells of Langerhans, 
differentiated stem/progenitor cells, transformed β cells, and genetically engineered non-
β cells, each of which has their own advantages and disadvantages.  Despite a much more 
physiologic insulin release profile from harvested islet cells, islets have several caveats 
that impede their use as pancreatic substitutes.  For example, islets cannot be expanded in 
tissue culture and when one considers that allogeneic islets only account for 1-2% of a 
pancreas and that two or more cadavers are needed for one transplant, the scale-up to 
widespread clinical use of islets as pancreatic substitutes seems impracticable.  Attractive 
renewable sources of insulin secreting cells are differentiated embryonic or adult stem 
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cells.  The differentiation of both human and mouse embryonic and adult stem cells into 
β-like cells has been demonstrated [52-54].  However, several significant challenges 
currently impede the use of stem cells, including: low insulin content of differentiated 
adult cells, the chance of growing a teratoma upon in vivo implantation, as well as ethical 
issues involved with embryonic stem cells, to name a few. Transformed β cells alleviate 
the issue of cell source availability since such cells can be expanded in cell culture.  
However, the disadvantage of transformed β cells is that many have sub-optimal insulin 
secretion characteristics, i.e. the cells are hypersensitive to glucose and continuously 
secrete insulin when glucose is in the normal physiologic range [55].  This increased 
sensitivity of the transformed β cells to surrounding glucose may lead to hypoglycemia, a 
serious condition that can lead to coma or death.  Genetically engineered cells that have 
transcriptionally controlled insulin release are often significantly slower at releasing 
insulin than islets [56-58].  Thus, a thorough characterization of any β cell line is needed 
before the cell line is used clinically. 
 The development of continuous β cell lines has been led by the laboratory of Dr. 
Shimon Efrat [55, 59-61].  A library of these β cells was created by expressing the simian 
virus 40 tumor antigen gene under the control of the insulin promoter in transgenic mice 
[60].  One of the early β tumor cell (βTC) lines, βTC3, has been well characterized in 
terms of bioenergetics and the metabolic and secretory properties both in monolayer and 
in calcium alginate-polylysine-alginate (APA) beads by our group [16, 62-66].  The 
reduced oxygen requirements needed to maintain βTC cell function is an additional 
benefit. However, due to the hypersensitivity of these cells to glucose, βTC3s would not 
be suitable for an implanted pancreatic substitute, as hypoglycemic events would occur.  
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A more recent cell line that has emerged from Dr. Efrat’s laboratory is βTC-tet cells [67].  
βTC-tet cells are closely related to βTC3 cells, but exhibit a growth control mechanism.  
Specifically, the growth of these cells is controlled by a well-known tetracycline operon 
system.  In this system, βTC-tet cell proliferation is halted by exposure to tetracycline; 
when the tetracycline is removed, the cells regain their ability to divide.  The insulin 
secretion characteristics of βTC-tet cells have been reported to be closer to those of islets, 
making them an appealing cell source [61, 68].   Additionally, βTC-tet cells encapsulated 
in alginate were shown to restore normoglycemia in non-obese diabetic mice for up to 8 
weeks without inducing an inflammatory response [69]. Given the scale-up capability of 
continuous cell lines, these cells have become an attractive alternative to islet 
transplantation.  However, as mentioned above, there are some key attributes of these cell 
systems that must be fully understood if they are to be of therapeutic use. 
 
2.5  Perfluorocarbons (PFCs) 
 Due to their ability to dissolve large amounts of gases and their general chemical 
and biologic inertness, perfluorinated carbons have been used in a variety of medical 
applications, as well as tissue engineering.  These hydrophobic organic compounds 
gained the interest of the medical community in 1966 when Clark and Gollan 
demonstrated that a mouse submerged in such a PFC liquid could sustain life [70].  Since 
then, PFCs have been combined with emulsifying agents and investigated for use as 
blood substitutes, oxygen reservoirs, and as a tool for monitoring oxygen concentrations 
non-invasively by 19F nuclear magnetic resonance (NMR) [36, 37, 41, 71, 72].  However, 
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prior to use in any medical application, careful consideration must be given to the type of 
PFC, the emulsifying agent, stability, droplet size, and aseptic preparation. 
A number of types of PFC molecules have been characterized as blood substitutes 
and as NMR imaging agents, since the early 1980s [23, 28, 29, 71, 73-81].  Fluosol-DA 
(combination of perfluorodecalin and perfluorotripropylamine), perfluorooctylbromide 
(PFOB), perfluoro-15-crown-5-ether (PFCE), perfluorotributylamine (PFTBA), and 
perfluorohexane (PFH) are just a few that have been reported in the literature.  Of these, 
PFTBA and PFCE were chosen for use in this thesis.  PFTBA has been used as an 
oxygen carrier with no reports of adverse effects in cells [31]. Additionally, the relatively 
high sensitivity of PFTBA to oxygen (discussed in section 2.5.2) [20] made it a clear 
choice.  In this thesis, PFCE is used as a second PFC in the development of a dual-PFC 
system, enabling monitoring of oxygen concentrations within two constructs 
simultaneously.  PFCE was chosen primarily because its chemical shift is close to that of 
PFTBA (enabling simultaneous T1 relaxation measurements) and secondly, because it has 
a high signal-to-noise ratio (the 20 fluorine atoms of PFCE all resonate at a single 
frequency [74]). 
As mentioned previously, PFCs must be emulsified due to the hydrophobic nature 
of the molecules.  During emulsification, an amphiphilic molecule is used at the interface 
between the PFC phase and the surrounding aqueous phase, which is diagramed in Figure 
2.2.  An emulsion droplet size of approximately 0.2 µm is typically created by either 
sonication or high pressure homogenization.  In medical applications, the choice of an 
emulsifying agent (surfactant) is based on biocompatibility and stability.  Surfactants that 
have been commonly used in blood substitutes include Pluronic-68, egg yolk lecithin 
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(phosphotidylcholine), and triglycerides [75, 82].  In this thesis, egg yolk lecithin was 
chosen because it has been shown to create micelles that are very stable (little change in 
emulsion diameter over 80 days at 37°C) [83], and it does not cause immune complement 
activation [30, 31]. 
 
 
2.5.1  PFCs as Oxygen Reservoirs 
 PFC emulsions are known to have an oxygen solubility that is 15-20 fold higher 
than that of water [35].  An example of this capacity is shown in Table 2.1, where the 
solubilities of oxygen and carbon dioxide are given for PFTBA and PFOB, along with 
that of water.  Also, the amount of oxygen dissolved in the PFC is linearly related to the 
partial pressure of oxygen in the surrounding medium.  This inherent high solubility of 
oxygen in PFC emulsions has led several research groups to study the effect of 
incorporating these emulsions into medium – static and perfused – and sequestering the 





Figure 2.2  Diagram of a perfluorocarbon micelle. 
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PFC in organ preservation (specifically, pancreas preservation) was demonstrated as a 
component of the two-layer method by Kuroda et al. [85].  During this study, the 
pancreas was suspended between a layer of PFC and Euro-Collins’ solution, which was 
later replaced by University of Washington (UW) solution. The PFC-UW two-layer 
method (TLM) increased the preservation of canine pancreata from up to 24 hours to up 
to 96 hours [86].  Additionally, the use of PFCs has been shown to improve survival of 
pancreata after transplantation and to increase the yield of purified islets [37, 40].  Further 
characterization of the effect of PFCs on cultured islets indicated that despite having 
significant benefit in transportation, islet stimulated insulin secretion was compromised 
by the TLM [87].  However, Brandhorst et al. [88] determined that preserving islets by a 
one-layer method (PFC-only) had no detrimental effect on stimulated insulin secretion.  
Thus, it is essential that a full characterization of the effect of PFCs on the function of 
cells be performed prior to implementation in any tissue engineered device. 
 
 
Table 2.1   Solubility of oxygen and carbon dioxide in water and two PFCs 
at 1 atm and 37°C.  In parentheses, the fold increase in solubility above 
water is given.  
 
Liquid Oxygen Carbon Dioxide
Water 0.21 mM 5.44 mM
Perfluorotributylamine 
(PFTBA) 3.36 mM (16x) 11.7 mM (2.2x)
Perfluorooctylbromide 
(PFOB) 4.2 mM (20x) 17.7 mM (3.2x)
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In the context of tissue engineered substitutes, PFCs have been used to increase 
DO concentrations within constructs and in perfused bioreactors.  Specifically, Radisic et 
al. [38] demonstrated through experimentation and a mathematical model that adding the 
commercially available PFC emulsion, Oxygent, to medium perfusing a parallel plate 
cardiac bioreactor, increases the DO concentration throughout the bioreactor and 
consequently supports a greater density of cardiomyocytes.  In these studies, the oxygen 
partial pressure of the medium entering the bioreactor was kept constant at 160 Torr; 
hence, after releasing the oxygen within the bioreactor, PFCs were reloaded in the gas 
exchanger.  In a study by Khattak et al. [33], the presence of sequestered PFC emulsions 
in alginate capsules caused an enhanced proliferation of HepG2 cells compared to beads 
without PFC over two weeks.  Additionally, improved metabolic activity of the HepG2 
cells was demonstrated at the physiologically relevant DO concentration of 5% oxygen 
(0.04 mM).  Although these results are promising, the mechanism for such increased 
viability and metabolic activity remains unclear, as PFC sequestered within an 
encapsulated cell system are unable to be reoxygenated after equilibration with the 
surrounding aqueous phase.  However, if the surrounding DO concentration were cycled 
to higher levels (which did not occur in the studies by Khattak et al), the PFC emulsions 
would indeed be capable of being reoxygenated and therefore maintain a higher DO 
concentration within the encapsulated cell system. 
2.5.2  PFCs as Oxygen Monitors 
 PFC emulsions are ideal for non-invasively monitoring DO concentrations in vivo 
by 19F NMR since (1) the inverse T1 relaxation rates of the fluorines are linearly 
correlated to the surrounding DO concentration; (2) Fluorine is not found in natural 
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abundance in the body; and, (3) the 19F nucleus is the second most sensitive nucleus with 
a sensitivity 0.83 times that of 1H.   
The T1, or spin-lattice, relaxation rate is an NMR parameter that is defined by the 
time it takes nuclear spin to be restored to 63% of the original magnitude (M0) after being 
placed into disequilibrium by a radio-frequency pulse, see Figure 2.3.  This rate is 
directly influenced by the environment around the nuclei.  Thus, oxygen, a paramagnetic 
molecule, in the surrounding environment shortens the relaxation rate of 19F.  Figure 2.4 
shows one of the early calibration curves for a PFC emulsion (Fluosol-DA) which was 
















Figure 2.4  Calibration curve relating the R1 (1/T1) of Fluosol-DA to the surrounding 












Figure 2.3  An illustrative representation of a T1 relaxation, where MZ is the direction 
of the applied magnetic field along the z-axis and M0 is the net macroscopic 
magnetization of nuclear spins. 
 22
19F NMR has been used extensively in the evaluation of tumor oxygenation [25, 
89-93], since knowing the oxygen tension within tumors is an important parameter during 
radiotherapy treatments [94, 95].  In these experiments, investigators inject a PFC 
emulsion intravascularly, which subsequently circulates into perfused regions of tumors.  
19F NMR imaging of the tumor is then performed, thus quantifying the mean oxygen 
tensions at various locations within the tumor.  More recently, the use of PFCs as 
molecular imaging agents has been explored [96-100].  Specifically, the surfactant is 
functionalized for molecular imaging by the addition of homing ligands, such as those 
used in a study by Lanza et al. [99].  Since then, paramagnetic chelates, such as 
gadolinium, have also been attached to the PFC emulsions, creating enhanced NMR 
imaging contrast [96]. 
The immobilization of PFCs into alginate beads to measure oxygen tensions at 
various locations within the human body has also been demonstrated [24, 32].  In the 
study by Noth et al. [24], perfluorobutyl-ethylene (F-44E) was encapsulated into cell-free 
barium alginate capsules at a concentration of 50% v/v.  The capsules were then 
implanted into the peritoneal cavity, the musculus quadriceps femoris, and beneath the 
kidney capsule of rats.  The DO concentrations at these sites were capable of being 
quantified by 19F NMR for over three months.  It should be noted that the peritoneal 
cavity and the kidney capsule were found to have the lowest oxygen concentrations.  In 
addition, the greatest variability and range were observed in the peritoneal cavity (14±9% 
air saturation).  This study by Noth et al. was significant as it demonstrated the range of 
DO concentrations that an implanted tissue substitute may experience; however, 
knowledge of intra-construct sharp oxygen gradients that are created by cellular oxygen 
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consumption are also expected to have a significant impact in dictating the functionality 
of the encapsulated cells, in addition to the DO concentration surrounding such implants.   
Pilatus et al. [101] and McGovern et al. [102] demonstrated the utility of 19F 
NMR in measuring oxygen consumption rates of encapsulated cells.  Specifically, 
McGovern et al. [102] encapsulated a PFC emulsion into alginate gels that contained 
EMT6/Ro murine tumor cells and used DO concentration measurements to determine 
oxygen consumption rates of cells.  However, the technique was limited to a system in 
which cell distribution was homogeneous and thus was unable to account for the well 
documented cellular remodeling that typically occurs in such systems [103].  Conversely, 
Pilatus et al. [101] placed cell-free alginate beads containing a PFC emulsion at both the 
inlet and outlet of a bioreactor to acquire oxygen consumption rates of both breast and 
prostate cancer cells by 19F NMR.  However, such a technique is limited to quantifying 
oxygen consumption rates only in an in vitro system, where other methods exist to 
quantify such rates more accurately (e.g. fiber-optic DO sensors).  Thus, neither the 
technique by McGovern et al. or Pilatus et al. is capable of assessing the DO 
concentration experienced by implanted cells at various locales within constructs in vivo, 
which is of significance in the overall function of encapsulated cell systems.   
 
2.6  Alternative Methods for Monitoring Oxygen 
 As mentioned previously, the importance of oxygen availability to cellular growth 
and function has been demonstrated for many cell systems, including the sequestered 
cells in APA beads.  There are several techniques that can be used to monitor oxygen 
levels available to cells, some of which are given below. 
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2.6.1  Polarographic Probes 
 Polarographic probes have been used to monitor oxygen concentrations within 
cell culture systems in vitro and within tissues in vivo [8, 9, 16, 94, 95, 104, 105].  These 
sensors rely upon DO reacting with the silver cathode, resulting in an ion flux to the 
silver or lead anode and this ion flux (current) measured by the probe is proportional to 
the surrounding oxygen tension.  The reaction of DO with the silver cathode consumes 
small quantities of oxygen during the process; thus, DO gradients may develop at the tip 
of polarographic probes, which subsequently results in erroneous measurements.  The 
invasiveness of polarographic sensors and their need for frequent calibration are 
additional obstacles to their use in vivo.   
2.6.2  Fiber Optic Probes 
 Similar to polarographic probes, these probes represent an invasive method of 
measuring dissolved oxygen.  The long-term stability of the probe calibration is an 
improvement over the polarographic probes.  Additionally, these probes do not consume 
oxygen, rather, they rely upon fluorescence quenching of a sequestered material at the tip 
of the probe.  A spectrometer at the base of the probe correlates the amount of quenching 
with the oxygen tension surrounding the probe using the Stern-Volmer equation [106], 
shown here: 
[ ]21 pOkI
I O ⋅+=  
Where, Io is the fluorescence intensity when no oxygen is present, I is the fluorescence 
intensity at a given oxygen tension, k is a constant inherent to the fluorescent material, 
and [pO2] is the surrounding oxygen tension. 
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2.6.3  Near-Infrared Spectroscopy (NIRS) 
 This non-invasive technique is currently used clinically to monitor dissolved 
oxygen.  The method relies on a molecule, such as hemoglobin or myoglobin, to absorb 
the light emitted into the tissue.  Despite being a non-invasive technique, the penetration 
depth of this method is at maximum 2-6 cm [107]; thus, for this method to be used in 
monitoring implanted pancreatic substitutes a probe placed inside the peritoneal cavity 
would be needed, making the technique invasive. 
2.6.4  17O NMR 
 17O NMR has recently been used to study oxygen concentrations within a human 
brain [108].  Despite the ability to measure oxygen non-invasively, this method suffers 
from a lack of sensitivity.  In addition, inhalation of gaseous 17O is required for the 
technique to work, as 17O is not found naturally in the body. 
2.6.5  Electron Paramagnetic Resonance 
 Electron paramagnetic resonance (EPR) is a relatively non-invasive method of 
measuring DO concentrations within tissues. For example, oxygenation within the brain 
and tumors has been demonstrated by this technique [109, 110].  However, it has two 
significant caveats: (1) it requires the injection of a paramagnetic oxygen-sensitive 
material, prior to being monitored; and, (2) significant heating of the material is a 
problem and therefore is restricted to small tissue sizes. 
 
2.7  Nuclear Magnetic Resonance 
In the realm of non-invasive monitoring, NMR is a potent tool that can track and 
image tissue engineered constructs in vivo and in vitro.  This is accomplished by aligning 
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nuclei that have a spin greater than zero with a powerful external magnetic field.  The 
alignment is then perturbed using an electromagnetic field pulse.  The resulting response 
of the nuclei to the external perturbation is the phenomenon that is exploited in NMR 
spectroscopy and imaging.  Specifically, after nuclei are perturbed – i.e. forced to a 
higher energy state – the nuclei will spin back to equilibrium, which creates radio 
frequency signals that can be detected by a receiver coil.  This spin back to equilibrium, 
known as relaxation, comes in two forms: T1 and T2.  Using this method, a wealth of 
information can be obtained about living systems.  Specifically, through monitoring of 
various nuclei, the intracellular metabolite fluxes (13C), the bioenergetics (31P), and viable 
cell number and distribution (1H) (to name a few) can all be ascertained. 
Due to the strong sensitivity of the 1H nuclei, 1H NMR has been used broadly in 
both imaging and spectroscopy.  Images are acquired by placing gradients within the bore 
of an NMR magnet.  1H NMR imaging has been used to study the structural integrity of 
tissue engineered constructs and more specifically, it has recently been used to acquire 
detailed information on alginate and agarose encapsulation systems [111, 112].  The 
NMR techniques used by Simpson et al. [111] demonstrated the ability to quantify the 
guluronic acid content, as well as several other characteristics of alginate beads.  
Additional studies using 1H NMR spectroscopy, have demonstrated the ability to 
accurately assess the viable cell number within agarose disk-shaped constructs, in vitro 
and in vivo [112, 113].  To accomplish this, localized, water-suppressed 1H spectroscopy 
of the total-choline peak – a peak comprised of choline-related metabolites – was directly 
correlated to the number of viable cells within a disk-shaped pancreatic substitute. 
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31P NMR spectroscopy has proven to be a robust tool in determining total 
concentrations of intracellular metabolites, specifically, nucleotide triphosphates, 
inorganic phosphates, and phosphoesters, to name a few.  These intracellular metabolites 
become increasingly important in the studies of insulin secreting cell lines since ATP and 
ADP are directly involved in the glucose-stimulated insulin secretion of these cells [114].  
Research from our laboratory has used 31P NMR spectroscopy to study the effects of 
nutrients, such as oxygen and glucose levels on alginate encapsulated βTC3 cells [9, 15, 
16].  In these studies, alginate beads were placed into an NMR-compatible perfusion 
system and monitored constantly for 38 days [9, 16].  The DO concentration entering the 
bioreactor was reduced to hypoxic levels at various points throughout the experiment for 
3-4 days.  It was found that decreasing the DO concentration in the surrounding medium 
drove encapsulated cells to a more anaerobic glycolytic metabolism, increased glucose 
consumption rates, and reduced the rates of oxygen consumption and insulin secretion.  
Upon re-oxygenation, all parameters returned to their prehypoxic levels.  Shorter term 
hypoxic studies (24 hr) revealed that a decrease in ATP and an increase in glucose 
consumption rate correlated positively to hypoxic environments, regardless of the amount 
of cellular remodeling that took place within the alginate beads [15].  However, glucose-
induced insulin secretion was suppressed by short-term hypoxia only after beads were 
perfused for 10 days.  This was attributed to changes in cell number and distribution 
within the pancreatic substitutes, which resulted in lower average oxygenation of cells 




MODELING OF ENCAPSULATED CELL SYSTEMS1 
 
3.1 Abstract 
 Tissue engineered substitutes consisting of cells in biocompatible materials 
undergo remodeling with time as a result of cell growth and death processes.  With inert 
matrices that do not directly influence cell growth, remodeling is driven mainly by the 
concentration of dissolved oxygen (DO).   Insulin-secreting cell lines encapsulated in 
alginate-based beads and used as a pancreatic substitute represent such a case.  Beads 
undergo remodeling with time so that an initially homogeneous distribution of cells is 
eventually replaced by a dense peripheral ring of primarily viable cells, whereas inner 
cells are mostly necrotic.  This paper develops and analyzes a mathematical model of an 
encapsulated cell system of spherical geometry that tracks the viable and dead cell 
densities and the concentration of DO within the construct as functions of radial position 
and time.  Model simulations are compared with experimental histology data on cell 
distribution.  Correlations are then developed between the average intrabead DO 
concentration (AIDO) and the total viable cell number, as well as between AIDO and the 
radial cell and DO distributions in beads.  As AIDO can be measured experimentally by 
incorporating a perfluorocarbon emulsion in the beads and acquiring 19F nuclear 
magnetic resonance (NMR) spectroscopic data, these correlations can be used to track the 
                                                 
 
 
1 Modification of a paper published in Journal of Theoretical Biology, 244(3): 500-510 (2006). 
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remodeling that occurs in the construct in vitro and potentially in vivo.  The usefulness of 
mathematical models in describing the dynamic changes that occur in tissue constructs 
with time, and the value of these models at obtaining additional information on the 
system when used interactively with experimental measurements, are discussed.  
 
3.2 Introduction 
 The engineering of living tissues, or tissue engineering, involves the use of living 
cells, manipulated through their extracellular environment or genetically, to develop 
biological substitutes for implantation into the body and/or to foster the remodeling of 
tissue in some other active manner [115].  Tissue substitutes often consist of cells in 
hydrogel materials, such as collagen, agarose, or calcium alginate, in appropriate three-
dimensional configurations that enable cell and construct function and permit handling of 
the substitute for in vitro manipulations and in vivo implantation.  Substitutes may 
undergo significant remodeling with time, especially when the cells can proliferate in the 
matrix environment.  Remodeling occurs as a result of cell growth and death processes 
and does not necessarily involve cell migration within the matrix [21, 22, 116].  The 
matrix itself may directly affect the cellular growth kinetics and the type of remodeling 
that occur, as is the case with proliferative βTC mouse insulinomas encapsulated in 
calcium alginate/ poly-L-lysine/ alginate (APA) beads made using high guluronic 
alginate [21, 116].  Although plausible explanations for the observed effects have been 
proposed, the precise mechanism remains unclear.   On the other hand, with permissive 
matrices which do not inhibit cell growth, there exists ample experimental evidence that 
cellular reorganization is driven by the concentration of available oxygen.  For example, 
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βTC insulinomas encapsulated and homogeneously distributed in APA beads made with 
permissive high manuronic alginate, form, after a period of 14-16 days, a dense 
peripheral ring of mainly viable cells, whereas inner cells are mostly necrotic [116].  This 
type of remodeling occurs because, as cells at the bead periphery - where oxygen is more 
abundant - grow, oxygen gradients across the bead radius become steeper, hence inner 
cells are exposed to increasingly hypoxic conditions and eventually die. 
 To directly monitor the dynamic changes that occur in tissue constructs with time, 
in vitro and post-implantation in vivo, our group has been developing methods based on 
nuclear magnetic resonance (NMR) imaging and spectroscopy.  While NMR imaging 
allows the assessment of structural features of the construct, localized NMR spectroscopy 
enables the evaluation of the number of viable cells and of the cellular metabolic state in 
a volume of interest (VOI) contained within the construct [113, 117-121].  For instance, 
the resonance of total cellular choline, measured by water-suppressed 1H NMR 
spectroscopy, correlates positively and linearly with the viable cell number, hence it is a 
reliable estimate of the latter [113, 121, 122].  The resonances of intracellular metabolites 
measured by 31P NMR, which include nucleotide triphosphates and phosphorylcholine, 
offer an assessment of the cellular bioenergetic status [119, 123].   
Due to the sensitivity of the 1H nucleus, 1H NMR spectroscopy can be performed 
both in vitro and in vivo.  On the other hand, 31P NMR spectra have, thus far, been 
obtained from tissue engineered constructs only in vitro [113, 118-121, 123].   To 
indirectly assess the cellular metabolic state, one could alternatively use measurements of 
dissolved oxygen (DO) concentration within the construct.  Indeed, DO is a critical 
parameter determining many aspects of cell function, including viability, metabolism and 
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protein secretion [5, 8, 9, 18, 124-126].  Given this importance of oxygen, our laboratory, 
as well as others [102, 127], are developing NMR–based methods to measure DO 
concentration in tissue constructs by incorporating a perfluorocarbon emulsion in the 
hydrogel.  Using the linear correlation between DO concentration and the inverse of the 
T1 relaxation of 19F [102, 127] the average oxygen concentration in a VOI can be 
measured.  It should be noted that 19F is the second most sensitive nucleus after 1H and 
there is no significant amount of 19F normally present in tissues, hence 19F NMR 
spectroscopy is particularly suitable for constructs in NMR-compatible bioreactors and in 
vivo situations. 
 As a construct remodels, the distributions of viable cells, cellular metabolic states, 
and DO change with time. To evaluate these distributions non-invasively, one could 
collect spectra from a series of VOIs within the construct using chemical shift imaging in 
one, two, or possibly three dimensions, as previously reported in one dimension in vitro 
with encapsulated cells [9, 16, 122, 123].  However, even if feasible, these are time-
consuming techniques with limited applicability especially in vivo due to cost and the 
long anesthesia times required for experimental animals.  Since collecting signal from the 
entire tissue construct is a more rapid process, a methodology that permits an evaluation 
of the cellular and oxygen distributions from concentration measurements averaged over 
the entire construct, or by measuring the overall metabolic activity of the construct, 
would thus be highly desirable. 
 In this paper, we present the development of a quantitative mathematical model 
describing the cellular remodeling and changes in DO profile when proliferative cells are 
encapsulated in hydrogel beads.  The model considers only a permissive material, which 
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does not directly influence cell growth and in which remodeling of the cell distribution 
occurs only in response to the available oxygen.  Model parameters were representative 
of mouse insulinoma βTC cells in permissive high manuronic calcium alginate beads.  
This encapsulated cell system constitutes a model pancreatic substitute appropriate for in 
vitro and small animal in vivo experiments [9, 16, 69, 116].  Model solutions on changes 
of the cellular and oxygen profiles with time are first presented and compared with 
experimental results.  Importantly, the model was also used in a reverse fashion, 
specifically to decipher cell and oxygen distributions – both critical in determining the 
functional ability of a construct – from measurements of the average oxygen 
concentration in the tissue substitute or of the total oxygen consumption rate by the 
construct.  The use of the model in synergy with experimental measurements to obtain 
spatial information on intra-construct gradients, and the significance of such information, 
are discussed. 
 
3.3 Mathematical Model and Assumptions 
A number of assumptions were incorporated in the development of the model and are 
listed below.  These assumptions were based on experimental data collected with βTC3 
mouse insulinoma cells encapsulated in calcium alginate and agarose matrices [113, 118-
121, 123].  Hence, the assumptions are realistic for this and likely other similar systems 
of proliferative cells in inert permissive hydrogels. 
1. DO is the only nutrient that limits cell proliferation.  Thus, all other essential 
nutrients are assumed to be in excess throughout the construct.   
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2. Spatial constraints are the only other factor besides DO concentration that limits 
the rate and extent of cell proliferation within the construct. 
3. Cells do not migrate within the matrix, hence the observed remodeling in cell 
distribution is due entirely to cellular growth and death at each locale.  This is 
supported by the fact that cells do not attach to alginate hydrogels without 
modification of the alginate by grafting adhesion molecules [128, 129]. 
4. The values of the model parameters, including the effective diffusivity of DO 
through the encapsulated system, remain constant over the time period of the 
simulations. 
5. There is no external boundary layer effect.  This is a reasonable assumption for 
systems in which there is significant velocity of the medium relative to the surface 
of the beads, as is the case in perfusion bioreactors where beads are retained in 
place while medium flows through the bed. 
The model equations for spherical geometry are as follows. 






















∂      (1) 
( )dg μμX(r,t) dt
dX(r,t)
−=         (2) 
In the above equations, t is time and r is radial position in the construct; C(r,t) and X(r,t) 
are the concentration of oxygen and the cell density, respectively, as functions of radial 
position and time; Deff is the effective oxygen diffusivity; S(r,t) is the rate of oxygen 
consumption per unit volume as a function of radial position and time; and μg and μd are 
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the specific cell growth and death rates, respectively.  Equations (1) and (2) need two 
initial and two boundary conditions to be solved, which are given below. 
ot CC ==0       (3) (the initial concentration of oxygen is constant throughout the 
spherical construct and known) 
ot XX ==0      (4) (the cells are initially distributed homogeneously throughout the 




C      (5) (symmetry condition for oxygen concentration at the center of the 
sphere) 
bRr CC ==       (6) (the concentration of oxygen at the surface of the construct is equal 
to the concentration in the surrounding medium, which is known) 
The expressions used for the kinetics of oxygen consumption by the cells, cell growth 








⋅=         (7) (Monod’s model with kinetic parameters 
νmax and Km) 
















= 1     (8)   (Monod’s model with kinetic parameters 









−−= minmaxmax   (9)  (modified Monod’s model maximizing the 
cell death rate at C=0 and minimizing it at 
C>>Kd) 
 
In the above equations, μg,max and μd,max are the maximum specific growth and death 
rates, respectively; μd,min is the minimum death rate, which prevails under an abundance 
of oxygen; Kg and Kd are Monod model parameters; and Xmax in the maximum cell 
density that can be accommodated in the construct.  The ratio X/Xmax is thus the fractional 
maximum occupancy at a particular locale in the construct. 
 The cumulative number of dead cells D(r,t) as a function of time and position can 
be obtained by integrating over time the specific death rate multiplied by the cell density, 
as in the following equation. 




,, μ         (10)       
 
3.3.1 Baseline Model Parameters 
 Baseline parameter values for the above mathematical model are representative of 
βTC3 mouse insulinoma cells encapsulated in calcium alginate beads and are listed in 
Table 3.1.  The continuous βTC3 cell line, a member of the βTC family of insulinomas 
established by Efrat and co-workers [60, 130, 131], has been extensively studied by our 
group and others both as such and following alginate encapsulation as a model tissue 
engineered pancreatic substitute [8, 9, 16, 116, 126].  
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Calculated based on a 10μm 
diameter cell
9x108 cells/mlXmaxMaximum Cell Density
Tziampazis et al. 
(unpublished)
0.001 mMKdMonod Parameter – Death
Tziampazis et al. 
(unpublished)
0.01 mMKgMonod Parameter – Growth
Tziampazis et al. 
(unpublished)
0.00273 day-1µd,minMinimum Specific Death Rate
(Graeber, Osmanian et al. 
1996)
1.4 day-1µd,maxMaximum Specific Death Rate
Monolayer growth rate, 
(Stabler, Wilks et al. 2001)
0.35 day-1µg,maxMaximum Specific Growth 
Rate
(Tziampazis and Sambanis 
1995)
0.01 mMKmMonod Parameter – O2





(Tziampazis and Sambanis 
1995), (Mehmetoglu, Ates 
et al. 1996), (Stabler 2004)
1.4 cm2/dayDeffEffective Diffusivity
ReferenceValueParameter
Table 3.1  Baseline parameter values used in simulating the spatio-temporal 
profiles of cells and oxygen in a system of βTC3 cells encapsulated in spherical 
calcium alginate/ poly-L-lysine/ alginate (APA) beads. 
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 The maximum oxygen consumption rate, νmax, and parameter Km were estimated 
from reported results for encapsulated βTC3 cells as 2 µmole/(min·109cells) and 0.01 
mM, respectively [125, 132, 133].  The maximum specific death rate μd,max was estimated 
using published rates of hypoxia-induced apoptosis.  Oncogenically transformed cells 
(with wild-type p53) exposed to low DO concentrations (<0.0001 mM) had an 
approximate 15% viability after 24 hours [6], which corresponds to a specific death rate 
of 1.9 day-1.  The p53 gene status of βTC3 cells is not known.  Thus, for the mathematical 
model presented here, a conservative maximum specific death rate of 1.4 day-1 was 
assumed.  The maximum specific growth rate was estimated from growth rates observed 
in T-flask experiments where death is negligible.  In particular, T-175 flasks seeded with 
βTC3 cells at a surface density corresponding to 35 cm2 became confluent (at 175 cm2) in 
five days, which results in a specific growth rate of 0.32 day-1.  Thus, a value of 0.35 day-
1 was used for a maximum growth rate.  This estimate is also compatible with data from 
freshly encapsulated cells [116], in which the glucose consumption rate (GCR) doubled 
over a period of 50 hours.  Although the per cell GCR depends on the DO concentration, 
encapsulated cells are all well oxygenated before remodeling occurs [116, 132], hence 
GCR is a measure of viable cell number under these conditions.  In the sensitivity 
analysis section of this paper, the effect of μg,max and μd,max on the steady state cell and 
DO profiles is investigated. 
To estimate the maximum cellular density, Xmax, which can be accommodated in 
the calcium alginate matrix, βTC3 cells were assumed to be 10 µm in diameter.  At this 
diameter, the maximum viable cell density with no void space is 1.9x109 cells/ml.  To 
account for space occupied by the matrix, for dead cells, and for voids revealed by 
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histology even after extensive cell growth [16, 21, 116], the baseline value of Xmax was 
set equal to 1/2 of the theoretical maximum, or 9x108 cells/ml.  A sensitivity analysis was 
also performed on the effect of changing Xmax from its baseline value in regards to the 
resulting cell and oxygen profiles. 
The effective diffusivity of oxygen Deff in cell-loaded alginate beads was 
estimated as follows.  Using the Wilke-Chang equation, the oxygen diffusivity in water at 
37ºC is calculated to be 1.8x10-3 cm2/min [132].  Oxygen diffusivity is lower in cell-free 
and, more so, cell-containing alginate beads [134].  In cell-free alginate beads, the 
oxygen diffusivity was found to be 1.53x10-3 cm2/min [135].  In cell-containing beads, 
reported values of the effective oxygen diffusivity range from 0.764x10-3 cm2/min to 
1.39x10-3 cm2/min [132, 135].  An intermediate value of 0.972x10-3 cm2/min, or 1.4 
cm2/day, was chosen for the simulations in this study.  It should be noted that, since Deff 
depends on cell density, it likely changes with time at a particular radial position in the 
beads as remodeling occurs.  In this initial study, however, a constant value of Deff – 
independent of time and position – was assumed; a sensitivity analysis was performed by 
changing Deff from its baseline value for all positions within the bead. 
3.3.2 Numerical Methods 
The steady state solution was calculated numerically using finite difference 
equations programmed in MatLab software.  Accuracy was verified by ensuring that the 
solution did not change by decreasing Δr. 
The transient model equations were also solved using finite difference equations 
programmed in MatLab.   Convergence of the calculations was ensured by keeping the Δt 
 39
component much smaller than Δr [136].  Specifically, for all simulations presented here 




t  [day/cm2] 
The accuracy of the simulations was then verified by (i) ensuring that the transient 
solution after 150 days closely approximated the steady state solution, and (ii) confirming 
that the solution did not change by decreasing Δr. 
 
3.4 Results 
3.4.1 Steady State Solution 
 The steady state oxygen and cell density profiles were calculated by setting the 
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and equation (2) to 
0])[( =− dgrX μμ          (12) 
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By a simple algebraic manipulation, the cell density, X(r), is found as a function of C(r) 
resulting in the following equation 




































   (14) 
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Equation (14) was then substituted in Equation (11) and the resulting equation was solved 
numerically.  Results are shown in Figure 3.1A and 3.1B for a 1.0 mm diameter bead and 
external DO concentrations of 0.20 mM and 0.06 mM, respectively.  The DO 
concentration of 0.20 mM corresponds to normal incubator conditions, while 0.06 mM is 
representative of the peritoneal environment.  The cellular profile in Figure 3.1A 
illustrates the viable cell ring at the periphery which has been observed experimentally by 
histological sectioning of the beads [16, 21, 116].   
Reported results on the effect of oxygen on the βTC3 cell line indicated that 
cellular metabolism shifts to enhanced anaerobic glycolytic activity below 0.032 mM (25 
mmHg), whereas insulin secretion becomes inhibited as DO is reduced to 0.01 mM (7 
mmHg) or lower [8].  As seen in Figure 3.1, for beads exposed to 0.20 mM external DO, 
0.032 mM DO occurs at a position approximately 136 µm from the bead’s periphery, and 
the lower 0.01 mM DO occurs at 224 µm from the periphery.  Hence, at steady state, 2% 
of the cells have their secretory capacity compromised under these conditions.  On the 
other hand, with beads exposed to 0.06 mM external DO, the DO concentration reached 
0.032 mM and 0.01 mM only 37 μm and 124 μm, respectively, from the bead’s 
periphery.  Thus, in this case, 6% of the cells have their secretory capacity compromised.  
The steady state oxygen profiles correspond to average intrabead DO concentrations 
(AIDO) of 0.073 mM and 0.020 mM for 0.20 mM and 0.06 mM external DO, 
respectively.  The average viable cell densities in the beads are 6.52 x 108 and 3.88 x 108 
cells/ml and the total cell numbers are 3.41 x 105 and 2.03 x 105 cells/bead for the high 









































































































































































































































































Figure 3.1   Steady state viable cell density and DO profiles in a 1.0 mm diameter 
bead at two external DO concentrations.  (A) External DO equal to 0.20 mM.  At the 
periphery (radial position equal to 0.5mm), the cell density reaches 8.74 x 108 
cells/ml due to the high DO concentration (0.20 mM).  The cell density declines 
towards the center of the bead attaining its lowest value of 1.8 x 105 cells/ml at the 
center where the DO concentration is 0.008 mM.  (B) External DO equal to 0.06 
mM.  The maximum cell density at the periphery is 8.23 x 108 cells/ml.  At the 
center where the oxygen concentration is 0.008 mM, the cell density declines to 5.0 
x 103 cells/ml. 
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3.4.2  Sensitivity Analysis of the Steady State Solution 
 A sensitivity analysis was performed to evaluate the effect Deff on the steady state 
viable cell density and DO concentration in beads. Figures 3.2A and 3.2B show the 
simulated steady state cell density and DO profiles, respectively, at an external DO 
concentration of 0.20 mM and with values of Deff ranging from 1.0 to 2.0 cm2/day.  As 
the diffusivity was increased, the thickness of the dense peripheral band of cells also 
increased and oxygenated conditions extended to longer distances from the bead 
periphery.  Decreasing Kd caused the cell density profile to become steeper (results not 
shown).  Parameter Kg had little effect on the steady state solutions.  In regards to the 
maximum specific growth and death rates, Equation (14) indicates that it is the ratio of 
these two parameters that determines the viable cell distribution in beads.  Figure 3.3 (A 
and B) shows the sensitivity of the steady state cell and oxygen profiles for different 
values of μg,max/μd,max around the baseline value of 0.25.  The effect of the two oxygen 
consumption parameters, νmax and Km, on the steady state solutions was comparable to 
previous reported findings [17, 137] and was as follows.  Increasing νmax resulted in 
steeper cell density gradients and a decrease in the number of viable cells that could be 
supported towards the center, as oxygen concentrations quickly reached hypoxic levels 
away from the bead periphery.  Similarly, increasing νmax resulted in sharper DO 
gradients.  Changing Km from the baseline value had little effect on the viable cell and 
DO profiles compared to νmax (results not shown). 
 To investigate the sensitivity of steady state solutions to Xmax, model solutions 
were obtained with this parameter increased and decreased by 50% from the baseline 
value.  Changes in Xmax influence primarily the cell density close to the bead periphery, as 
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the cell density closer to the center is determined mainly by the DO concentration.  Thus, 
increasing Xmax resulted in steeper cell density profiles and, conversely, decreasing Xmax 









































































































































Figure 3.2  Sensitivity analysis of the steady-state cell (A) and DO (B) 
distributions in a 1.0 mm diameter bead at 0.20 mM external DO for 









































































































































Figure 3.3   Sensitivity analysis of the steady-state cell (A) and DO (B) 
distributions in a 1.0 mm diameter bead at 0.20 mM external DO for μg,max/μd,max 
values of 0.125, 0.25, 0.5, and 1.0. 
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3.4.3  Unsteady State Solutions 
 Using the parameters listed in Table 1, the changes in cellular and oxygen profiles 
in spherical geometry were tracked over 30 days.  Figures 3.4A and 3.4B illustrate the 
radial changes in cell density and DO concentration starting from a uniform cell density 
of 5 x 107 cells/ml alginate and a uniform DO concentration of 0.20 mM.  Initially, the 
dissolved oxygen concentration throughout the bead is sufficient to facilitate cell 
proliferation regardless of radial position (Figures 3.4A and 3.4B, days 1-5).  However, 
as the cell density at the periphery increases, the DO concentration towards the center of 
the bead decreases, consequently the number of cells that can be supported at this locale 
also decreases.  The proliferation of cells at the periphery continues until spatial 
constraints are reached, whereas at positions closer to the center the equilibrium cell 
density is determined by the equilibrium DO concentration (Figures 3.4A and 3.4B, days 
5-30).  Comparing the steady state and unsteady state solutions, the viable cell number in 
a bead reaches 95% of its steady state value within 16 days.  This is consistent with the 
growth profiles observed experimentally, where the total metabolic activity of a culture 
reaches a plateau after approximately 15 days [116].  Figure 3.4C shows the 
spatiotemporal accumulation of dead cells in the beads.  Interestingly, the highest 
accumulation of dead cells at later time points occurs not at the center of the beads, but at 













Implant antigens exiting the bead are thought to be recognized by the host and 
invoke an immune response via the indirect antigen presentation pathway [138].  
Antigens are released in the capsule as a result of cellular death and lysis, possibly also 
protein secretion.  For this reason, the accumulation of dead cells was tracked using 
Equation 10 for two different initial cell densities (1.0 and 10 x 107 cells/ml) and at 
external DO concentrations of 0.20 mM and 0.06 mM.  The temporal accumulation of 
dead cells in beads is shown, along with the corresponding accumulation of viable cells, 
in Figures 3.5A and 3.5B.  At both external DO concentrations, the rates of dead cell 
accumulation reached the same values irrespective of initial cell density  (1.1 x 104 
cells/day at 0.20 mM external DO, Figure 3.5A, and 1.3 x 104 cells/day at 0.06 mM 
external DO, Figure 3.5B), as shown by the equal slopes of the lines at later time points 
in the simulations.  However, at the DO concentration of 0.20 mM, the beads with the 
higher initial cell density reached 95% of the steady state dead cell accumulation rate 
within 10 days, whereas the beads started with the lower initial cell density reached the 
95% value on day 18.  The times to reach 95% of the steady state rate were somewhat 
higher at the lower external DO, and they were equal to 13 and 23 days for the high and 
low initial cell densities, respectively. 
As is seen in equations 7, 8, and 9 above, the final viable cell number within a 
construct is a function of both the available oxygen and spatial constraints.  Because of 
this relationship, the total viable cell number and the viable cell distribution within a bead 
are the same at steady state for a given external DO, irrespective of the initial cell density.  
Figures 3.5A and 5B show the temporal profiles of the viable cell numbers in a bead at 
two different external oxygen concentrations—0.20 mM and 0.06 mM—and two initial 
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densities (1 and 10 x 107 cells/ml).  At each external DO, the cell number plateaued at the 
same level, irrespective of initial conditions.  Reducing the external DO by 70%, or from 
0.20 mM to 0.06 mM, decreased the steady state viable cell number by 59%.  This 
difference in percentages is due to the spatial constraints.  When oxygen is more 
abundant (0.20 mM), the cells at the periphery are predominantly affected by the spatial 
constrains, while at lower oxygen levels the DO concentration is the major contributor to 
the steady state cell density throughout the bead, including the periphery. 
Simulated changes in cellular distribution were compared against experimental 
data obtained with βTC3 mouse insulinomas encapsulated in high mannuronic alginate 
APA beads and reported by Stabler et al. [116].  Initially, the cells were homogeneously 
distributed in the beads, but with time in culture the cells proliferated at the periphery 
creating a ring of cells at the bead’s edge.  Histological data on the cell distribution on 
days 1, 7, 16 and 29 post-encapsulation [116] are in agreement with the model-predicted 
cell redistribution at these time points.  Furthermore, the model-predicted thickness of the 






Figure 3.5   Viable cell number and accumulated dead cells in a 1.0 mm diameter 
bead as a function of time for 0.20 mM (A) and 0.06 mM (B) external DO 
concentrations.  At each external DO concentration, simulations were performed with 
two initial cell densities – 1.0 and 10 x 107 cells/ml.  All constructs eventually attain 
the same viable cell number per bead and rate of cell death (equal slopes of the 
accumulated dead cells vs. time curves); however, the total number of accumulated 































































































































































































































































































































































3.4.4 Experimentally Useful Correlations 
To investigate whether measurements of the average intrabead DO concentration 
(AIDO), which are acquired through a single T1 NMR relaxation from an entire bead, 
could offer information on the number and distribution of cells and on the DO gradients 
in a bead, pertinent correlations were developed and the following graphs were 
constructed.  Figure 3.6 shows the total viable cell number in a bead vs. AIDO for 
different initial cell densities and for two DO concentrations in the surrounding medium.  
For a given external DO, all points fall on the same curve, irrespective of the initial cell 
density.  Time is a parameter along each curve.  Thus, these graphs demonstrate that with 
a given external DO, an AIDO value uniquely identifies the number of viable cells within 
a construct, irrespective of the initial cell density.  It should be noted that similar 
correlations are obtained when the viable cell number is plotted vs. the total oxygen 
consumption rate (OCR) exhibited by a certain number of beads (results not shown).  The 
latter can be measured in vitro when the beads are in a perfusion bioreactor with 
dissolved oxygen sensors positioned upstream and downstream of the bed [9, 16].  With 
beads implanted in experimental animals, however, OCR cannot be measured and AIDO 






















To evaluate whether AIDO could offer information on the cell distribution within 
a bead for a particular external DO, the distances from the bead periphery to the points at 
which the cell density dropped to 50% and 90% of the peripheral cell density – which is 
the maximum in the bead - were adopted as measures indicative of cell distribution.  
Figure 3.7 shows this distance as a function of AIDO for two external DO concentrations.  
Each curve was obtained by performing calculations with different initial cell densities 
and again all points fell on the same curve, irrespective of the initial density; time is a 
parameter along each curve.   When the distance is 0.5 mm, i.e., it extends all the way to 
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Figure 3.6   Correlation between the total viable cell number in a bead and the 
average intrabead dissolved oxygen concentration (AIDO) for two external DO 
levels.  For a given external DO, the correlation is independent of the initial cell 
density.  Time (t) is a parameter along the trajectories. 
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either 50% or 90% of the maximal even at the bead center.  This occurs with fresh bead 
preparations, in which oxygen-driven remodeling has not yet occurred and for which 
AIDO is relatively high. However, as the density of cells close to the periphery increases, 
the position of 50% and 90% maximum cell density shifts closer to the bead’s edge.  
Additionally, the AIDO decreases while this redistribution occurs.  Hence, this 
correlation can be used to assess the cell distribution in the bead from experimentally 
measured AIDO.  It should be noted that similar correlations are obtained when the 
measures of cell distribution are plotted vs. the OCR exhibited by a certain number of 



























































































Figure 3.7   Correlation between a measure of the cellular distribution 
in beads (distance from the periphery to the points corresponding to 
50% and 90% of maximum viable cell density) and AIDO for two 
external DO levels.  For a given external DO, the correlation is 
independent of the initial cell density.  Time (t) is a parameter along 
the trajectories. 
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 To determine the correlation between the oxygen profile and the AIDO, the 
distances from the bead’s edge to the radial positions at which the DO concentration is 
20% and 50% of the external DO (indicative of intrabead DO distribution) were plotted 
against AIDO.  As is seen in Figure 3.8, at a high AIDO, the DO concentration within the 
bead is everywhere higher than 20% and 50% of the external DO, hence the plotted 
distance extends to the center of the bead.  However, as the AIDO decreases, so does the 
distance from the periphery to which 20% and 50% of external DO is reached.  Thus, as 
with cell distribution, experimentally measured AIDOs can be used to assess the DO 
distribution in this encapsulated cell system.  Again, similar correlations are obtained 
when the measures of DO distribution are plotted vs. the OCR of a certain number of 






















































































Figure 3.8   Correlation between a measure of the DO distribution in 
beads (distance from the periphery to the points corresponding to 20% 
and 50% of the external DO concentration) and AIDO for two external 
DO levels.  For a given external DO, the correlation is independent of the 
initial cell density.  Time (t) is a parameter along the trajectories. 
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3.5 Discussion 
Understanding the oxygen-driven remodeling in tissue engineered substitutes in 
general and encapsulated cell systems in particular is essential in determining how tissue 
constructs will ultimately function.  The mathematical model developed in this paper 
simulated the microenvironment within a spherical pancreatic substitute in regards to the 
cell and oxygen profiles.  The surrounding dissolved oxygen concentration and spatial 
constraints were the two parameters that had the greatest influence over the final cell 
distribution.  The influence of the DO concentration and spatial constraints parameters 
were seen in the sensitivity analysis.  For the simulations presented here, external mass 
transport limitations were not accounted for, which is a reasonable approximation for 
perfusion and well mixed in vitro culture systems.  On the other hand, boundary layer 
effects are likely to be present in vivo, with beads implanted extravascularly, such as 
intraperitoneally, in experimental animal models.  The maximum oxygen consumption 
rate νmax dictated the distance to which dissolved oxygen could diffuse before being 
reduced to hypoxic levels.  The maximum cell density, Xmax, also influenced the cell 
profile, specifically the cell density within 200 µm of the construct’s edge.  After 
approximately 15 days, equilibrium was essentially reached, where the rate of cell growth 
equaled the rate of cell death at all radial positions.  The simulated growth profile and 
cellular remodeling closely matched data from βTC insulinoma cells encapsulated in high 
mannuronic, growth permissive alginate beads.  Simulating cellular remodeling within 
non-permissive materials would require additional constraints within the mathematical 
equations.  As the precise nature of the cell-material interactions for non-permissive 
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matrices is currently unclear, a robust mechanistic model describing such a system cannot 
presently be developed. 
Given the strong dependence of cell viability and insulin secretion on the DO 
concentration a cell experiences, the ability to non-invasively monitor DO concentration 
profiles would be beneficial in determining how a construct is functioning in vivo.  For 
instance, in experiments with diabetic small animal models, an animal is made diabetic 
by an injection of streptozotocin, a chemical which specifically destroys the insulin-
secreting β cells of the pancreas; a tissue engineered substitute is then implanted and its 
efficacy is evaluated by monitoring blood glucose levels during normal feeding or 
glucose injection episodes.  However, the implant itself is evaluated only at the end of the 
experiment when the animal is euthanized and the construct is explanted.  Non-invasive 
monitoring of cell viability and construct function on the same animal during the course 
of an experiment is thus especially useful in establishing an important link between 
implantation and end-point physiologic effects.  Monitoring the DO concentration in a 
tissue substitute offers an indirect but clear indication of cell function within the 
construct.   
Previous literature demonstrated the capacity of 19F and 1H NMR spectroscopy to 
quantify oxygen concentrations and the number of viable cells in a VOI, respectively.  
Nonetheless, determining the local DO concentrations and viable cell number using 
chemical shift imaging requires a significant amount of time that may limit in vivo 
applications.  We have demonstrated in this paper the feasibility of using a mathematical 
model to evaluate cellular and oxygen profiles from a single 19F NMR measurement 
(AIDO), which can be performed relatively quickly. 
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For a given external DO, the AIDO uniquely identified the viable cell number per 
bead irrespective of the initial cell density (i.e. a construct with 2 x 108 viable cells had 
the same AIDO regardless of whether it started with 1 x 107 or 5 x 107 cells/ml).  At 
lower external DO concentrations, the correlation between AIDO and viable cell number 
becomes more difficult to discern, in the sense that a certain change in AIDO corresponds 
to a larger difference in viable cell number.  However, if AIDO measurements are used in 
combination with 1H NMR measurements performed on the same VOI, it is reasonably 
expected that a more accurate assessment of viable cell number can be made. 
For a given external DO, cellular and DO profiles were also uniquely identified 
by the AIDO regardless of initial cell density.  Indeed, at higher AIDO concentrations, 
the cell density is low and homogeneous enough to allow proliferation throughout the 
bead, and a drop to 90% of maximum density or below is not attained.  Similarly, at a 
low cell density the oxygen consumption is not sufficient to reduce the DO concentration 
to less than 50% of the external DO.  At lower external DO concentrations, the measures 
of cell and DO distribution become more difficult to decipher from an AIDO 
measurement, as small changes in AIDO correspond to large changes of the distributions.  
Tissue engineered constructs are fabricated in many shapes and sizes, and the 
modeling framework presented here can be easily adapted to other construct geometries.  
Simulations for a disk-shaped construct of the type reported by Stabler et al. [113, 121] 
have also been performed (results not shown), and there was generally good agreement 
between simulated and experimentally measured viable cell numbers over a 14 day 
period.  For the disk-shaped construct, too, AIDO could be used to assess viable cell 
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number and cell and DO distributions for a given external DO through correlations 
similar to those shown in Figures 3.6 - 3.8.  
Current work in our laboratory involves further validating the model by 
measuring the intra-bead DO distribution in vitro using magnetic resonance techniques.  
The model will then be applied to in vitro and in vivo experimental systems in order to 
assess the viable cell number and cell and DO distributions from non-invasive 






MONITORING OF DISSOLVED OXYGEN AND CELLULAR 
BIOENERGETICS WITHIN A PANCREATIC SUBSTITUTE2 
 
4.1  Abstract 
 
 This work investigated the use of nuclear magnetic resonance (NMR) 
spectroscopy in combination with a mathematical model of an encapsulated cell system 
as a method for rapidly assessing the status of a pancreatic substitute.  To validate this 
method, an in vitro experiment was performed in which the encapsulated cells were 
perfused in an NMR-compatible system and the dissolved oxygen (DO) concentration of 
the perfusing medium was lowered from 0.20 to 0.05 mM, then returned to 0.20 mM in a 
stepwise fashion.  The cellular metabolic activity and bioenergetics were evaluated by 
measuring the oxygen consumption rate (via DO sensors) and nucleotide triphosphate 
levels (via 31P NMR).  By incorporating a perfluorocarbon emulsion into the alginate 
beads, the cellular oxygenation state was monitored by measuring the average intrabead 
DO (AIDO) concentration by 19F NMR.  The in vitro measurements were then compared 
with model predictions based on the measured external DO concentration and time.  
Model-predicted cell growth and AIDO closely matched the experimentally acquired 
data.  As the DO concentrations both external to and within the pancreatic substitute are 
needed to apply this methodology in vivo, the feasibility of measuring the DO 
concentration from two distinct bead populations implanted in the peritoneal cavity of 
mice was established.  It is concluded that PFC incorporation and 19F NMR 
                                                 
 
 
2 Modification of a paper published in Biotechnology and Bioengineering, in press (2007). 
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measurements, in combination with a mechanistic model of the encapsulated system, 
allow the tracking of the state of a pancreatic substitute in vitro and potentially in vivo. 
 
4.2  Introduction 
  
Tissue engineered substitutes, consisting of cells and biomaterials organized in 
specific three-dimensional architectures, have the potential to provide effective 
replacement of the function of natural tissues that have failed as a result of disease or 
injury [4].  Function of these substitutes is influenced by a variety of mechanical, 
chemical and possibly electrical cues.  During in vitro culturing, conditions are monitored 
and controlled, so the development and function of tissue constructs are at least 
somewhat predictable.  However, post-implantation in vivo, a multitude of poorly known 
factors affect the function of implanted cells and of a construct as a whole, hence also the 
achieved therapeutic effect.  Thus, non-invasive methods to monitor construct integrity 
and function are invaluable.  In particular, non-invasive in vivo monitoring allows 
investigators to establish important links between implant function and end-point 
physiologic effects during the entire life of an animal and not only at the end of an 
experiment when the animal is euthanized and the construct explanted for examination. 
In previous studies, we established that nuclear magnetic resonance (NMR) 
spectroscopy and imaging are effective methods to non-invasively monitor tissue 
engineered pancreatic substitutes [9, 16, 112, 113, 140, 141].  1H NMR imaging was used 
to visualize construct integrity and localized, water-suppressed 1H NMR spectroscopy to 
obtain information on the number of viable cells in a construct by monitoring the 
resonance of choline-related metabolites.  Studies were performed with βTC3 mouse 
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insulinoma cells encapsulated in calcium alginate/ poly-L-lysine/ alginate (APA) beads 
and perfused in a packed bed reactor [141]; also, with βTC3 cells encapsulated in disk-
shaped agarose constructs and cultured in vitro [113] or implanted in the peritoneal cavity 
of mice [112].  Additionally, use of 31P and 13C NMR provides information on the 
bioenergetic status and metabolic pathways of cells in pancreatic constructs [9, 140, 142].  
However, due to the low sensitivity of 31P and 13C, use of these nuclei is currently limited 
to the in vitro setting for tissue engineered substitutes.  A method that directly or 
indirectly monitors the physiologic status of cells in vitro and in vivo would thus be 
highly beneficial. 
 A key parameter affecting cellular function is the concentration of dissolved 
oxygen (DO).  Several studies have shown that the DO concentration influences cell 
viability, apoptosis [6, 7] and various aspects of cellular function.  Importantly, hypoxia 
may inhibit cellular function without affecting viability.  For instance, reducing the DO 
concentration to below 60 mmHg inhibits insulin secretion from perfused pancreatic 
islets.  This effect is rapidly reversed upon reoxygenation, which demonstrates that it is 
not associated with cell death [5, 18].  βTC3 mouse insulinomas have been found to be 
more resistant to hypoxia, having their insulin secretory capacity compromised only at 
DO concentrations below 7 mmHg [8].  
Due to its low solubility in aqueous media, oxygen is the most challenging 
nutrient to deliver to cells in three-dimensional constructs.  Furthermore, even when 
properly designed for all cells to be properly oxygenated shortly after fabrication, tissue 
substitutes undergo remodeling with time due to cell growth, death, and possibly cell 
migration processes.  Such remodeling changes the DO concentrations to which cells in 
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the construct are exposed.  Interactions of a substitute with the host post-implantation in 
vivo are also likely to alter the cellular oxygen environment.  For instance, development 
of a fibrotic layer as a result of a non-specific host response towards a construct may 
severely limit the delivery of oxygen to the cells within and cause malfunction or death of 
the implant.  In most cases, implant failure is only detected at the point of complete loss 
of function, and at this endpoint discerning the true mode of failure may be problematic.  
A method allowing for the continuous monitoring of cellular viability and function in an 
implanted construct could help decipher the mechanism of implant failure and thus lead 
to improved design and ultimately enhanced clinical outcome.   
Previous studies have shown that the DO concentration can be monitored using 
19F NMR when perfluorocarbon (PFC) emulsions are employed.  Specifically, the inverse 
of the T1 relaxation time of specific perfluorinated chemical groups are known to vary 
linearly with the DO concentration surrounding the emulsion [19, 25, 26, 103, 143] and 
we, as well as others, have incorporated PFC emulsions into constructs to quantify the 
DO concentration available to encapsulated cells.  It should be noted that 19F is the 
second most sensitive nucleus after 1H and that there is no significant amount of 19F 
normally present in tissues, hence 19F NMR spectroscopy is particularly suitable for 
constructs in NMR-compatible bioreactors and in vivo situations.  Nonetheless, if intra-
construct oxygen profiles are to be acquired using 19F chemical shift imaging, long 
acquisition times are required, which are a caveat to in vivo applications due to the long 
anaesthesia times required of experimental animals.  To overcome this limitation, one can 
acquire a single DO concentration from the entire construct, representing a volume-
average measurement of the oxygen profile within the volume-of-interest (VOI); a 
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mathematical model can then be used to assess the cellular and oxygen spatial profiles 
within the construct, thus allowing for rapid measurements in vivo [144] (CHAPTER 3). 
In this work, we investigated the ability to track a pancreatic substitute by 
combining experimental measurements with mathematical modelling of the construct.  
Encapsulated cells were propagated in an NMR-compatible perfusion bioreactor and 
subjected to a series of step-wise decreases followed by step-wise increases of DO in the 
perfusion medium.  The overall cellular metabolic activity was monitored by the oxygen 
consumption rate (OCR) of the culture and by the level of intracellular nucleotide 
triphosphates (NTP), measured by 31P NMR spectroscopy.  The cellular oxygenation 
state was monitored by measuring the average intrabead DO concentration (AIDO) as a 
function of time by 19F NMR.  To test the validity of the model, the model-predicted 
viable cell number and cellular oxygenation state were compared with the experimental 
results.  For construct monitoring in vivo, both the AIDO and the external DO need to be 
measured with time, hence the ability to simultaneously monitor the DO concentrations 
in two distinct bead populations was demonstrated in mice.  The importance of 
characterizing the dynamic responses of tissue constructs to changing environmental 
conditions, and the implications of such results in understanding the construct function in 
vitro and in vivo, are discussed.   
 
4.3  Materials and Methods 
4.3.1 Cells and Cell Encapsulation 
βTC-tet cells [67] were obtaind from the laboratory of Shimon Efrat, Albert 
Einstein College of Medicine, Bronx, NY.  Cells were cultured as monolayers in T-flasks 
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with culture medium changed every 2-3 days. Culture medium consisted of Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. Louis MO) with 25 mM 
glucose, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and L-
glutamine to a final concentration of 6 mM.  Cell monolayers that reached 80% to 90% 
confluence were trypsinized with 0.05% trypsin-EDTA (Sigma) and split at a 1:5 ratio; 
passage number increased by one at each splitting.  Cells of passage number 36-40 were 
used in this study.   
Cells were harvested by trypsin-EDTA and encapsulated at a density of 7x107 
cells/ml alginate in 2% w/v low viscosity high mannuronic content alginate (product 
LVM, NovaMatrix, Drammen, Norway) containing 4 μl/ml of perfluorotributylamine 
(PFTBA) emulsion (see below).  Using an electrostatic droplet generator (Nisco 
Engineering Inc., Zurich, Switzerland), cells were encapsulated according to the 
procedure of Stabler et al. [51], except that a PLL and a final alginate layer were not 
added.  The final bead size was 960±50 µm in diameter.  Some beads prepared for the in 
vivo study (described below) were coated with PLL (MW = 19,200, Sigma), without a 
final alginate coat, to form alginate/PLL beads.  The PLL coating was performed as 
described previously [51].  The final layer of alginate was not added to ensure that the 
beads would induce an inflammatory response in vivo.  
The PFTBA and a second PFC used in the in vivo studies, perfluoro-15-crown-5-
ether (PFCE) (Exfluor Research Corp, Round Rock, TX), were prepared following a 
protocol adapted from Joseph et al. [23].  An amount of 95mg of egg yolk lecithin (~99% 
purity, Sigma) was added to 600 µl of cold Tyrode’s salt solution (pH 7.4).   While being 
stirred in a 0°C ice bath, the mixture was sonicated twice for 15 seconds at 300 Watts 
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with a 1 minute interval between sonications.  A volume of 400 µl of the desired PFC 
was then added and the mixture was sonicated for 15 seconds at 300 W seven times with 
a 1 minute interval between each sonication. The emulsion was filtered through a 0.4 µm 
membrane filter and mixed with alginate at a ratio of 4 µl emulsion per ml of alginate. 
4.3.2  Perfusion System 
 
Figure 4.1 is a schematic of the computer controlled bioreactor and the perfusion 
circuit, which consisted of a perfusion, a replenishing, and a switching medium 
circulation loops.  The perfusion loop allows for continuous delivery of nutrients and 
dissolved oxygen to the cells located in the bioreactor.  The replenishing loop is capable 
of maintaining desired nutrient (e.g., glucose) concentrations during long-term perfusion 
experiments; however, this was not needed for experiments described in this paper.  The 
switching medium loop is utilized to deliver an alternative medium, e.g. medium with a 
higher or lower glucose concentration.  The volume in the medium reservoir was held 
constant by a second tube that was placed at the desired level and continuously pumped 






















Figure 4.1  Schematic of the NMR-compatible perfusion bioreactor and support 
system used to control the temperature and DO concentration in the medium entering 
the bioreactor. 
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The medium within the perfusion loop circulated continuously at 8 mL/min from the 
medium reservoir to the bioreactor and back to the medium reservoir.  At this flow rate, 
the bioreactor operated differentially, allowing the DO concentration to drop across the 
cell bed by no more than 0.025 mM, as evaluated by calculations and confirmed 
experimentally.  The differential operation of the bioreactor made certain that the 
conditions for the cells at the outlet of the bioreactor were similar to the inlet, which 
ensured that no macroscopic heterogeneities with respect to cell viability and metabolic 
activity were present in the bed.  On the other hand, heterogeneities of cell density and 
DO profiles within beads were present, and these are discussed below. 
Dissolved oxygen was measured using fiber optic dissolved oxygen sensors 
(Ocean Optics, Dunedin, FL) both upstream and downstream of the bioreactor.  The 
upstream dissolved oxygen probe provided the most critical measurement, henceforth 
referred to as DOin, since this was the DO level in the medium immediately before 
entering the bioreactor.  The DO sensors were calibrated in the perfusion loop, first at 
0.20 mM using medium equilibrated with air, and then at 0 mM using medium 
supplemented with 20 mM sodium hydrosulfite (Sigma).  Perfusion with sodium 
hydrosulfite was performed single-pass, from a bottle labeled “Test Medium” in Figure 
4.1 to a waste bottle.  Following calibration of the sensors, the perfusion loop was purged 
with medium in preparation for introducing the cell-loaded bioreactor in the system. 
For the monitoring and control of the perfusion circuit, a Dell Inspiron 2650 
(Dell, USA) laptop computer with LabVIEW™ Full Development software (National 
Instruments, Austin, TX) was implemented.  A constant temperature (37°C) was 
maintained in the medium entering the bioreactor using a 10 W/m2 output heating tape 
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wrapped around foam insulation that covered the tubing both to and from the medium 
reservoir; a second piece of foam insulation covered the heating tape.  The heating tape 
maintained the desired temperature via a duty cycle, which was dictated by a 
proportional-integral feedback loop from an infrared (IR) thermocouple placed 
immediately before the NMR magnet bore entrance.  The temperature in the medium 
reservoir and at the (IR) thermocouple were kept at 38°C to account for an 
experimentally measured temperature drop of approximately 1°C from the NMR bore 
entrance to the bioreactor inlet.   
Control of DO in the medium was accomplished with a control loop similar to the 
temperature control loop.  A proportional-integral-derivative block was then connected to 
the DO probe upstream of the bioreactor.  The algorithm controlled both the flow of air 
(5% CO2, balanced with air) and nitrogen (5% CO2, balanced with nitrogen) into the 
humidifier via solenoid valves (Omega Engineering, Inc., Stamford, CT) that worked in 
an on/off fashion.  The humidifier consisted of a glass container filled with water and a 
glass tube with a fritted end, in which the gas entered and was dispersed into the water.  
The water was held at 37°C by a heating mat.  An air filter was placed between the 
humidifier and the headspace of the medium reservoir, which was heated to 45°C to 
prevent condensation in the filter.   
The bioreactor was designed to accommodate approximately 1.7 mL of beads.  It 
consisted of a 10 mm diameter quartz NMR tube (Wilmad-Lab Glass, Buena, NJ) fitted 
with a custom-made glass cap.  With the glass cap secured to the NMR tube by a 
compression fitting, medium entered the bioreactor through a 2 mm, outer diameter, 
capillary tube that ran down the center of the 10 mm NMR tube to 4 mm below the 
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sample at the bottom of the tube.  The medium then passed through the packed bed of 
beads and exited through the top, returning to the medium reservoir.  Beads were held in 
place with cotton plugs.  The bioreactor was positioned in the magnet so that the beads 
were placed within the RF antenna of the NMR probe.   
4.3.3  Dissolved Oxygen versus T1 Relaxation Calibration Curves 
 
The correlation between DO concentration and the T1 relaxation time of 
perfluorocarbons was assessed at two different magnetic field strengths.  Calibration 
curves were generated at 11.7 and 4.7 Tesla (T) for use at subsequent in vitro and in vivo 
studies, respectively. 
4.3.3.1  Calibration Curve in 11.7 T Magnet  
Cell-free alginate beads containing 4μl/ml of PFTBA or PFCE emulsion were 
loaded into the bioreactor and perfusion system.  19F NMR spectra were acquired on an 
11.7 T vertical bore magnet equipped with a Bruker Avance console (Bruker, Billerica, 
MA) using a 10 mm broadband probe equipped with a 1H decoupling channel.  T1 
relaxation measurements of these perfluorocarbons (with the CF3 and the CF2 resonance 
used for the PFTBA and PFCE, respectively) were made at 4 or more DO concentrations, 
ranging from 0 to 0.2 mM, using a standard inversion recovery pulse sequence provided 
by the Bruker operating software.  The choice of resonances was based on literature 
reports demonstrating that they had the greatest sensitivity for their individual 
perfluorocarbon to changes in DO concentration [20].  For each T1 measurement, 14 
delay times were obtained ranging from 0.040s to 2s.  Additional key acquisition 
parameters were: sweep width = 2.8 kHz, number of transients = 1.  The T1 relaxations 
were calculated using Bruker Avance software.  Since beads did not contain cells, the 
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intrabead DO concentration was set equal to the DO concentration at the inlet of the 
bioreactor.  The linear correlation between the inverse of the T1 relaxation and DO is 






where DO is the concentration of dissolved oxygen in the aqueous phase [mM], M is the 
slope [s-1mM-1] of the 1/T1 vs. DO line,  and I is the anoxic, y-intercept [s-1].  
4.3.3.2  Calibration Curve in 4.7 T Magnet:   
A 4.7 T horizontal bore magnet equipped with a Varian Inova console (Varian, 
Palo Alto, CA) was utilized for all in vivo experiments; calibration curves between DO 
and perfluorocarbon T1 were constructed at this magnetic field as well.  The protocol 
described above for the 11.7 T was also used for the 4.7 T, except that the PFC 
concentrations were 50 μl/ml and the beads were not perfused.  Instead, beads were 
placed in buffer equilibrated with pure nitrogen or air and sealed in a 50 ml Falcon tube.  
The tube was then placed on a surface coil and heated by a water bath that pumped 37°C 
water through tubing wrapped around the tube.  
4.3.4  In Vitro DO Step Change Experiment 
4.3.4.1  19F NMR  
A total of 4-5 consecutive T1 relaxations were acquired at the beginning and end 
of each DOin concentration setpoint in the 11.7 T Bruker magnet.  Since each T1 
measurement took 4.34 minutes to complete, 20 to 30 minutes at the beginning and end 




4.3.4.2  31P NMR   
Using the same 10 mm broadband probe that was used for the acquisition of the 
19F NMR spectra, 31P NMR spectra were acquired on the 11.7 T Bruker magnet at each 
DO concentration immediately following the acquisition of 19F NMR spectra.  A total of 
six to nine 31P NMR spectra were acquired at each DOin concentration, except for 0.12 
mM, where a total of 27 spectra were acquired overnight, as manual switching back to 
19F NMR was required.  Each spectrum consisted of 343 scans and a spectral width of 
approximately 16 kHz.  Other key parameters were TR = 3 s and tip angle = 45°.  Spectra 
were processed using MestReC Software  (Mestrelab Research, A Caruña, Spain).  The 
MestReC software was specifically used to integrate the β-NTP and inorganic phosphate 
(Pi) peaks.  The β-NTP peak integral was then normalized to the Pi peak. 
4.3.5  Mathematical Modelling 
Previously a mathematical model was developed, which describes experimentally 
the observed cell rearrangement in capsules as a result of cell growth and death processes 
in alginate beads (CHAPTER 3).  The cellular growth and death at specific locales within 
the beads were dictated by an interplay between spatial constraints and the DO 
concentration at each radial position [144].  To provide an initial validation, the model 
was used to compute the intrabead radial cellular and DO distributions vs. time.  In these 
calculations, the model inputs were the intrinsic parameters for βTC-tet cells in APA 
beads [144] and the measured DOin during the in vitro experiment.  The model output 
was the time-dependent cell and DO distributions, from which the total viable cell 
number and a volume-average intrabead DO were calculated and compared against 
experimental results. 
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4.3.6  In Vivo Study 
 
Two groups of cell-free alginate beads were fabricated as described in the Cell 
encapsulation section of Materials and Methods.  The first set of beads contained 50 
µl/ml of PFTBA emulsion, while the second contained 50 µl/ml of PFCE emulsion and 
was coated with a layer of PLL to induce an inflammatory response upon implantation 
[145].  PFCE represented an optimal second PFC due to the small 9 ppm difference in 
chemical shift from PFTBA; thus, allowing for simultaneous acquisition of the T1 
relaxation from both PFCs.  To ensure that any effects observed were not due to the type 
of PFC emulsion used, in a second experiment the PFC emulsions were switched in the 
two types of beads.  
 Eight C57BL/6J mice age 8-13 weeks were acquired from Jackson Labs (Bar 
Harbor, ME).  On Day 0, mice were anesthetized using a chamber that contained 
isofluorane gas. A 1 ml, 50:50 mixture of the alginate only beads (containing PFTBA) 
and alginate-PLL beads (containing PFCE) were injected into the peritoneal cavity of six 
mice following a small incision to facilitate injection.  The last two mice also received a 1 
ml, 50:50 mixture of beads, in which the PFC emulsions were switched – alginate only 
beads contained PFCE and alginate-PLL beads contained PFTBA.  On days 0, 1, 2, 6, 
and 7, three to six mice were anesthetized initially with 2.5% and then maintained with 
1.5% isofluorane gas mixed with 95% O2 and 5% CO2.  The mice were positioned on a 
rectangular saddle shape (30mm x 23.7 mm) surface coil that was attached on the outer 
surface of a 32 mm OD polycarbonate tube.  This assembly was placed into a 4.7 T 
horizontal bore Varian magnet and four to six T1 relaxation measurements were acquired 
from both PFC emulsions using an adiabatic inversion.  A total of 23 delay times were 
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used ranging from 0.005s to 7s.  Other acquisition parameters included acquisition time = 
0.205s, TR = 12.0 s, and the number of transients = 1.  The T1 relaxation was calculated 
using Varian software.  Standard tuning and matching were used.  All T1 measurements 
were then converted into DO concentrations using the previously established calibration 
curves.  
After T1 measurements were acquired on Day 7, mice were euthanized by CO2 
asphyxiation.  Beads were collected via a peritoneal cavity lavage with 0.9% NaCl.  
Harvested beads were washed with 1.1% CaCl2 and fixed with 3% gluteraldehyde for 
histological processing. Beads were embedded into paraffin blocks, sectioned, and 
stained with hematoxylin/eosin (H/E). 
4.3.7  Statistical Methods 
 
 The differences of average intrabead DO concentrations measured via T1 
relaxation at various external DO levels (in vitro) studies were evaluated by two-tail t-
tests.  The differences in DO concentration measurements (in vivo) over time and 
between beads containing PFCE and beads containing PFTBA were evaluated using an 
ANOVA two-factor with replication. 
 
4.4  Results  
4.4.1  Calibration Curves 
The relationship between the inverse of T1 relaxation of the encapsulated PFTBA 
emulsion and the DO concentration in the perfusion medium is shown in Figure 4.2.  DO 
concentrations were measured via the DO sensors at the inlet of the bioreactor.  The 1/T1 
measurements correlated positively and linearly with the DO concentration (R2 = 0.9915) 
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with slope and y-intercept values of 1.80 (s · mM)-1 and 1.12 s-1, respectively.  Each point 
on the graph is the average of at least five T1 measurements at each DO concentration, 
and the error bars represent the standard deviation of the 1/T1 values.  Additionally, the 
fully relaxed 19F NMR spectrum of the PFTBA is given with the CF3 peak noted by an 
asterisk. 
Table I lists the parameters for the four calibration curves determined for the two 
PFCs in the two magnets used in this study.  As T1 relaxations increase with decreasing 
magnetic field, the anoxic y-intercept was lower for both PFCs in the 4.7 T.  The slopes 
were comparable among all four PFC calibration curves. 
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Figure 4.2    Calibration curve correlating the inverse T1 relaxation of the 
encapsulated PFTBA emulsion to the dissolved oxygen concentration in the 
medium at 11.7 T.  T1 measurements were based on the CF3 resonance of 
PFTBA.  The insert displays the fully relaxed 19F NMR spectrum of PFTBA as 
a reference.  The resonance identified by an asterisk is the one used to generate 






















4.4.2  Inlet DO Concentration Effect on Intrabead Oxygenation 
 
Figure 4.3 shows measurements from one of two independent studies that 
demonstrated similar trends.  The DO concentration at the bioreactor inlet, DOin, was 
decreased in a stepwise fashion over a period of 30 hours, followed by a stepwise 
increase to the initial value.   The oxygen consumption rate (OCR, normalized to an 
initial value of 100, Figure 4.3A) was measured by the sensors bracketing the bioreactor, 
whereas intrabead DO concentrations at the beginning and end of each DOin step were 
measured by 19F NMR spectroscopy (AIDO start and AIDO end, connected by a solid 
line, Figure 4.3B).  In this Figure, the DOin x-axis bar gives the duration over which the 
DOin concentration was held at a particular setpoint, while the y-axis bar is the standard 
deviation of the DOin measurements, which ranged from ±0.002 to ±0.008 mM.  Each 
AIDO was lower than the corresponding DOin because of oxygen consumption by the 








Table 4.1  Slope (M) and y-intercept (I) of the linear calibration curves of 
1/T1 vs. aqueous DO concentration.  Calibrations were performed on a 11.7 T 
vertical bore Bruker magnet used for in vitro experiments and on a 4.7 T 
horizontal bore Varian magnet used for in vivo studies. 
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were not statistically significant, except at the initial DOin of 0.20 mM.  However, the 
differences in AIDO when comparing the same DOin concentrations from the DOin 
decline phase and the DOin increase phase were statistically different (p<0.05) with the 
exception of the DOin at 0.08 mM.   The lower AIDO values measured during the DOin 
increase phase were the result of a net cell growth in the beads, in accord with the uptrend 
of the OCR (Figure 4.3A).  Similarly, the overall uptrend of the OCR, as denoted by the 
positive slope of the OCR regression line (Figure 4.3A), indicates a net cell growth 
during the experiment.  However, as OCR is the product of the viable cell number and the 
specific consumption rate of the cells, changes in the latter caused by changes in DOin 
resulted in fluctuations of the OCR profile.  The β-NTP/Pi integral ratios at each DOin 
setpoint are plotted in Figure 4.3C.  At the initial high oxygen levels, the β-NTP/Pi 
increased from an average of 0.23 at a DOin = 0.20 mM to approximately 0.34 at a DOin 
= 0.12 mM.  It is likely, however, that the initial β-NTP peaks were suppressed due to 
factors related to loading the bioreactor and incorporating it into the perfusion system.  
This is also evidenced by the dramatic reduction in AIDO from the start to the end of the 
DOin = 0.20 mM period.  A regression line fitted to the points from the beginning of the 
DOin = 0.16 mM to the end of the DOin = 0.12 mM period indicates a specific cell 
growth rate of 0.21 day-1, or a doubling time of 3.3 days, which is reasonable for 
encapsulated βTC-tet cells [51, 139, 144].  However, as the DOin was further decreased 
to hypoxic levels, the β-NTP/Pi also decreased, reaching a minimum of approximately 
60% of the initial value.  Increasing the DOin concentration from 0.05 to 0.08 mM 
caused the average β-NTP/Pi to increase from approximately 0.14 to 0.23 (p<0.05).  
Further increases in DOin resulted in statistically significant higher values of β-NTP/Pi, 
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which reached an average of 0.40 (173% of the initial or 154% of the β-NTP/Pi values at 
DOin = 0.16 mM).  The overall increase in the β-NTP/Pi from the beginning to the end of 








Figure 4.3   Results from typical perfusion experiment involving alginate-
encapsulated βTC-tet cells.  (A) Time profile of the overall oxygen consumption rate 
(OCR) normalized to an initial value of 100 over the course of the experiment (the 
actual initial value for the OCR was 1.5 mmole/(day · 109 cells)).  A linear regression 
line through the OCR data and the corresponding equation are also given.  (B) 
Prescribed changes in the DO concentration in the medium entering the bioreactor, 
DOin, and measured average intrabead dissolved oxygen concentrations (AIDO) in the 
aqueous phase.  For each DOin value, the x- and y- error bars show the time period 
over which the DO was held at the setpoint and the standard deviation from the 
average DOin value, respectively.  AIDO values were acquired at the very beginning 
(□) and end (x) of each constant DOin period; each pair of points is connected with a 
straight line.  (C) β-NTP/Pi integral (□) plotted over the course of the experiment. 






































































































4.4.3  Simulated Cell Density and DO Profiles 
 
A previously developed mathematical model of the encapsulated system [144] 
was used to simulate the results of Figure 4.3.  The model used as input the DO 
concentration in the perfusion medium, averaged over the length of the bioreactor, and 
intrinsic parameters of the alginate-encapsulated βTC-tet cells to compute the cell density 
and DO distribution in beads.  From those two, the total viable cell number in the 
bioreactor and the AIDO were calculated. 
Comparisons of model simulations with experimental results are shown in Figure 
4.4.  Figure 4.4A shows the linear regression obtained from experimentally measured 
OCR and the model-predicted viable cell number, both normalized to an initial value of 
100.  The OCR regression line (solid line) closely matched the model-predicted viable 
cell number (dashed line).  The experimentally acquired AIDOs are compared with the 
simulated AIDOs in Figure 4.4B.  Simulations closely matched experimental data with 
few exceptions.  Specifically, disparities were noted at the initial DOin of 0.20 mM and 
when DOin was increased from the minimum of 0.05 to 0.08 mM and from 0.08 to 0.12 
mM.  However, upon reaching 0.16 mM, the simulations again predicted the 
experimentally measured AIDO.  At the initial 0.20 mM, the cause of the difference 
between the simulated and experimental AIDO is not entirely clear, but it is likely due to 
start up effects.  Similar to the initially suppressed β-NTP/Pi peak, both the loading of the 
bioreactor, the brief period of no perfusion, and the initial connection to the perfusion 
system may have caused the cells to have a reduced oxygen consumption rate, which is 
manifested as a higher experimental than simulated AIDO.  
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To obtain insight into the β-NTP/Pi profile, the model was used to evaluate the 
fraction of cells exposed to DO concentration below 0.032 mM as a function of time.  
Previous studies with the βTC3 insulinoma line have shown that cells switch to a more 
anaerobic glycolytic metabolism as DO decreases below this value [8].  Results on the 
model-predicted fraction of cells below 0.032 mM DO are shown, along with the data on 
β-NTP/Pi and the simulated viable cell number, in Figure 4.4C.  It can be seen that the 
decline in β-NTP/Pi correlates with the increase in the fraction of cells below 0.032 mM 
DO.  When the fraction of hypoxic cells is negligible, as is the case prior to 20 and after 
45 hours in the experiment, the β-NTP/Pi generally tracks the predicted viable cell 
number.  The overall uptrend of β-NTP/Pi from the beginning to the end of the 
experiment correlates well with the simulated viable cell number. 















































































































































































































Figure 4.4   Comparison of experimental data with mathematical modelling results.  
(A) Comparison of the OCR regression line (solid line) with the model-predicted 
viable cell number (dashed line) over the course of the experiment; both initial values 
were normalized to 100 (actual value of the model-predicted viable cell density was 
9.16 x 107 cells/ml).  (B) Experimentally acquired AIDO concentrations compared 
with the simulated AIDO concentrations at each DOin concentration. (C) Change in 
the number of viable cells (dashed line), as calculated by the mathematical model and 
normalized to 100 at t = 0, compared against the experimentally measured change in 
the β-NTP/Pi integral (□), also with the initial value normalized to 100 (actual values 
reported in Figure 3C).  The percent of viable cells exposed to less than 0.032 mM 
DO (solid line) is plotted for comparison against the β-NTP/Pi profile. 
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4.4.4  Two Perfluorocarbon System – In Vivo   
 
The DO concentrations measured by 19F NMR within implanted PLL and non-
PLL coated alginate beads were compared between the two bead populations over the 
course of one week (Figure 4.5).  Shortly after injecting the beads into the peritoneal 
cavity of six mice and on Day 1 post-implantation, measured DO concentrations in the 
coated and uncoated beads were statistically the same.  However, on Day 2, the DO 
concentration in the PLL-coated beads was 0.03 mM lower than in the uncoated beads; 
this difference was statistically significant (ANOVA two-factor with replication).  The 
DO concentration in the coated beads remained statistically lower than in the uncoated 
ones on Days 6 and 7, when the experiment was terminated.  The range of DO 
concentrations within the peritoneal cavity over the course of the experiment was 0.02 to 
0.27 mM.  To verify that the above differences between the two bead populations were 
not PFC-specific, two mice received beads in which the PLL coating was switched to the 
PFTBA beads and indeed, the same trend was observed, i.e., the intrabead DO 
concentration became statistically lower in the PLL-coated beads relative to the uncoated 
ones on Day 2 post-implantation (results not shown).  The Day 0 to 2 decline of intrabead 
DO could be the result of numerous factors that were either physiologic (e.g. heart rate 
and respiration rate) and/or experimental in nature (e.g. recovery from surgery and depth 
of anesthesia), making an explanation of the time profiles speculative and outside the 
scope of the study. 
Histological sections of beads harvested from the peritoneal cavity of mice on 
Day 7 are displayed in Figure 4.5B.  Approximately half of the beads exhibited fibrotic 
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overgrowth.  A control experiment determined that alginate-only beads did not exhibit 




















 Nuclear magnetic resonance (NMR) imaging and spectroscopy allow non-
invasive monitoring of tissue constructs and other implants for both in vitro and in vivo 
studies.  In this work, 19F and 31P NMR spectroscopy in combination with mathematical 









































Figure 4.5   Dissolved oxygen concentrations measured within poly-L-lysine (PLL)-
coated and uncoated alginate beads implanted into the peritoneal cavity of mice.  
PLL is known to induce an inflammatory response).   (A) DO concentration in 
uncoated beads (♦) and in PLL-coated beads (□); the points for the uncoated (coated) 
beads are connected with a solid (dashed) line. (B) Histological image of 
representative beads harvested from mice containing a 50:50 mixture of PLL-coated 
and uncoated beads.  A clear ring of fibrosis is seen around one of the beads. 
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substitute consisting of encapsulated, insulin-secreting cells.  Additionally, we 
demonstrated the ability to utilize 19F NMR in vivo to measuring the DO concentration 
within two distinct bead populations in the mouse peritoneal cavity.  Given that the 
ultimate success of a tissue substitute depends upon many factors that are intrinsic, i.e., 
inherent to the construct design, or extrinsic to the construct, including supply of 
nutrients and oxygen and the in vivo immune response towards the implant, monitoring 
the structural integrity of a construct, as well as the viability and function of the cells, 
could aide in understanding mechanisms of failure and improving functionality of the 
implant.   In vitro, NMR monitoring has been used to study the biochemistry (water-
suppressed 1H) [141], bioenergetics (31P) [9, 16] and metabolic fluxes (13C) [139, 140] of 
the cells within alginate-based beads.  In vivo, imaging has proven useful for monitoring 
structural integrity, and localized, water-suppressed 1H NMR spectroscopy for 
monitoring viable cell number in a construct [112, 113].  However, in vivo 31P and 13C 
studies of encapsulated systems are very challenging due to the low NMR sensitivity of 
these nuclei and the relatively small number of cells within a construct.  To monitor 
cellular physiology, we thus opted for an indirect approach that uses a low concentration 
of PFC emulsion in the encapsulated cell system to monitor the DO concentration in 
beads.  Results demonstrate that 19F NMR can effectively monitor an average intrabead 
DO concentration in vitro and in vivo.  Preliminary data (not shown) indicate that 
incorporation of the PFC emulsion in the capsules at a low concentration of 0.4% does 
not affect the viability and function of βTC-tet cells. 
 Obtaining accurate DO concentration measurements from the sequestered PFTBA 
and PFCE emulsions is critical to tracking the pancreatic substitute and determining the 
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bioenergetic status of encapsulated cells.  Since the DO values depend on the calibration 
curves, the slopes and intercepts of the calibration lines obtained in this study were 
compared to published values.  The PFTBA slopes found in the 4.7 and 11.7 T magnets 
(1.81 s-1mM-1 and 1.80 s-1mM-1, respectively) were comparable to the value reported by 
Shukla et al. [26] at 7.05 T (1.85 s-1mM-1).  However, due to the dependence of the T1 
relaxation on magnet strength, the y-intercept reported by Shukla et al. was comparable 
only to the y-intercept obtained in the 4.7 T magnet (0.852 s-1 vs. 0.857 s-1, respectively).  
Similarly, the slope (1.865 s-1mM-1)  and the y-intercept (0.407 s-1) of the PFCE 
calibration curve at 4.7 T fell within the range observed by Noth et al. (2.127 s-1mM-1 and 
0.346 s-1, at 1.9 T) and Fan et al. (1.485 s-1mM-1 and 0.375 s-1, at 4.7 T) [25, 143]. 
 Dissolved oxygen concentration is an extrinsic factor that significantly influences 
both cellular bioenergetics and viability.  In this study, the DO concentration entering the 
bioreactor was decreased stepwise from 0.20 to 0.05 mM and then subsequently returned 
to 0.20 mM stepwise, and the cell number and cellular responses were studied 
experimentally and modeled mathematically.  The effect of short and long-term hypoxia 
on the biochemistry of encapsulated βTC mouse insulinomas has been extensively 
studied in the past.  Using perfused alginate-encapsulated βTC3 cells, Papas et al. [15] 
observed that short-term (up to 24 hours) hypoxia always resulted in a decrease of NTP, 
measured by 31P NMR spectroscopy, although the effects on insulin secretion varied 
depending on the rearrangement that the encapsulated cells had undergone due to growth.  
In longer-term (3-4 days) hypoxic episodes conducted with the same experimental system 
[9], the levels of NTP and phosphorylcholine were reduced, whereas inorganic phosphate 
exhibited a transient increase. Upon restoring the DO concentration in the perfusion 
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medium, all parameters returned to their pre-hypoxic levels either via gradual 
unidirectional changes or, for OCR, via an abrupt initial rise followed by a gradual 
increase to the pre-hypoxic level.  This pattern of OCR increase is compatible with an 
initial adjustment of viable cells to the higher DO concentration followed by a net cell 
growth to the pre-hypoxic level.  In the present study, NTP increased to approximately 
170% of the initial level upon restoration of the oxygen level in the perfusion medium.  
This is likely due to the fact that experiments were performed shortly after the 
preparation of beads with an initial cell density below that supported in medium in 
equilibrium with air; hence, net cell growth during the experiment occurred.  It can be 
reasonably expected that if the experiment was started with beads containing cells at the 
density supported under 0.20 mM dissolved oxygen, no net cell growth would have 
occurred over the duration of the experiment.  
A previously developed mathematical model [144] simulates the changes in the 
distribution of cells and DO, which occur over time in a system of encapsulated βTC-tet 
cells.  The model could also be used to provide information on the viable cell number and 
the cell and DO distributions in beads based on measured AIDO and the DO 
concentration in the surrounding milieu.  Therefore, a method in which the DO 
concentration could be determined simultaneously from two distinct bead populations in 
vivo was explored.  The method involved placing PFTBA and PFCE emulsions, which 
chemical shifts are only separated by 9 ppm, into two types of beads, allowing for 
simultaneous T1 relaxation measurements.  The beads containing PFTBA emulsion were 
coated with PLL, while the no additional coating was placed on beads containing PFCE.  
Thus, it is reasonable to assume that the lower DO concentrations measured by beads 
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with PFTBA were due to a fibrotic overgrowth induced by the PLL.  Although in this 
study both bead types did not contain cells, one of the PFC emulsions could be 
encapsulated with cells, while the second PFC emulsion would be encapsulated in cell-
free beads.  The cell-free population of beads is then used to measure the DO 
concentration at the implantation site, as equilibration of the intrabead and the external 
DO is rapidly accomplished.  It should also be noted that the DO level at various 
anatomic locales changes significantly with conditions, as was also noted in this study.  
For instance, Noth et al. [24] reported a -0.007 mM to 0.24 mM DO concentration range 
in the peritoneal cavity of rats, which is comparable to the range measured in this study 
(0.02 to 0.27 mM).  However, in contrast to the single perfluorocarbon (F-44E) emulsion 
used by Noth et al. [24], the dual PFC system developed in this study allows for accurate 
comparisons of an experimental implant vs. a control measuring the implantation site 
DO.  The dual PFC system could potentially also be used in biocompatibility studies 
addressing the inflammatory response towards various implanted materials.  In this, a 
material that induces inflammation would rapidly develop a lower DO concentration 
within its volume relative to a control, non-inflammatory implant, as was observed with 
the PLL-coated and uncoated beads in this study.     
 In summary, we have shown that incorporation of a low concentration of PFC 
emulsion in an encapsulated cell system allows for the rapid, non-invasive measurement 
of the average intrabead DO concentration by 19F NMR.  A system of alginate-
encapsulated mouse insulinomas was subjected to changes in external DO in a perfusion 
bioreactor and studied by following intrabead DO and cellular β-NTP by NMR 
spectroscopy, and by measuring the oxygen consumption rate of the culture by dissolved 
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oxygen sensors.  Using a mathematical model of the encapsulated cells can significantly 
assist the tracking of this system on the basis of a limited amount of rapidly obtained 
experimental data.  In vivo experiments demonstrated the feasibility of measuring 
simultaneously the intrabead DO in two different bead populations in the peritoneal 
cavity of mice.  The developed experimental and mathematical modeling methodologies 
are expected to enable the non-invasive tracking of the dynamic changes in encapsulated 





MONITORING A PANCREATIC SUBSTITUTE DURING TRANSIENT 
HYPOXIA AND CELL DEATH 
 
5.1  Abstract 
  
Upon implantation, tissue engineered substitutes are subject to a variety of 
conditions that could ultimately lead to the loss of function.  In this work, we have 
investigated the utility of a previously established non-invasive monitoring method in 
tracking pancreatic substitutes exposed to two mimicked in vivo scenarios – specifically, 
fluctuations in dissolved oxygen (DO) due to an inflammatory response and a cytokine 
attack due to a biocompatibility issue with the substitute.  To mimic the changes in DO 
levels, encapsulated βTC-tet cells were placed in an NMR-compatible perfusion circuit 
and the medium DO concentration perfusing the bioreactor was declined stepwise from 
0.20 to 0.04 mM and then returned in the same increments to 0.20 mM.  During the 
study, the cellular metabolic activity and bioenergetics were evaluated by measuring the 
oxygen consumption rate (OCR) (via DO sensors) and nucleotide triphosphate levels (via 
31P NMR).  The average intrabead DO (AIDO) concentration was also acquired using a 
PFC emulsion sequestered within the pancreatic substitute and 19F NMR.  AIDO 
measurements were converted to an estimate of cell density using a mathematical model 
(CHAPTER 3) over the course of the study, and the AIDO-based estimates were 
compared to those based on OCR.  In the second study, the ability to track cell death 
(induced by puromycin) using AIDO measurements and the mathematical model was 
evaluated.  Again, OCR and AIDO-estimated changes in cell density were compared.  It 
was found that, in both studies, the AIDO measurement, which can be performed non-
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invasively in vitro and in vivo, was indeed capable of tracking a pancreatic substitute.  
The use of this method in distinguishing between modes of tissue substiute failure upon 
in vivo implantation is discussed. 
 
 
5.2  Introduction 
 
The engineering of living tissues, also known as tissue engineering, has shown 
tremendous promise in replacing or repairing normal body functions that have been lost 
due to injury or disease [4].  Typically, cells are manipulated external to the body through 
either their environment or genetic engineering and then joined with an appropriate 
scaffold to allow for handling and proper function.  Prior to transplantation, this tissue 
substitute is often cultured, manipulated, and monitored in vitro until the desired 
properties are achieved with the most critical properties being cell viability and proper 
function.  Numerous methods are available for the in vitro assessment of these construct 
properties.   However, upon implantation such parameters prove difficult to track, leaving 
physicians and researchers to rely on indirect methods of monitoring.  Such indirect 
monitoring methods are non-ideal as they typically only show a substitute is not 
functioning properly when it is too late to provide any adjustments to reverse the course 
of malfunction.  Therefore, a method that can directly monitor a tissue substitute in vivo 
would be valuable. 
Nuclear magnetic resonance (NMR) imaging and spectroscopy have been shown 
to be robust non-invasive monitoring techniques by our group and others [9, 16, 112, 113, 
120, 139, 142, 146].  1H NMR imaging and spectroscopy have been used to monitor 
structural features and the number of viable cells, respectively, within pancreatic 
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substitutes both in vitro and in vivo [112, 113].  Specifically, the pancreatic substitute 
consisted of βTC3 mouse insulinoma cells encapsulated in alginate/poly-L-lysine/alginate 
(APA) beads or agarose disks and either maintained in a long-term perfusion system or 
implanted into the peritoneal cavity of mice, respectively.  13C NMR and 31P NMR have 
also been used to assess the metabolic fluxes and the bioenergetic status of cells 
contained in pancreatic substitutes in vitro [16, 123, 126, 142].  However, given the 
especially low sensitivity of these NMR nuclei, in vivo utilization is not currently 
plausible; thus, a non-invasive method that directly or indirectly monitors the physiologic 
status of cells in vitro and in vivo would be highly beneficial. 
The dissolved oxygen (DO) concentration is known to have an impact on both 
cell viability and function [6, 7, 9, 15, 17].  This impact has been demonstrated in 
pancreatic substitutes involving islets of Langerhans and the βTC3 mouse insulinoma cell 
line [5, 9, 15, 18, 124], where islets were shown to have diminished insulin secretion 
below a DO concentration of 60 mmHg and βTC3 cells below 7 mmHg.  It should be 
noted that the effect of DO on viability and function is not always proportional, as 
cellular function is often diminished at higher DO concentrations than that which would 
cause cellular apoptosis and death [7, 8].  This becomes increasingly important in tissue 
substitutes, where dissolved oxygen gradients are created due to oxygen consumption by 
cells at the periphery and the low solubility of oxygen in water.  In tissue substitutes in 
which continuous cell lines are used, these DO gradients change with time due to cell 
growth and death processes.  Additionally, upon implantation, many in vivo factors cause 
constantly changing DO concentrations immediately external to the tissue substitutes.  
For example, Noth et al [24] and Gross et al [43] (CHAPTER 4) reported that the DO 
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concentration varied widely over time in the peritoneal cavity of rats and mice, ranging 
from -0.007 to 0.24 mM and 0.02 to 0.25 mM, respectively 
Given the strong dependence of cellular viability and function on DO 
concentrations, our group, as well as others, has been developing NMR-based methods 
for assessing the DO concentration within tissue constructs [24, 32, 102].  Specifically, 
the inverse T1 relaxation of perfluorocarbon emulsions sequestered in hydrogels has a 
linear relationship with the DO concentration in the surrounding aqueous solution.  The 
T1 relaxation rate is measured using 19F NMR spectroscopy, which should be noted as the 
second most sensitive NMR nucleus and is not found naturally in vivo.  Therefore, one 
could quantify the oxygen profiles within an implanted tissue substitute by performing 
two or three dimensional localized spectroscopy.  However, such a three-dimensional 
reconstruction of oxygen profiles would require high concentrations of perfluorocarbon 
emulsion and may prove impractical due to the long anesthesia time that would be 
required.  Alternatively, one DO concentration measurement can be acquired from the 
entire construct, representing a volume-averaged value of the entire construct; a 
mathematical model can then be used to assess the cellular and oxygen spatial profiles 
within the construct, which would greatly increase the speed of acquisition. 
In CHAPTER 4, we demonstrated the ability to track cellular growth and oxygen 
profiles using 19F NMR and a mathematical model.  In these experiments, freshly 
encapsulated βTC-tet mouse insulinoma cells were placed into an automated long-term 
perfusion system and subjected to DO concentration step changes over the course of 50 
hours.  During the study, 19F NMR was used to measure the volume averaged intrabead 
dissolved oxygen (AIDO) concentration within the pancreatic substitutes, whereas the 
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bioenergetic status of the cells was monitored using 31P NMR, and the oxygen 
consumption rate of the cells was monitored using two DO sensors bracketing the 
bioreactor.  Mathematical simulations of cell growth and AIDO were in good agreement 
with experimental data.  In addition, the study demonstrated the ability to acquire DO 
concentration information from two distinct constructs in vivo via a dual perfluorocarbon 
system. 
This chapter augments the above work by implementing the method to two 
mimicked in vivo scenarios.  First, the ability of the mathematical model and 19F NMR to 
track cell growth in alginate beads that were cultured for one week prior to being placed 
in the NMR-compatible perfusion system and then subjected to DO concentration step 
changes is evaluated.  This study is designed to reproduce monitoring that may occur 
during in vivo experiments, where parameters influencing cell function and viability are 
not continuously monitored and the DO concentration can vary widely from day to day.  
The second scenario is designed to study the ability of the system to monitor cell death if 
a cytotoxic immune response occurs after such a pancreatic substitute is implanted.  
Specifically, the AIDO and medium DO concentration are used to assess the cell density 
within alginate beads after the addition of puromycin, a toxic antibiotic.  The translation 
and importance of these studies to in vivo monitoring of implanted pancreatic substitutes 
are discussed. 
 
5.3  Materials and Methods 
5.3.1  Cells and Cell Encapsulation 
βTC-tet cells [67] were obtained from the laboratory of Shimon Efrat, Albert 
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Einstein College of Medicine, Bronx, NY.  Cells were cultured as monolayers in T-flasks 
with culture medium changed every 2-3 days. Culture medium consisted of Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. Louis MO) with 25 mM 
glucose, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and L-
glutamine to a final concentration of 6 mM.  Cell monolayers that reached 80% to 90% 
confluence were trypsinized with 0.05% trypsin-EDTA (Sigma) and split at a 1:5 ratio; 
passage number increased by one at each splitting.  Cells of passage number 36-40 were 
used in this study.   
Cells were harvested by trypsin-EDTA and encapsulated at a density of 7x107 
cells/ml alginate in 2% w/v low viscosity high mannuronic content alginate (product 
LVM, NovaMatrix, Drammen, Norway) containing 4 μl/ml of perfluorotributylamine 
(PFTBA) emulsion (see below).  Using an electrostatic droplet generator (Nisco 
Engineering Inc., Zurich, Switzerland), cells were encapsulated according to the 
procedure of Stabler et al [51], except that a PLL and a final alginate layer were not 
added.  The final bead size was 925±52 µm in diameter. 
The PFTBA was prepared following a protocol adapted from Joseph et al [23] and 
previously described by Gross et al [43] (CHAPTER 4).   
5.3.2  Perfusion System 
The NMR-compatible perfusion system and bioreactor utilized in this study has 
been fully described previously [43] (CHAPTER 4).  In brief, the perfusion system 
consisted of a perfusion, a replenishing, and a switching medium circulation loop.  For 
the purpose of these experiments, the perfusion loop was used exclusively, which allowed 
for continuous delivery of nutrients and dissolved oxygen (DO) to the cells located in the 
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bioreactor.  The DO concentration at the bioreactor inlet and the medium temperature 
were maintained at user defined set-points via computer directed proportional-integral 
control loops, DO sensors bracketing the bioreactor, and an infrared T thermocouple. 
5.3.3  DO Step Change Experiment 
βTC-tet cells were encapsulated in alginate beads and cultured in a 37°C 
incubator for one week.  At the start of the study, approximately 2 mls of beads were 
loaded into the bioreactor and attached to the perfusion system.  The bioreactor was 
placed into a 11.7 T vertical bore magnet equipped with a Bruker Avance console 
(Bruker, Billerica, MA) and a 10 mm broadband probe.  The DO concentration entering 
the bioreactor was initially set to 0.20 mM, after which the DOin setpoint was decreased 
by increments of 0.04 mM approximately every 4 hours.  Upon reaching 0.04 mM, the 
DOin was then returned to 0.20 mM using the same increments as during the decline 
phase. It should be noted that during both the decline and incline phase, the DOin 
setpoint of 0.12 mM was maintained for approximately 10 hours overnight.  To assess the 
intrabead DO concentration, a total of 4-5 consecutive T1 relaxations were acquired by 
19F NMR (see parameters below) at the beginning and end of each DOin concentration 
setpoint.  Since each T1 measurement took 4.34 minutes to complete, 20 to 30 minutes at 
the beginning and end of the DOin setpoint were used to acquire the T1 relaxations.  The 
T1 relaxation rates were converted into DO concentrations using a previously established 
calibration curve [43] (CHAPTER 4).  31P NMR spectra were acquired (see parameters 
below) at each DO concentration immediately following the acquisition of 19F NMR 
spectra for T1 determination.  A total of six to nine 31P NMR spectra were acquired at 
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each DOin concentration, except for 0.12 mM, where a total of 27 spectra were acquired 
overnight. 
5.3.3.1  31P NMR 
Each 31P NMR spectrum consisted of 344 scans and a spectral width of 
approximately 16 kHz.  Other key parameters were TR = 3 s and tip angle = 45°.  Spectra 
were processed using MestReC Software  (Mestrelab Research, A Caruña, Spain).  The 
MestReC software was specifically used to integrate the β-NTP and inorganic phosphate 
(Pi) peaks.  The β-NTP peak integral was then normalized to the Pi peak. 
5.3.3.2  19F NMR 
For each T1 measurement, 14 delay times were obtained ranging from 0.040s to 
2s.  Additional key acquisition parameters were as follows: sweep width = 2.8 kHz, 
number of transients = 1.  The T1 relaxations were calculated using Bruker Avance 
software. 
5.3.4  Toxicity Experiment 
One day after encapsulation, approximately 2 ml of beads were loaded into the 
bioreactor, at which point the bioreactor was attached to the perfusion system.  The 
bioreactor was placed into the 11.7 T vertical bore magnet, as described above.  The 
DOin was set to 0.14 mM and maintained at this concentration for the remainder of the 
study.  With the DOin stabilized at the desired value, three 31P NMR spectra were 
acquired over the course of one hour (see parameters and processing in previous section), 
serving as the pre-stressed condition of the cells.  The 31P NMR spectra were followed by 
5 T1 relaxation measurements of the immobilized PFTBA emulsion acquired by 19F NMR 
(see parameters and processing in previous section) over 30 minutes.  At the 2 hour mark, 
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puromycin (Sigma) was added to the system at a final concentration of 10µg/ml – 
preliminary tests showed that an approximately 40% reduction in viable cell number 
occurred in 24 hrs at this concentration (data not shown).  Puromycin is an antibiotic that 
interferes with protein synthesis by ending mRNA translation prematurely [147].  For the 
next hour, several T1 relaxation measurements by were taken for an hour followed by T1 
measurements being acquired every 55 minutes.  Approximately 11 hours after the 
addition of puromycin, 31P NMR spectra were acquired again amongst intermittent T1 
relaxation measurements for the remainder of the experiment.  The entire study lasted 
approximately 48 hrs.   
 
5.4  Results 
5.4.1  Monitoring Cell Growth 
 Figure 5.1, A and B, shows measurements from one of two independent studies 
that demonstrated similar trends, while Figure 5.1 C included data from both studies to 
demonstrate the reproducibility.  The DO concentration entering the bioreactor (DOin) 
was decreased stepwise from 0.20 mM to 0.042 mM and then returned to 0.20 mM 
(Figure 5.1 B).  During the experiment, the oxygen consumption rate (OCR), the average 
intrabead DO (AIDO) concentration, and the β-NTP/Pi integral ratio were monitored 
(Figure 5.1 A, B, and C, respectively).  During the first 8 hours, the measured OCR– 
determined by DO sensors bracketing the bioreactor –increased from an initial value of 
1.9 to approximately 2.5 mmole/(day·109 cells).  The OCR then remained between 2.4 
and 2.7 mmole/(day·109 cells) until the DOin was changed from 0.08 mM to 0.042 mM, 
at which point the OCR dropped by almost 50% to 1.3 mmole/(day·109 cells).  The OCR 
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quickly returned to 2.4 mmole/(day·109 cells) when the DOin was increased back to 0.08 
mM.  For the remainder of the DOin step increases, the OCR remained essentially 
constant with only a slight increase observed going from a DOin of 0.12 mM to 0.16 
mM.  The small difference in OCR from the DOin decline phase to the incline phase 
indicates that there was little to no net cellular growth over the 55 hours.  Likewise, little 
difference was observed in the AIDOs (Figure 5.1 B) when comparing values from the 
DOin decline to incline phase.  However, a statistical difference (p<0.05) was observed in 
the β-NTP/Pi integral ratios (Figure 5.1 C) when comparing ratios from the start of the 
experiment (100) to ratios at the end of the study (53 ± 6 in Exp-1 and 65 ± 8 in Exp-2).  
As expected, the lowest integral ratios were observed at a DOin of 0.042 mM, where the 
ratios were 31 ± 6 and 43 ± 14 for Exp-1 and Exp-2, respectively. 
 OCR and AIDO measurements were converted into cell density estimates and 
plotted in Figure 5.2.  The OCR measurements were converted to cell densities based on 
a previously published specific oxygen consumption rate, qO, of encapsulated βTC-tet 
cells (1.65 mmole/(day•109cells))  [43] (CHAPTER 4), which was comparable to 
previously published qO of βTC3 cells (1.63 mmole/(day•109cells))  [125].  The AIDOs 
were converted using a previously established mathematical model [148] (CHAPTER 3).  
It should be mentioned that using a constant qO value to convert the OCR measurements 
to cell densities scales the former linearly; hence, the OCR-estimated cell density profile 
in Figure 5.2 is identical to that of the OCR profile in Figure 5.1 A.  However, the cell 
density estimates based on AIDO may be more accurate, as this conversion accounts for 
the reduction in oxygen consumption rates at lower oxygen levels.  Nonetheless, the 
initial OCR and AIDO-estimated cell densities were approximately the same at 8.15 and 
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7.48 x 107 cells/ml, respectively (Figure 5.2).   The change in estimated cell densities 
were in general agreement for the remainder of the study with each indicating a 
significant drop from hour 25 to 29, corresponding to the DO concentration drop in the 
surrounding medium.  It should be pointed out that AIDOs are the only measurements of 













Figure 5.1 Results from a typical perfusion experiment involving alginate-
encapsulated βTC-tet cells.  (A) Time profile of the overall oxygen consumption rate 
(OCR) over the course of the experiment.  (B) Prescribed changes in the DO 
concentration in the medium entering the bioreactor, DOin, and measured average 
intrabead dissolved oxygen concentrations (AIDO) in the aqueous phase.  For each 
DOin value, the x- and y- error bars show the time period over which the DO was held 
at the setpoint and the standard deviation from the average DOin value, respectively.  
The AIDO y-error bars represent the standard deviation of the measurements.  (C) β-
NTP/Pi integral ratios normalized to 100 from two separate experiments plotted over 




































































































































































































5.4.2  Monitoring of Cell Death 
 The status of encapsulated cells immediately prior and after being exposed to 10 
µg/ml puromycin was tracked for over 45 hours (Figure 5.3).  Specifically, the OCR, the 
AIDO, and the β-NTP/Pi integral ratios were monitored (Figure 5.3 A, B, and C, 
respectively).  During the first 2 hours, the OCR increased from 1.8 to 2.1 




































Figure 5.2   Estimated cell densities based on OCR measurements acquired from DO 
sensors bracketing the bioreactor and AIDO measurements acquired by 19F NMR.  
OCR-based estimates used a previously measured value of the oxygen consumption 
rate of encapsulated βTC-tet cells (1.65 mmole/(day•109cells)) [148].  AIDO-based 
estimates were determined from a previously established mathematical model. 
Vertical bars indicate the standard deviation from the average.   
 102
temporary plateau at approximately 1.9 mmole/(day·109 cells) and by hour 5 (3 hours 
after the addition of puromycin), the OCR began a steady descent.  The final OCR value 
was approximately 0.9 mmole/(day·109 cells), 50% below the starting value.  A quick 
response to the addition of puromycin was also observed in the change of AIDO (Figure 
5.3 B).  Initially, the AIDO was approximately 0.08 mM, 0.06 mM below the DOin 
concentration of 0.14 mM.  It should be noted that the difference between the AIDO and 
DOin is due to the DO concentration profiles created by the cellular oxygen 
consumption; thus, a smaller difference is the result of fewer viable cells.  Like the OCR, 
the AIDO began to increase at hour 5, which was quick and pronounced, reaching 0.12 
mM by hour 12.  The AIDO then fluctuated between 0.11 and 0.136 mM for the 
remainder of the study.  Unlike the relatively quick response of the OCR and AIDO to 
the addition of puromycin, the β-NTP/Pi integral ratios remained at approximately 100 
for the first 13 hours of the study (Figure 5.3 C).  Approximately 11 hours after the 
addition of puromycin to the medium, the β-NTP/Pi integral ratio began to decrease.  
Initially, the decrease occurred rapidly, dropping from 100 to 50 in 14 hours.  The rate of 
decrease then slowed for the remainder of the study (27 to 48 hours), reaching an ultimate 










































































































































Figure 5.3  Results from a typical toxicity experiment involving alginate-
encapsulated βTC-tet cells.  (A) Time profile of the oxygen consumption rate (OCR) 
over the course of the experiment.  (B) The DO concentration in the medium entering 
the bioreactor, DOin, and measured average intrabead dissolved oxygen 
concentrations (AIDO) in the aqueous phase.  Vertical AIDO bars are the standard 
deviation of five contiguously measured AIDO concentrations.  (C) β-NTP/Pi integral 
ratios normalized to 100 from two separate studies plotted over the course of the 
experiment.  The gap in β-NTP/Pi integral from 2 to 13 hours is due to continuous 
AIDO measurements during this time period.  The dashed line stretching through the 
three panels at 2 hours is the time point at which the 10 µg/ml puromycin was added. 
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As in the previous study (Figure 5.2), OCR and AIDO measurements were 
converted into cell density estimates and plotted in Figure 5.4.  Initially, the AIDO 
predicted a higher density than the OCR, 13.3 x 107 cells/ml vs 7.5 x 107 cells/ml, 
respectively.  However, this difference was within one standard deviation of the AIDO 
measurement and by hour 7, the AIDO-estimated cell densities closely matched the 
OCR-based cell density estimates.  Both AIDO and OCR-based estimates exhibited a 
steady decline for the remainder of the study, reaching a final value of approximately 3.8 
x 107 cells/ml. 
 
 
Figure 5.4  Estimated cell densities based on OCR measurements 
acquired from DO sensors bracketing the bioreactor and AIDO 
measurements acquired by 19F NMR.  The vertical bars of the AIDO-
based estimates represent the standard deviation of five or more 
AIDO measurements.  The dashed line at hour 2 is the point at which 





































5.5  Discussion 
 
 Cell-based pancreatic substitutes have the potential of becoming a treatment 
option for insulin-dependent diabetics, as the need for insulin injections would decrease 
and the long-term complications would likely be mitigated as the substitute could provide 
near physiologic control of blood sugar.  However, upon in vivo implantation, these 
substitutes can be subjected to an array of conditions that could ultimately be detrimental 
to the function and viability of the sequestered cells.  Hence, non-invasive methods that 
are capable of monitoring an implanted pancreatic substitute are essential.  Nuclear 
magnetic resonance (NMR) imaging and spectroscopy allow non-invasive monitoring of 
tissue constructs and other implants for both in vitro and in vivo studies.  Previously, we 
established a method – consisting of DO measurements obtained by 19F NMR and a 
mathematical model – that enabled the tracking the DO concentrations within the 
capsules and the bioenergetic status of freshly encapsulated βTC-tet cells.  In this 
CHAPTER, we performed two studies to test the ability of the method to monitor βTC-tet 
cells (encapsulated in alginate) that were cultured for one week in vitro and that were 
subjected to changes in medium DO concentration and to the addition of puromycin, a 
potent antibiotic.  These two in vitro studies were designed to mimic potential in vivo 
scenarios that occur upon implantation.   
 The first study tested the ability to monitor encapsulated cells that were subjected 
to changing DO concentrations.  Specifically, the DO concentration of the medium 
entering the bioreactor was decreased stepwise from 0.20 to 0.042 mM and then returned 
to 0.20 mM, while the OCR was monitored by DO sensors bracketing the bioreactor, 
AIDO concentrations were measured by 19F NMR, and the β-NTP/Pi integral ratio was 
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determined by 31P NMR.  Such changes in the DO concentration at the surface of 
implanted beads could occur in vivo due to normal DO fluctuations or from an induced 
fibrotic response to the tissue substitute – each of these two scenarios were noted during 
the in vivo study in CHAPTER 4.   In this study, beads were cultured in an incubator for 
one week prior, since such encapsulated cell systems potentially have more pronounced 
DO gradients due to a net increase in viable cell number from the time of encapsulation 
and may more closely represent the type of bead that would be implanted.  Additionally, 
the more pronounced DO gradients of beads cultured for longer periods may make the 
higher viable cell number within such beads more susceptible to hypoxic environments 
compared to freshly encapsulated βTC-tet cells that have relatively shallow DO gradients 
from the bead periphery to the center [148] (CHAPTER 3).  However, upon measuring 
the OCR and the AIDO of the encapsulated cells, it was noted that over the one week of 
culture only a minimal net cell growth had occurred within the beads.  Indeed, the initial 
encapsulation cell density was 7 x 107 cells/ml and both OCR and AIDO measurements 
estimated the starting cell density to be approximately 8 x 107 cells/ml.  In addition, over 
the 55 hours of the study, little change was observed in the cell density.  This minimal net 
cell growth over the one week of culture and during the 55 hours of the study was 
unexpected, as encapsulated βTC-tet cells in CHAPTER 4 almost doubled in 4 days.  
However, the purpose of this experiment was not to evaluate the underlying cause of the 
behavior of the encapsulated cells, rather to use the measurements and the model to track 
the system, and in this the objectives of the experiment were met.  In particular, OCR, 
AIDO and the β-NTP/Pi integral ratio were tracked non-invasively, and the mathematical 
model was in general agreement with experimental results.  An exception was the 
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deviation of AIDO and OCR measurements from the β-NTP/Pi integral ratio during the 
DOin incline.  However, this lag in β-NTP changes compared to changes in OCR has 
been shown previously in studies of hypoxia on βTC3 cells by Papas et al. [9, 15].  
 The second study performed in this CHAPTER investigated the ability of the 
AIDO measurement and the mathematical model to detect a net loss of viable βTC-tet 
cells within an encapsulated cell system.  The study was designed to mimic an in vivo 
immune cytokine attack against an implanted pancreatic substitute.  Such an 
immunological attack has been noted by Safley et al [149], where increased amounts of 
inteleukin-5 (IL-5), IL-12, TGF-β, and IL-1β were found within the peritoneal cavity of 
mice after encapsulated islets were transplanted to this site. Mimicking such an immune 
response was accomplished by the addition of puromycin to the perfusing medium.  Prior 
to the addition of the puromycin, baseline values for the OCR, AIDO, and β-NTP/Pi 
integral were acquired by DO sensors bracketing the bioreactor, 19F and 31P NMR, 
respectively.  Within a few hours after the addition of puromycin, the OCR began to 
decrease and the AIDO increased, approaching that of the external DO concentration.  
Both of these changes indicated a loss in cell number and thus demonstrated the ability of 
the AIDO to detect a loss in viable cell number.   
 In summary, the combination of 19F NMR measured average intrabead DO 
concentrations and a mathematical model was capable of estimating the cell densities 
within pancreatic substitutes during two in vitro conditions.  The in vitro conditions were 
designed to mimic changes in the DO concentration – due to either natural fluctuations or 
an inflammatory response – and a cytotoxic immune response – due to a biocompatibility 
issue with a pancreatic substitute.  Given the validation provided in this CHAPTER, it is 
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likely that the methodology of using 19F NMR to measure AIDO, enabled by the 










EFFECT OF PFC EMULSIONS ON ENCAPSULATED CELLS 
 
6.1  Abstract 
 
 Perfluorocarbon (PFC) emulsions have been indicated to improve oxygenation 
within tissue substitutes and consequently increase cell viability and function.  In this 
paper, we investigated the effect of PFC emulsions on encapsulated βTC-tet cells both 
experimentally and through mathematical simulations.  In the experiment, βTC-tet cells 
were encapsulated in alginate beads that contained 0%, 5%, or 10% v/v PFC emulsion.  
The viability and insulin secretion rates (ISR) of these cells were assessed during 16 days 
of culture.  In these studies, the addition of PFC emulsions to the alginate beads had no 
effect on viability or rate of insulin secretion of the cells.  These findings were 
corroborated through simulations by a mathematical model that was developed.  
Additional simulations that investigated the effect that PFC emulsions would have during 
constant hypoxia or transient hypoxic episodes were then performed.  These simulations 
found that indeed PFC emulsions do have the capacity to buffer encapsulated cells from 
hypoxic episodes, however, the effect on the viable cell density is only small and thus not 
expected to influence the function of the construct in a major way.  The implications of 
these findings, in regards to in vivo applications, are discussed. 
 
6.2  Introduction 
 
 Tissue engineered substitutes are designed to repair or replace the function of 
damaged tissue within the body [4].  The design often consists of cells, from an 
appropriate source (autologous, allogeneic, or xenogeneic), sequestered in a hydrogel 
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matrix (e.g. collagen, alginate, or agarose) that provides a three-dimensional architecture 
for maintenance of cell function and ease of handling.  For proper function, the construct 
must be designed to provide adequate nutrients and oxygen to all the cells within.  
However, a problem that has been a challenge in the design of tissue engineered 
substitutes, is the inability to effectively oxygenate tissues or cell-constructs greater than 
several hundred microns in size due to the low solubility of oxygen in medium [17, 38, 
148, 150-152].  Thus, a method that increases the amount of dissolved oxygen (DO) by 
either increasing the solubility of DO or by increasing the effective diffusivity of DO 
within a substitute is highly beneficial and desirable in tissue engineered constructs.   
 The unique properties of perfluorocarbon (PFC) emulsions have led investigators 
to explore their use in tissue engineered devices, in blood substitutes, and oxygen 
monitoring [33, 38, 43, 76, 77, 153-155].  Specifically, PFC emulsions are known to have 
an oxygen solubility that is 15-20 fold higher than that of water [35]; they are non-toxic 
[31, 102]; and the 1/T1 relaxation – a nuclear magnetic resonance parameter – correlates 
linearly with the surrounding DO concentrations [19, 20, 23].  Given the inherent high 
solubility of oxygen in PFC emulsions, several groups of researchers have studied the 
effect of incorporating these emulsions into perfusing medium and/or sequestering the 
emulsion directly into tissue engineered substitutes [33, 38, 102].  Radisic et al. [38] 
demonstrated through experimentation and a mathematical model that adding the PFC 
emulsion, Oxygent, to medium perfusing a parallel plate cardiac bioreactor increases the 
DO concentration throughout the bioreactor and consequently supports a greater density 
of cardiomyocytes.  It should be noted that in the study by Radisic et al., the medium DO 
concentration entering the bioreactor was kept constant at 160 Torr using a gas 
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exchanger, thereby reloading PFC emulsions with oxygen after each pass through the 
bioreactor.    In a study by Khattak et al. [33], the presence of sequestered PFC emulsions 
in alginate capsules caused an enhanced proliferation of HepG2 cells compared to beads 
without PFC over two weeks.  Additionally, improved metabolic activity of the HepG2 
cells was also demonstrated at the physiologically relevant DO concentration of 20% air 
saturation.   
In organ transplantation, PFCs have been used to increase organ preservation 
times.  Specifically, the development of the two-layer method, in which a pancreas is 
suspended between oxygenated PFCs and University of Washington (UW) solution, 
increased the preservation of canine pancreata from up to 24 hours to up to 96 hours [84].  
Additionally, the use of PFCs has been shown to improve survival of pancreata after 
transplantation and to increase the yield of purified islets [37, 39, 40].  Without the 
addition of PFCs, a 50% to 75% early graft loss is typically observed upon intraportal 
islet engraftment [156].  It is believed that a major contributing factor to the graft loss is 
the hypoxic environment experienced by the islets, as there is no immediate 
revascularization [157].  A recent study showed that intraperitoneal injection of PFCs 
after intraportal islet transplantation in rats increased the success rate from 1/6 to 5/6 
[40]; thus, it is reasonable to assume that the incorporation of PFCs transiently buffered 
the islets from the hypoxic episode.  Bergert et al [87], further characterized of the effect 
of PFCs on cultured islets, assessing parameters such as cell death, apoptosis, mRNA 
levels of insulin, insulin content and stimulated insulin secretion.  The results of this 
detailed study indicated that the two-layer method, despite having significant benefit in 
transportation and relatively no effect on numerous other islet parameters, compromised 
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stimulated islet insulin secretion in the presence of PFCs [87].  Thus, it is essential that 
the effect of PFCs on the viability and, perhaps, more importantly the stimulated insulin 
secretion of cells be evaluated prior to implementation in a pancreatic substitute.  
 In this Chapter, we study the effect of an alginate encapsulated PFC emulsion, 
perfluorotributylamine, on the viability and function βTC-tet cells sequestered in alginate 
beads.  Over the 16 day study, cell viability was assessed by alamarBlue®, a metabolic 
indicator, while function was monitored by stimulated insulin secretion tests every four 
days.  A mathematical model of the alginate-PFC-cell system was developed and 
simulations are compared with the experimentally acquired data.  The model was also 
used to simulate the effect of having a PFC emulsion sequestered in a pancreatic 
substitute subjected to a constant, moderately hypoxic DO concentration of 0.04 mM, as 
well as switched from incubator conditions (DO of 0.20 mM) to a severely hypoxic 
environment (0.01 mM), and then to moderately hypoxic conditions (0.04 mM).  The 
implications of the modeling results and the potential uses for the model are discussed.   
 
6.3  Materials and Methods 
 
6.3.1  PFTBA Effect on Encapsulated Cells 
6.3.1.1  Cells and Cell Encapsulation 
βTC-tet cells [67] were obtained from the laboratory of Shimon Efrat, Albert 
Einstein College of Medicine, Bronx, NY.  Cells were cultured as monolayers in T-flasks 
with culture medium changed every 2-3 days. Culture medium consisted of Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma Chemical Co., St. Louis MO) with 25 mM 
glucose, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and L-
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glutamine to a final concentration of 6 mM.  Cell monolayers that reached 80% to 90% 
confluence were trypsinized with 0.05% trypsin-EDTA (Sigma) and split at a 1:5 ratio; 
passage number increased by one at each splitting.  Cells of passage number 36-40 were 
used in this study.   
Cells were harvested by trypsin-EDTA and encapsulated at a density of 3.5x107 
cells/ml alginate in 2% w/v low viscosity high mannuronic content alginate (product 
LVM, NovaMatrix, Drammen, Norway) containing the appropriate concentration of 
PFTBA emulsion (0%, 5%, or 10% v/v) (see below).  Using an electrostatic droplet 
generator (Nisco Engineering Inc., Zurich, Switzerland), cells were encapsulated 
according to the procedure of Stabler et al [51], except that a PLL and a final alginate 
layer were not added.  The final bead size was 900±42 µm in diameter. 
The PFTBA was prepared following a protocol adapted from Joseph et al [23] and 
previously described by Gross et al [43] (CHAPTER 4). 
Alginate encapsulated βTC-tet cells were placed into T-75 flasks and cultured on 
a rocking platform in a 37°C, 5% CO2 incubator.  The medium was replaced every 2-3 
days for the duration of the study. 
6.3.1.2  Viability Assessment – AlamarBlue 
On Days 1, 4, 8, 12, and 16 after encapsulation, three 0.1 ml samples were taken 
from the control and PFC groups. The beads were placed in the wells of a 24-well plate 
and mixed with 1 ml of medium and 0.1 ml of alamarBlue® reagent (Invitrogen Corp, 
Carlsbad, CA).  The samples were placed on a rocking platform located in a 37°C 
incubator with 5% CO2 for 2.5 hours.  After the incubation, a 0.1 ml medium sample was 
taken from each well and quantified with a Spectra Max Gemini Plate Reader (Molecular 
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Devices, Sunnyvale, CA) using an excitation wavelength of 544 nm and an emission 
wavelength of 590 nm.  Relative intensity units (RIUs) were normalized to the RIUs of 
the Day 1 control sample and to the aqueous bead volume. 
6.3.1.3  Insulin Secretion Assessment 
On Days 4, 8, 12, and 16 after encapsulation, three 0.1 ml samples were taken 
from the control and PFC groups.  The beads placed into 6-well dishes, washed twice 
with 4 ml of 0 mM glucose DMEM, and incubated in 4 ml of unsupplemented, 0 mM 
glucose DMEM on a rocking platform at 37°C.  After one hour, the 0 mM glucose 
DMEM was replaced with 3 ml of 16 mM glucose DMEM and incubated on a rocking 
platform at 37°C for 20 min.  At the start and end of the 20 min, 0.3 ml medium samples 
were acquired and frozen for later assay of insulin.  Insulin in collected samples was 
assayed by rat insulin radioimmunoassay (Linco Research, St Charles, MI). 
6.3.2  Statistical Analysis 
 Viability and insulin secretion results were evaluated using a two tail t-test.  
Statistical significance was defined as p<0.05. 
 
 
6.4  Mathematical Model and Assumptions 
 
 The assumptions used to build the model are listed below.  These are based on a 
previously developed mathematical model [148] (CHAPTER 3) with some additional 
assumptions to accommodate the incorporation of a perfluorocarbon emulsion. 
1. DO is the only nutrient that limits cell proliferation (ie, all other essential nutrients 
are assumed to be in excess throughout the construct) 
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2. Spatial constraints are the only other factor besides DO concentration that limits 
the rate and extent of cell proliferation within the construct. 
3. Cells do not migrate within the matrix, hence the observed remodeling in cell 
distribution is due entirely to cellular growth and death at each locale. 
4. The PFC emulsion is homogeneously distributed through the alginate matrix. 
5. Equilibration of dissolved oxygen between the aqueous and PFC phases at each 
locale is instantaneous.   
6. The values of the model parameters, including the effective diffusivity of DO 
through the encapsulated system, remain constant over the time period of the 
simulations. 
7. The concentration gradient within the aqueous phase is the only driving force for 
oxygen diffusion (Figure 6.1). 
8. There is no external boundary layer effect when modeling the beads placed on a 
rocking platform, as performed in this paper.  This is a reasonable assumption for 
systems in which there is significant velocity of the medium relative to the surface 
of the beads.  
The model equations describing DO diffusion for spherical geometry are as follows (see 
also Figure 6.1). 
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where, t is time and r is radial position in the construct; CT(r,t), Caq(r,t), and Cp(r,t) are 
the concentrations of dissolved oxygen in the total volume (VT), aqueous phase (Vaq), and 
PFC phase (Vp) volume, respectively, as functions of radial position and time;  Deff is the 
effective oxygen diffusivity through the alginate/PFC matrix; VT, Vaq, and Vp are the total, 
aqueous, and PFC volume; S(r,t) is the rate of oxygen consumption per unit volume of 
aqueous phase as a function of radial position and time, which is based on a Monod 
model with kinetic parameters νmax (maximum oxygen consumption rate) and Km (Monod 
model parameters);  X(r,t) is the cell density as a function of radial position and time.  













The effective diffusivity was calculated using the equation given by Radisic et al. [38], 
























=γ           (5) 
Daq and Dp are the diffusivities of oxygen through alginate-only and PFC; K is the 
partition coefficient of oxygen in PFC vs. the aqueous phase; φ is the volume fraction of 
the PFC emulsion (Vp/VT). 
 The equations used for determining the growth and death of cells radially through 
the alginate matrix over time are the same as reported in Gross et al [148] (CHAPTER 3) 









Figure 6.1   Schematic illustrating the method used to solve the DO concentration profile.  
In solving for the total (aqueous plus PFC phases) DO concentration (CT) at compartment 
‘0’, diffusional transport occurs by the DO concentration differences in the aqueous phase 
(Caq) between compartment ‘0’ and the neighboring compartments.  Additionally, the DO 
in the PFC and aqueous phase are always in equilibrium based on the partition coefficient.  
S(r) is the oxygen consumption rate by the cells per unit volume of aqueous phase, as 
described in Equation 3. 
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( )dgaqaq μμ(r,t) Xdt
(r,t)dX
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    1
max
















=             (7)   (Monod’s model with kinetic 









−−= minmaxmax     (8)   (modified Monod’s model maximizing 
the cell death rate at C=0 and minimizing it 
at C>>Kd) 
In the above equations, μg and μd are the specific cell growth and death rates, 
respectively; μg,max and μd,max are the maximum specific growth and death rates, 
respectively; μd,min is the minimum death rate, which prevails under an abundance of 
oxygen; Kg and Kd are Monod model parameters; and Xmax in the maximum cell density 
that can be accommodated in the construct.  The ratio X/Xmax is thus the fractional 
maximum occupancy at a particular locale in the construct. 
6.4.1   Boundary Conditions  
otaq CC ==0       (9) (the initial concentration of oxygen is constant throughout the 
spherical construct and known) 
otaq XX ==0      (10) (the cells are initially distributed homogeneously throughout the 








     (11) (symmetry condition for oxygen concentration at the center of the 
sphere) 
Mathematical simulations of alginate encapsulated cells with an infinite volume outside 
the bead – e.g. simulating beads in T-flasks in a large volume of medium on a rocking 
platform – used Equation 12.  To simulate conditions in which encapsulated cells are 
placed into a finite volume (e.g. beads implanted into a confined space in vivo), Equation 
13 was used. 
bRraq CC ==             (12)   (the concentration of oxygen at the surface of the construct is 














   (13)  (the change in oxygen concentration in the surrounding 
medium is dependent on the flux of oxygen in/out across the bead 
surface) 
 
6.4.2  Baseline Parameters 
 Parameters used in the simulations were obtained from Gross et al [148] 
(CHAPTER 3).  In addition, the diffusivity of oxygen in perfluorotributylamine (Dp) is 
2.59 cm2/day [158] and the partition coefficient for oxygen in the PFC phase vs. the 
aqueous phase (K) is 16 [34, 35]. 
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6.5  Results 
6.5.1  PFC Effect on Cell Viability 
 The viability of alginate encapsulated βTC-tet cells with 0%, 5%, or 10% v/v PFC 
emulsion was assessed by the metabolic indicator alamarBlue® (Figure 6.2).  The data 
were normalized to the aqueous volume of the alginate beads, as this is the volume in 
which cells reside, and to Day 1 control beads (0% PFC emulsion), which was set at 100.  
On Day 1, the cell number within the aqueous phase of the three alginate bead types was 
approximately equal, as they were encapsulated at the same initial cell density.  Four days 
after encapsulation, beads containing PFC emulsion tended have a slightly higher viable 
cell number in a concentration dependent manner with 5% PFC beads increasing by 10% 
and 10% PFC beads increasing by 20%, while beads containing no PFC showed only a 
small reduction.  On day 8, a statistically significant increase in viable cell number was 
observed in the 10% PFC beads compared to day 1.  However, the average viable cell 
density among the three bead types on day 8 remained was statistically significant.  From 
day 8 to 12 in the study a decrease in viable cell number was observed, which was 
statistically significant (p<0.05) in beads with 10% PFC emulsion.  Again, there was no 
















Figure 6.2  Change in number of metabolically active cells within the aqueous phase 
















































































































6.5.2  PFC Effect on Stimulated Insulin Secretion 
 The stimulated insulin secretion rates (ISRs) of the encapsulated βTC-tet cells 
(normalized to Day 1 cell numbers) are given in Figure 6.3.  On Day 4, the three groups 
of beads all secreted insulin at approximately 215 pmole/(hr•108cells).  By Day 8, the 
alginate beads containing 10% v/v PFC emulsion had statistically significant (p<0.05) 
lower ISR (148±9 pmole/(hr•108cells)) compared to the 0% (261±46 pmole/(hr•108cells)) 
and 5% (254±15 pmole/(hr•108cells)) PFC beads.  However, this difference was not 
observed for the remainder of the study, as all beads increased to a secretion rate between 
656 and 731 pmole/(hr•108cells) on Day 12.  This increase on Day 12 was statistically 
significant compared to Day 8 in all three beads (p<0.05).  On the last day (Day 16), the 
ISR of the three bead types decreased to approximately 400 pmole/(hr•108cells).  


























Figure 6.3  Stimulated insulin secretion rates of alginate 
encapsulated βTC-tet cells containing 0%, 5%, or 10% PFC 



















































6.5.3  Mathematical Simulation – Incubator Conditions (DO of 0.20 mM) 
The changes in average intrabead DO (AIDO) concentration in the aqueous phase 
and in cell density (normalized to the aqueous volume fraction within a bead) were 
simulated for 16 days (Figure 6.4, A and B, respectively), using the parameters listed in 
Table 3.1 of CHAPTER 3 and the PFC parameters given in Section 6.4.2.  The effective 
diffusivities for the no PFC, 5%, and 10% PFC beads were calculated (Equation 4) to be 
1.4, 1.6, and 1.8 cm2/day, respectively.  Due to the increased effective diffusivity, the 
AIDO concentrations in the three simulated beads started at different values – 0.179, 
0.180, and 0.181 mM, respectively (Figure 6.4 A).  As the cell density increased within 
the beads, the AIDO dropped accordingly, since more cells increase the total oxygen 
consumption within the bead.  However, the decrease in AIDO was less severe in beads 
containing 5% and 10% PFC emulsion.  On day 16, the AIDO concentrations within the 
no PFC, 5% and 10% PFC beads were 0.075, 0.079, and 0.083 mM, respectively.   
The cell densities in the alginate beads start at 3.5x107 cells/ml.  It should be 
noted that when cell densities were calculated using the volume of the bead as a reference 
point, the beads containing PFC had lower cell densities than that of the bead with no 
PFC.  Over the initial 8 days, no significant difference was observed between the three 
bead types, each reaching 2.75 x 108 cells/ml (Figure 6.4 B).  From day 8 to 16, however, 
the cell densities within beads containing PFC departed from the no PFC beads.  The 
maximum difference was attained on day 16, when the 0% and 10% PFC beads had cell 













Figure 6.4  Simulated changes in the (A) average intrabead DO concentrations and (B) 
cell densities of alginate beads containing no PFC, 5%, and 10%  PFC emulsion.  The DO 
concentrations are values within the aqueous phase.  In addition, cell densities are 














































































6.5.4  Mathematical Simulations – Reduced and Transient DO Concentrations 
6.5.4.1  Reduced DO Concentration (0.04 mM) 
The benefit of incorporating PFC emulsions into encapsulated cells systems was 
explored under additional conditions that may be experienced by such systems upon in 
vivo implantation.  Figure 6.5, A and B, show simulated changes in AIDO concentrations 
and cell densities within alginate beads that are placed into a reduced oxygen 
environment (0.04 mM).  As in the previous simulations, increasing concentrations of 
PFC emulsion resulted in higher AIDOs at time 0, which ranged from 0.031 to 0.033 mM 
(Figure 6.5 A).  The difference between the AIDO concentrations remained fairly 
constant while the concentrations dropped due to increasing cell densities over the 16 
days.  The final AIDO concentrations were 0.0154, 0.0160, and 0.0165 mM for the 0%, 
5%, and 10% PFC beads, respectively.  Unlike the simulated incubator conditions in the 
previous section where cell density differences did not appear until after day 8, the 
simulated cell densities at the reduced DO concentration began to deviate depending on 
PFC concentration on day 4 (Figure 6.5 B).  Beads containing 10% PFC emulsion had the 
highest cell density at the end of 16 days, at 2.73 x 108 cells/ml, followed by 5% and 0% 












Figure 6.5  Simulated changes in the (A) average intrabead DO 
concentrations and (B) cell densities of alginate beads containing no PFC, 
5%, and 10%  PFC emulsion at a surrounding DO concentration of 0.04 
mM.  The DO concentrations are values within the aqueous phase.  In 














































































6.5.4.2  Transient DO Concentration – Infinite and Finite External Volumes 
6.5.4.2.1  Infinite Surrounding Medium Volume 
 The DO concentration surrounding encapsulated cells often changes dramatically 
upon in vivo implantation.  To determine if the incorporation of a PFC emulsion into an 
encapsulated cell system would aide in buffering cells from a hypoxic episode, a 
simulation was run in which the surrounding DO concentration was held at 0.20 mM for 
24 hours and subsequently decreased to 0.01 mM and then increased to 0.04 mM.  Figure 
6.6 A-C simulates the changes in the surrounding DO concentration, cell density, and the 
AIDO concentration upon implementing the change in surrounding DO concentration 
(i.e. after the 24 hour incubation at 0.20 mM), while assuming that the volume in which 
the bead resides is infinitely large.  As one would expect, the surrounding DO 
concentration (Figure 6.6 A) is unaffected by the diffusion of oxygen out of the bead 
upon a step down in the surrounding DO.  The AIDO concentration quickly drops in both 
the 0% and 10% PFC beads (Figure 6.6 B).  However, the incorporation of 10% PFC 
appeared to buffer the decrease slightly, which was expected given the higher oxygen 
concentrations within the PFC phase.  Upon increasing the surrounding DO concentration 
to 0.04 mM, the AIDO concentration within both beads increased at the same rate with 
the 10% PFC beads reaching a slightly higher end value of 0.030 mM versus the 0% PFC 
beads that ended at 0.028 mM.  A decrease in the cell density was observed shortly after 
lowering the surrounding DO concentration in the 0% and 10% PFC beads (Figure 6.6 
C), which paralleled the decrease in AIDOs in the respective beads.  Nonetheless, the cell 










Figure 6.6  The simulated changes to beads containing no PFC and 10% PFC 
emulsion upon (A) changing the DO concentration surrounding such beads 
from 0.20 to 0.01 to 0.04 mM and assuming an infinite surrounding volume.  





















































































































6.5.4.2.2  Finite Surrounding Medium Volume 
 The change in surrounding DO concentration, AIDO, and cell density was 
simulated as described above with the exception that the volume in which the bead 
resided was only twice as large as the bead (Figure 6.7 A-C).  Again, at time equals zero, 
the DO concentration was switched from 0.20 to 0.01 mM in the surrounding volume.  
The diffusion of oxygen out of the bead and into the surrounding volume is observed in 
Figure 6.7 A.  Specifically, the DO concentration quickly rises from 0.01 to 0.057 mM in 
beads containing 0% PFC and from 0.01 to 0.10 mM in beads containing 10% PFC.  The 
point of inflection in the surrounding DO concentration – i.e., where the DO 
concentration changes from a positive to a negative slope – corresponds to the time at 
which the AIDO concentration (Figure 6.7 B) drops below that of the surrounding DO 
concentration.  The change of oxygen diffusion direction is due to the oxygen 
consumption of the cells within the bead; hence, the surrounding DO concentration 
continues to decrease until reaching the imposed lower limit of 0.01 mM.  Upon 
increasing the surrounding DO concentration to 0.04 mM, the AIDO concentration in 
both bead types increases likewise and again, the 10% PFC bead reaches a slightly 
elevated concentration compared to the 0% PFC bead (0.30 and 0.28 mM, respectively).  
The ability of the 10% PFC bead to buffer the AIDO during the decreased surrounding 
DO concentration had the added benefit of minimizing cell death within the bead and 








Figure 6.7  The simulated changes to beads containing no PFC and 
10% PFC emulsion upon (A) changing the DO concentration 
surrounding such beads from 0.20 to 0.01 to 0.04 mM and assuming 
a surrounding volume two fold greater than the bead volume.  (B)  
Changes in the average intrabead DO concentration.  (C) Changes in 





















































































































6.6  Discussion 
 The incorporation of perfluorocarbon (PFC) emulsions into tissue engineered 
substitutes has garnered the interest of researchers that face the difficult challenge of 
maintaining sufficiently high DO concentrations within tissue substitutes – either due to 
large diffusion distances or high cell densities.  PFC emulsions have an oxygen solubility 
that is 16-20 fold higher than that of water; thus, they can act as a large oxygen reservoir 
within tissue engineered devices.  In addition, the incorporation of PFC emulsions holds 
the added benefit of increasing the diffusivity of oxygen through the matrix.  This 
Chapter investigated the benefit of sequestering the PFC emulsions 
perfluorotributylamine (PFTBA) into pancreatic substitutes through experimentation and 
mathematical modeling.  As a model system, βTC-tet cells were encapsulated into an 
alginate hydrogel that contained 0%, 5%, or 10% v/v PFC emulsion.  Over the course of 
16 days, the cell viability and the stimulated insulin secretion were assessed in beads to 
determine if the incorporation of PFCs enhanced viability or function.  In the second 
portion of this paper, a mathematical model was then used to simulate the growth of cells 
within such an encapsulated cell system under various conditions that mimicked both in 
vitro and in vivo environments. 
 The first study found that there was no statistical difference in βTC-tet cell growth 
when PFTBA was added to the alginate beads.  During the first eight days, it appeared as 
though the beads containing PFC emulsion had a slight enhancement over beads that did 
not have PFC.  However, this difference was not statistically significant and by day 12, 
the difference had waned.  This finding is unlike an earlier publication by Khattak et al 
[33] where a statistically significant increase in cell growth was observed in a HepG2 
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alginate encapsulated system that incorporated 10% perfluorooctylbromide (PFOB).  The 
difference in observations could be due to the use of two different PFCs, as PFOB has a 
higher oxygen solubility than PFTBA (44.0 vs. 35.2 mM, at standard temperature and 
pressure [35]).  In addition, the higher oxygen partition coefficient of PFOB would 
increase the effective diffusivity of oxygen through the alginate matrix to a level slightly 
beyond that of PFTBA (1.788 vs. 1.780 cm2/day, respectively).  However, the difference 
made by such a small change in the effective diffusivity would not significantly change 
the simulations presented here. 
The stimulated insulin secretion from the βTC-tet cells within the three bead types 
also showed no advantage through the incorporation of PFC emulsion.  If there was any 
effect, the PFCs were detriment to the insulin secretion.  This finding is consistent with 
that of Bergert et al [87], in which the insulin secretion of islets was compromised after 
being cultured by the two-layer method (TLM), which consists of placing islets at the 
interface between University of Washington solution and PFC.  Specifically, Bergert et al 
found that the stimulation index (relation between the fraction of total insulin secreted 
after stimulation vs. the fraction of total insulin secreted at basal conditions) was 
approximately 55% of control (no PFC) on day 1 and 38% of the control on day 7 [87] 
after TLM.  However, a study by Brandhorst  et al [88] found that there was no statistical 
difference in the stimulation index if islets were cultured by a one-layer method of PFC 
(i.e. islets were completely submerged in PFC).  Given this variability, further 
investigation is needed as to the effect of PFCs on insulin-secreting cells. 
In the second portion of this paper, a mathematical model that was capable of 
simulating changes in cell growth based on the incorporation of PFC emulsions was used 
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to investigate several in vitro and in vivo environments.  The first study simulated the 
experiment performed in this paper, in which beads were cultured at a DO concentration 
of 0.20 mM with 0%, 5%, or 10% v/v PFC emulsion added to the matrix.  During the 
simulated initial 8 days, there was no discernable difference in cell densities between the 
various bead types.  This was expected since beads that have a low initial cell density do 
not create large DO concentration gradients, which would inhibit cellular growth at the 
center of such beads where DO levels are the lowest.  From day 8 to 16, the cell densities 
in the PFC containing beads increased slightly above that of beads with no PFC.  
Nevertheless, the difference was very slight and would be difficult to discern 
experimentally.  In addition, the slight benefit only remained as long as cell densities 
were normalized to the aqueous volume phase of the beads.  If cell densities were 
normalized to the bead volume, beads containing PFC would have lower cell densities 
than beads that had no PFC, since a portion of the bead volume is taken by the PFC 
phase.  
There are several conditions or environments in which one could imagine the 
incorporation of PFC emulsions would have an added benefit in maintaining viable cells 
within encapsulated cell systems.  One such condition that was simulated using the 
mathematical model is beads placed in a more hypoxic oxygen environment.  Beads 
cultured with 10% PFC emulsion at a constant DO concentration of 0.04 mM indeed 
maintained a somewhat higher viable cell density than beads that had no PFC, due to the 
increased average intrabead DO concentration within these beads.  
To determine if the incorporation of PFC emulsions buffers encapsulated cells 
from hypoxic episodes, the model was used to simulate beads that had been cultured for 
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24 hrs at 0.20 mM, subsequently placed into a hypoxic environment (0.01 mM) for 12 
min and finally returned to a moderately hypoxic DO concentration of 0.04 mM.  This 
study of transient DO concentrations was first simulated assuming that the volume 
surrounding the bead was infinite and then assuming that the volume was of a finite size 
– specifically, 2 fold greater than the bead volume.  In the simulation that assumed an 
infinite surrounding volume, the incorporation of the PFC emulsion offered only a very 
small buffer, as the 10% PFC bead AIDO reached the final value approximately 45 
seconds after the bead without PFC.  However, upon simulating the change in AIDO 
when beads were assumed to be within a finite volume, a greater buffering capacity of the 
PFC was noted.  Specifically, the 10% PFC bead AIDO took 3 minutes longer than the 
bead without PFC to reach the final DO concentration.  The buffering capacity of the 
10% PFC beads was due to the increase in the surrounding DO concentration that 
resulted from oxygen leaving the alginate/PFC beads and diffusing into the surrounding 
volume. 
 In summary, the addition of PFC emulsions to pancreatic substitutes that 
consisted of βTC-tet cell entrapped in alginate did not have a statistically significant 
benefit to cell growth, nor did it show a benefit to the stimulated insulin-secretion.  This 
finding was supported by mathematical simulations that noted only a small increase in 
cell density due to the incorporation of PFC.  An investigation of additional scenarios 
revealed through mathematical simulations that PFC emulsions indeed are beneficial at 
low oxygen concentrations and provide a slight buffering effect from hypoxic episodes.  
Additional studies investigating the use of other PFC emulsions and various DO 
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concentrations are needed to fully characterize the benefit of incorporating PFCs into 








CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1  Conclusions 
Dissolved oxygen concentrations within a pancreatic substitute influence the 
viability and function of insulin-secreting cells.  In this thesis, we have contributed to the 
field by developing a method that is capable of assessing the oxygenation of a tissue 
engineered construct non-invasively, which additionally could be used to evaluate viable 
cell number, DO and cell density profiles, and potentially the mode of an implant failure.  
A major limitation to assessing the DO concentrations within a construct containing a 
continuous cell line was that the DO profiles changed over time as the cells proliferated 
and remodeled.  In vitro this limitation could be overcome by using chemical shift 
imaging; however, the long acquisition times associated with such methods are 
problematic upon moving to an in vivo model.  In Chapter 3, this caveat was 
circumvented by the development of a mathematical model that simulated the changes in 
cell density and DO concentrations within an alginate bead construct.  Simulations using 
the model revealed that one could acquire a single average intrabead DO (AIDO) 
concentration measurement and uniquely identify the viable cell number, as well as cell 
density and oxygen distribution at a given external DO.  Indeed, at a certain DO 
concentration, this relationship was maintained regardless of the initial cell density. 
In the second part of this thesis, the ability to track a pancreatic substitute using 
the mathematical model along with NMR measurements was demonstrated.  During these 
studies, a custom built computer controlled NMR-compatible perfusion system and 
bioreactor maintained alginate encapsulated βTC-tet cells for 50 hours, over which the 
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DO concentration was changed stepwise from 0.20 to 0.05 mM and returned to 0.20 mM.  
The temporal changes in the medium DO concentration caused typical bioenergetic and 
metabolic changes in the sequestered cells; specifically, hypoxic DO concentrations 
caused a reduction in nucleotide triphosphates (NTPs) and oxygen consumption.  AIDO 
concentrations acquired during the experiment were then compared against simulations 
based on the external DO concentration and time.  The observed changes in both the 
experimentally acquired and simulated AIDOs closely matched.  Additionally, the 
experimentally observed reduction in NTP paralleled the percentage of cells calculated 
by the model to be below a critical DO concentration value.  From this validation we 
concluded that the mathematical model was indeed able to track a pancreatic substitute 
over time in vitro. 
Chapter 5 investigated the mathematical model and AIDO measurements as an 
evaluation tool, assessing viable cell number under two conditions that often occur in 
vivo. The ability to monitor constructs non-invasively in vivo can provide valuable 
information regarding the effect of construct integration and the biocompatibility of a 
substitute.  The activation of an inflammatory response or cytokine attack by the host 
immune system are two typical issues relating to an implanted tissue substitute.  In 
Chapter 5, these two in vivo scenarios were simulated in vitro by the NMR perfusion 
circuit and bioreactor.  The inflammatory response was mimicked via changes in the 
medium DO concentration entering the bioreactor.  During this study, the estimated cell 
density was tracked using the measured AIDO, the external DO concentration and the 
mathematical model developed in CHAPTER 3.  To mimic a cytokine attack, a cytotoxic 
dose of puromycin was added to perfusing medium.  Again, the estimated cell density 
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was tracked using the AIDO, surrounding DO concentration, and the mathematical 
model.  Estimated cell densities during both scenarios paralleled the cell density 
estimated by oxygen consumption rates that were acquired by bracketing DO sensors.  
Again, it should be noted that upon in vivo implantation, DO sensors cannot be used to 
measure OCRs, but the AIDO and surrounding DO concentrations could be acquired.  
From these studies, we concluded that the AIDO and external DO concentration 
measurements would indeed allow the tracking of cell densities during an inflammatory 
response or cytokine attack and could distinguish between these two modes of implant 
failure. 
Bridging the gap from employing the monitoring method in vitro to utilization in 
vivo was the development of a novel dual-PFC system that could be used to acquire 
simultaneous DO concentrations from two distinct bead populations.  Such a system was 
needed, as the mathematical model developed in CHAPTER 3 requires that both the 
AIDO and external DO concentrations be known.  The dual-PFC system was 
demonstrated by incorporating perfluoro-15-crown-5-ether (PFCE) emulsion into cell-
free alginate beads and perfluorotributylamine (PFTBA) emulsion into cell-free 
alginate/poly-l-lysine (AP) beads.  Implanted into the peritoneal cavity of mice, the AP 
beads elicited a strong inflammatory response, while no observable response was seen 
against alginate-only beads.  Given the fibrotic layer surrounding AP beads, it was 
expected that the DO concentration would be lower in these beads compared to beads 
with no fibrosis.  Indeed, through the acquisition of T1 relaxation measurements from 
PFCE and the PFTBA, a statistically significant lower DO concentration was quantified 
in AP beads versus alginate-only beads.  Therefore, we have developed a system of 
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acquiring DO concentrations from two distinct constructs simultaneously, meeting the 
requirements of the mathematical model in vivo.  Additionally, the dual PFC system has 
further reaching applicability in tissue engineering, as researchers studying 
biocompatibility of new materials could use the system to assess the degree to which a 
material elicits an inflammatory response. 
As reported in APPENDIX I, the low concentrations of PFTBA used in the 
monitoring studies had no impact on cell viability or function.  Additionally, we showed 
that there was no detectable leak of the PFC emulsion from the alginate beads after 5 
days of perfusion and that the T1 relaxation rates changed rapidly in response to changes 
in surrounding DO concentrations.  In the final portion of this thesis, the effect of 
incorporating higher concentrations of PFCs on the viability and function of encapsulated 
βTC-tet cells was evaluated (experimentally and through modeling), as increasing 
concentrations could have an effect on the oxygen buffering capacity and diffusivities.  
We found that incorporating PFC emulsions up to 10% v/v in alginate beads did not 
increase the viable cell number nor did it have any effect on stimulated insulin secretion 
of βTC-tet cells.  This was corroborated by a mathematical model we developed that 
simulated the increased oxygenation within a substitute of spherical geometry that had a 
PFC emulsion incorporated.  From the model we concluded that a slight benefit in cell 
proliferation occurs when incubator DO concentrations (0.20 mM) are used.  However, 
the benefit is small and would be challenging to distinguish experimentally.  It should 
also be noted that the total number of viable cells within a bead that contained PFC 
emulsion was lower than beads that did not contain PFC, which was due to the reduced 
aqueous volume fraction that cells could occupy.   Additional mathematical simulations 
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found that PFCs incorporated into alginate beads provided an oxygen buffering capacity 
when the DO concentration in the external environment decreased rapidly to hypoxic 
levels.  We concluded that such a capacity may be beneficial to pancreatic substitutes 
upon in vivo implantation, as such transient hypoxic episodes have been noted in the 
literature [157].   It was also found experimentally that the addition of PFC emulsions had 
no impact on cell function, as the insulin secretion rates of the β cell line in PFC-
containing beads were comparable to the PFC-free control. 
 
7.2  Future Directions 
7.2.1  Pancreatic Substitute Tracking Studies 
The foundation of using a mathematical model and 19F NMR to track βTC-tet 
cells encapsulated in alginate beads has been established by this thesis.  To further 
develop this method, improvements that could be made have been broken down into the 
following five areas:  (1) validation of the mathematical model, (2) tracking of pancreatic 
substitutes in vitro, (3) improvements to the NMR-compatible perfusion system, (4) 
move to in vivo monitoring, and (5) expanding to additional cell lines and geometries.  
These improvements are discussed in further detail below. 
The NMR magnet used in this thesis studies to develop the tracking system did 
not have spatial gradients and for this reason, the DO concentration profiles created 
within the alginate beads could not be discerned directly.  This forced the use of more 
indirect methods to validate the model.  Therefore, a more robust model validation could 
be obtained through the use of an NMR magnet with such gradients.  Specifically, 
gradients would be used to perform 19F NMR chemical shift imaging, which would 
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quantify the DO concentrations at distinct voxels within the alginate beads, allowing 
reconstruction of DO profiles.  The DO profile reconstruction would have to be 
performed while the DO concentration external to the beads was held constant.  In 
addition, the viable cell number could be ascertained through 1H NMR spectroscopy, 
which has been demonstrated previously by Stabler et al. [112, 113], where the total-
choline peak was shown to correlate with the number of viable cells.  Utilizing the 
combined measurements of DO concentration profiles and viable cell number, enhanced 
correlations could be made to the model.  Additionally, such studies would provide a 
greater understanding of the alginate bead microenvironment. 
Improvements to the system of tracking pancreatic substitutes in vitro could be 
accomplished by studying the insulin secretion rates of the encapsulated cells and 
investigating the substitutes at a lower, more physiologic, range of DO concentrations.  
By comparing the 1H NMR and AIDO measurements with the function (insulin secretion) 
of the pancreatic substitute, a more thorough understanding could be attained as to the 
effect of DO gradients on insulin secretion characteristics.  In regards to studies at lower 
oxygen concentrations, a study of cell viability and function at DO concentrations below 
0.04 mM (the lowest DO concentration used in this thesis) is warranted, as studies by 
Gross et al. [43] and Noth et al. [24] found the DO concentration within the peritoneal 
cavity of mice and rats, respectively, in the 0 to 0.04 mM range.  In these studies, 1H 
NMR spectroscopy could be used as described above to determine viable cell number and 
compared with AIDO predicted oxygen gradients.  This comparison would be useful in 
determining the number of cells that are in hypoxic regions of the substitute and 
consequently have switched to a more anaerobic metabolism.  Adding to a more complete 
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picture, 13C NMR studies could also be implemented to assess metabolic pathways being 
used. 
The experiments described above would also require an NMR-compatible 
perfusion system that had several design improvements, as this system was designed 
specifically for the 500 MHz NMR magnet used in this thesis.  To accommodate a 
stronger NMR magnet that had gradients, distances from the medium reservoir to the 
bioreactor would have to be increased without compromising oxygen and temperature 
control of the system.  In addition to the changes made to the perfusion circuit’s 
specifications to accommodate a new magnet, the system must also be improved by 
increasing the range of control at low dissolved oxygen levels, as such a design change 
would enable the experiments proposed in the previous paragraph.  Currently, a 
concentration of 0.04 mM is the lowest DO concentration that can be attained by the 
present design.  System parameters such as choice of tubing, breaks in the perfusion loop, 
and distances between the medium reservoir and bioreactor have all been optimized and 
implemented in the current design; therefore, a perfusion system with the capacity of 
delivering a lower DO concentration would require the addition of a gas exchanger 
placed at the opening of the NMR bore.  Each of the changes mentioned above would 
impact the DO concentration proportional-integral controller parameters, as the increased 
distance would create additional lag times and a second gas exchanger would add a layer 
of complexity to the system.  Hence, reprogramming of the LabVIEW™ automation 
software would also be required. 
Another aspect for future study is the move from in vitro to in vivo development 
of the monitoring system.  To accomplish this objective, the dual PFC system that was 
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established in this thesis should be first investigated with encapsulated cells in vitro.  In 
these studies, the βTC-tet cells would be encapsulated in alginate beads containing 
PFTBA, while a second group of cell-free beads would be made containing PFCE.  A 
mixture of the two bead groups would be placed into the bioreactor and DO 
concentrations from each bead population would be acquired.  Proof-of-concept studies 
have been performed using this system, but a more detailed investigation is needed prior 
to in vivo implementation.  Upon establishing the method in vitro, cell-free and cell-
containing beads with the two PFC emulsions would then be implanted into the 
peritoneal cavity of mice and the ability to monitor these two bead populations would be 
assessed.  Once the system has been fully characterized and established, a study 
investigating the ability of the pancreatic substitute to maintain normoglycemia with 
measures of AIDO and the DO concentration within the peritoneal cavity could be 
performed. 
 Lastly, the monitoring methods developed in this thesis are general enough to be 
applied to other cell types and construct types and geometries.  Making the transition to 
new cell lines and construct materials would require a change of the baseline parameters 
and assumptions used to run the mathematical simulations, as well as additional 
validations studies.  New cell types would likely have different oxygen consumption 
rates, in addition to distinct grow and death kinetics.  Given that biomaterials used in 
tissue engineered devices have various characteristics in regard to permissiveness (i.e. the 
degree to which the material impedes cell growth) and the ability of cells to adhere, 
model assumptions in regards to cell migration and growth would need change.  
However, utilizing systems with permissive hydrogels similar to alginate in different 
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geometries would require only slight variation in the model equations.  For example, 
disk-shaped agarose constructs that have been used previously by our laboratory, have 
already been modeled by changing the equations to account for slab geometry.  
7.2.2  Perfluorocarbon Studies 
The benefit of incorporating PFC emulsions into tissue engineered substitutes 
warrants further investigation.  Given that DO concentrations have been reported to vary 
widely within a specific locale, a detailed study as to the buffering capacity of PFCs 
against hypoxia should be studied, as mathematical simulations suggest there is a benefit 
in using the emulsions as a temporary oxygen reservoir.  Such experiments would require 
careful design that closely mimicked an in vivo environment, in which boundary layer 
effects are created within a finite volume.  Finally, upon establishing a greater 
understanding in regards to PFC benefit to cell viability, buffering against hypoxia, DO 
concentration monitoring, and effects on tissue function, concentration optimization 
could be established for various tissue substitutes based on oxygen demand, cell type, 
construct geometry, and location of implantation.  For example, during islet 
transplantation a transient hypoxic episode typically occurs immediately upon 
implantation.  The incorporation of PFC emulsions into alginate beads containing islets 
may both buffer the oxygen within the construct and allow for non-invasive monitoring 











A1.a  Distribution of PFC Emulsion within Beads 
 The PFC emulsion must be homogeneously distributed throughout the 
alginate beads to accurately assess the available oxygen in the encapsulated cell system.  
To determine the distribution of the emulsion, the PFC surfactant, lecithin, was tagged 
with fluorescent compounds.  The two lecithin tags used were 2-(6-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl) amino)hexanoyl-1-hexadecanoyl-sn- glycero-3-phosphocholine (460 
excitation/534 emission) and 2-(3-(diphenylhexatrienyl)propanoyl)-1- hexadecanoyl-sn-
glycero-3- phosphocholine (362 excitation/433 emission).  The tagged lecithin 
compounds were mixed with untagged lecithin at a ratio of 1mg/94mg, respectively, and 
were then used to create the emulsion according to the previously described protocol.  
The alginate beads containing a 50/50 mixture of the two tagged emulsions were then 
imaged using confocal microscopy, shown in Figure A1.  If the emulsions were not 
homogeneously distributed, clusters of green or blue would be found in the bead.  As it is 
shown in Figure A1, the blue/green fluorescence is seen throughout the bead and not 
concentrated in any specific region.  It should also be noted that this was further validated 








A1.b  Leak of PFC Emulsion from Alginate Beads 
 
The amount of PFC emulsion that would leak out of the alginate beads was assessed in a 
small perfusion system.  Cell-free alginate beads were created that contained 4% v/v 
PFTBA.  A total of 3 mls of beads were placed into bioreactors that were identical to 
those used in the long-term perfusion studies (CHAPTER 4).  The beads were then 
perfused for 5 days with approximately 10 mls of saline solution.  As a positive control, 
saline was replaced with a solution containing 200 mM sodium citrate with 0.85% NaCl, 
which dissolved the beads over the 5 days and thereby releasing all the PFTBA into the 
solution.  The perfusing solutions were collected at the end of the study for NMR 
analysis.  To each sample, perfluoro-15-crown-5-ether (PFCE) was added at a 
concentration of 20 µl per ml of solution.  19F NMR spectra were then acquired on a 
500MHz Bruker magnet.  Figure A2, A and B, show the results of the positive control 
and experimental groups, respectively.  No detectable amount of PFTBA could be found 
















A1.c  PFC Monitoring of Rapid Changes in DO Concentrations  
 To quantify the rate at which T1 relaxations change with changes in surrounding 
DO concentrations, cell-free alginate beads containing PFTBA were loaded into a 
bioreactor, attached to the NMR-compatible perfusion system and placed in a 500MHz 
NMR magnet.  The DO concentration of the medium entering the bioreactor was 
switched between the following user-defined setpoints: 0.20 to 0.16 mM; 0.16 to 0.12 
mM; and 0.04 to 0.08 mM.  During the DO concentration switches, T1 relaxation 
measurements were acquired by inversion recovery experiments that lasted 
approximately 5 minutes.  Figure A3 plots both the medium DO concentration – as 










Figure A2  19F NMR spectra from samples assessing the leak of PFTBA from alginate 
beads. (A) In the positive control, where beads were dissolved and PFTBA was 
released, the PFTBA is detectable along with the added PFCE emulsion. (B) A 
representative sample from the experimental group shows no detectable amounts of 
PFTBA, only the added PFCE. 
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concentrations within the alginate beads – as quantified by 19F T1 relaxation 
measurements.  As can be seen in Figure A3, T1 relaxation measured DO concentrations 






















































Figure A3  Data comparing the rate at which T1 relaxation 
measurements change in response to changes in external DO 
concentrations. 
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A1.d  PFC Effect on Cell Viability and Insulin Secretion  
 The effect of PFTBA on alginate encapsulated βTC-tet cells was evaluated at a 
concentration of 0.4% v/v PFC to alginate, as this was the concentration used in 
monitoring studies.  Specifically, the cell viability was assessed on Days 1, 3, and 7.  On 
these days, three 0.1 ml samples were taken from the control and PFC groups. The beads 
were placed in the wells of a 24-well plate and mixed with 1 ml of medium and 0.1 ml of 
alamarBlue® reagent (Invitrogen Corp, Carlsbad, CA).  The samples were placed on a 
rocking platform located in a 37°C incubator with 5% CO2 for 2.5 hours.  After the 
incubation, a 0.1 ml medium sample was taken from each well and quantified with a 
Spectra Max Gemini Plate Reader (Molecular Devices, Sunnyvale, CA) using an 
excitation wavelength of 544 nm and an emission wavelength of 590 nm.  Relative 
intensity units (RIUs) were normalized to the RIUs of the Day 1 control sample and to 
the aqueous bead volume.  The insulin secretion rate of encapsulated βTC-tet cells was 
assessed by taking three 0.1 ml samples from the control and PFC groups on Day 1.  The 
beads were placed into 6-well dishes, washed twice with 4 ml of 0 mM glucose DMEM, 
and incubated in 4 ml of unsupplemented, 0 mM glucose DMEM on a rocking platform 
at 37°C.  After one hour, the 0 mM glucose DMEM was replaced with 3 ml of 3 mM 
glucose DMEM and incubated on a rocking platform at 37°C for 20 min.  At the end of 
the 20 minutes, the 3 mM glucose DMEM was replaced with 3 ml of 16 mM glucose 
DMEM and incubated on a rocking platform at 37°C for an additional 20 min  At the 
start and end of the 20 min, 0.3 ml medium samples were acquired and frozen for later 
assay of insulin.  Insulin in collected samples was assayed by rat insulin 
radioimmunoassay (Linco Research, St Charles, MI).  
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 Results from the cell viability and insulin secretion tests are shown in Figure A4 
and A5, respectively.  It was determined that the presence of PFC had no effect on cell 

















































































































































































Figure A4  Change in number of metabolically active cells within the 
aqueous phase of alginate beads containing no PFC or 0.4% v/v PFC 
Figure A5  The Stimulated insulin secretion rates of alginate 





TECHNOLOGICAL INNOVATION: GENERATING ECONOMIC RESULTS 
 
1.1 A2.a  TI:GER® Project 
 
 During my graduate career, I had the opportunity to participate in the two year 
NSF-sponsored IGERT TI:GER® program that spanned across Georgia Institute of 
Technology and Emory University.  The program brought together Ph.D. candidates and 
M.B.A. students from Georgia Tech with two J.D. students from Emory University to 
learn about commercializing research.  The technology worked on by my team was aimed 
at assessing the quality of islets destined for implantation – a brief description of this 
technology is given in section A2.b.  My teammates and I developed a full 
commercialization and business plan based on this technology and competed in several 
business plan competitions, placing in the top three in two of the competitions.  The 
Executive Summary from the business plan is given in section A2.c.  In addition, it 
should be noted that a provisional patent on the technology has been filed. 
A2.b  Invention Description  
A system has been designed to evaluate pancreatic islets or other insulin-secreting 
cells, free or encapsulated in hydrogels, for quantitative, objective assessment of their 
functionality in a perfusion apparatus prior to transplantation.  The system evaluates both 
oxygen consumption and insulin secretion in response to prescribed glucose 
concentration profiles, at various dissolved oxygen concentrations.  Flow of medium and 
dissolved oxygen concentration at the bioreactor input are automatically controlled.  
Upon loading a population of insulin-secreting cells, free or encapsulated, the automated 
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tabletop device starts the evaluation process.  The measured oxygen consumption and 
insulin secretion profiles are compared to a pre-established database/algorithm and based 
on this comparison, a score is given to the tested sample, which reflects the overall health 
and quality of the cells and their capacity for secretion. The score given to the cells will 
act as a quality control system for the harvested sample and it is expected to reflect the 
probability that the graft will be functional in vivo following successful transplantation.  
Figure A6 illustrates a simplified schematic of the perfusion system.   Evaluation 
begins with basal glucose media being perfused through the bioreactor.  Dissolved 
oxygen probes placed immediately before and after the bioreactor take oxygen 
measurements that are directly integrated with a laptop computer.  The computer 
translates the measurements into oxygen consumption rates of the sample.  Additionally, 
samples collected downstream of the reactor are subjected to an insulin assay to create an 
insulin secretion profile.  Upon establishing the basal condition, the system switches to a 
stimulatory glucose media during which the oxygen consumption and insulin secretion 
are continuously monitored.  The system then switches to the basal condition for 
secretion, and the process is repeated at a different dissolved oxygen concentration.  
Typically, the two dissolved oxygen concentrations used are representative of 
atmospheric oxygen and the oxygen concentration at the implantation site in vivo.  At the 
end of the process, the computer compares the obtained profiles with established control 
profiles and gives a functional score to the sample. 
The advantages of this system include: 
(i) providing a well established functional score that is directly correlated with 
the functional quality of the insulin-secreting cells, free or encapsulated; 
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(ii) once the bioreactor is loaded, the machine is fully automated with flow, 
temperature and dissolved oxygen control.   
(iii) ease of loading with free or encapsulated cells 
(iv) expandability to other secretory cells 
 
In its present form, the apparatus focuses on providing a thorough assessment of 
the quality of the insulin-secreting cells.  The time period for the evaluation is determined 
by the time it takes for the collected fractions to be assayed for insulin.  Currently, speed 
of analysis is not a critical factor, as there exists a time period between islet isolation and 
implantation in all clinical procedures.  However, if speed of analysis becomes an issue, 
the device can be modified to accommodate a flow through insulin immunosensor, 

























Figure A6  Simplified schematic of the quality control system.  In 
addition to the glucose-containing medium, other 'Test Medium' could be 
used, as indicated. 
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A2.c  Executive Summary 
 
Diabetes is the fastest growing disease in both the United States and worldwide.  
Insulin dependant diabetes is the more severe type of the disease, and approximately 4 
million Americans suffer from this form of diabetes.  In the U.S. alone, 130,000 new 
cases of Type 1 diabetes (a subset of all insulin dependant diabetics) are diagnosed each 
year; a growth rate of 7.2%.  There is no cure for diabetes in the conventional sense, only 
various treatment options.   
In short, diabetics cannot produce insulin to regulate their blood sugar.  The 
newest and most promising way to treat insulin dependant diabetics is islet 
transplantation.  Islets are the cell clusters in the pancreas that produce insulin and control 
blood sugar.  Islet transplantation involves implanting functioning islet cells from donors’ 
pancreases into a diabetic to perform the vital process of regulating blood sugar.  A 
critical step in an islet transplantation procedure is evaluating the donor’s islet cells to test 
their functionality before implanting them.  The dominant design is very subjective: 
looking at islet cells under a microscope and assessing their functionality based on the 
cells’ appearance.  The head of an islet transplant center recently told EvIslet that the 
current method of islet cell evaluation “is not terribly predictive or functional.”  This is 
not surprising; cell size and appearance does not equate with functionality.  
As a result of this subjective proxy for testing functionality, transplants fail 42% 
of the time and four donors are needed for a single patient.  Evaluating cells based on 
their size under a microscope is not much of an advance over the way that Galileo 
worked in the 16th century.  EvIslet plans to revolutionize this methodology, bring new 
technology to the table, and take the guesswork out of islet evaluation.  EvIslet gives 
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transplant centers better diagnostic tools; in turn, doctors are able to make better 
decisions about transplants before surgery.  Better tools and better decisions translate into 
better quality of life for Type 1 diabetics, because successful transplants mean less pain 
and fewer procedures per patient.   
EvIslet’s technology is based on correlations between islets’ functional 
characteristics.  Through numerous in vitro and in vivo tests run in parallel, EvIslet has 
developed an algorithm that accurately assesses which islets are suitable for 
transplantation.  The algorithm is the backbone software of a table-top diagnostic device 
that will house a bioreactor to accept small samples of islets, gather data from the islets 
through an automated system, and assess the functional characteristics against successful 
islet profiles to determine the donor’s islets suitability for transplantation.   
Three pieces of intellectual property have been generated by the EvIslet team: the 
correlative algorithm, the table-top device that houses the testing apparatus, and the 
database of test results.  Both the algorithm and the table-top device will be protected 
with patents, and the database of clinical intelligence decisions will be held as a trade 
secret.  
While today’s initial market is admittedly small, it is artificially suppressed 
because the islet transplantation procedure itself is currently undergoing the final portion 
of its FDA approval process.  EvIslet projects that the number of hospitals performing 
this procedure will increase once FDA approval is obtained.  The number of transplants 
performed should be comparable to the annual number of kidney and liver transplants 
performed in the U.S. today: 15,000 and 6,000 respectively.  EvIslet estimates the returns 
from the sales and licensing of this initial algorithm and device combination to be at or 
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over $50 million a year, recurring annually, after the first three years of 
commercialization.  A tri-fold recurring revenue model for the algorithm, based on a per-
use fee, a disposable bio-reactor component, and the device leasing program is 
anticipated.  This will offer EvIslet a sustainable revenue stream with few additional 
annual costs.   
EvIslet plans to offer the algorithm, and companion table-top device on which to 
run it, to islet transplantation centers, those research universities spending at least $5 
million annually on scientific research, and various corporations in the cellular research 
industry.  Our market research has shown us that our potential customers are willing to 
pay a “premium price” for a tool that would put quantifiable data assessing islet 
functionality into the hands of transplant surgeons and diabetes researchers. 
EvIslet’s direct customers are the transplant centers (TC) and research companies 
who serve the needs of diabetic patients, the indirect customer.  The TC pain is rooted in 
the primitive evaluation methodology that wastes precious islets and valuable time, and 
often results in unsuccessful surgeries (further compounding the shortages of islets and 
time).  By taking the guesswork out of cell evaluation, and providing a quantifiable 
functional test for viability, islet transplantation will become a more efficient and 
effective procedure by reducing patients’ needs for a second, third, or even fourth 
transplant.  At EvIslet we are helping hospitals and surgeons make better decisions about 
treating patients. 
As the paragraphs above delineate, EvIslet’s initial innovation is centered on the 
growing demands of the diabetes epidemic and focused on delivering a functional test for 
islet cell evaluation prior to transplantation.  EvIslet’s revenue stream for this initial 
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innovation will mainly come from three sources: machine rentals from transplant centers, 
machines sales from particular corporations and research institution customers, and 
recurring revenues of database service fees and bio-reactor sales. EvIslet is estimated to 
generate revenue of $11 million in 2011 to $53 million in 2014.   Considering our 
relatively low fixed and variable costs, our gross margin is projected at near 99%; net 
profits are expected to be 57%.  In addition, future markets may be developed around 
liver transplants and stem cell research. We believe that EvIslet’s initial innovation will 
be the cornerstone/platform upon which to position the company as a medical device 
research and development company with a unique ability to develop diagnostic devices 
for cell implantation. 
Over the next 4 to 5 years EvIslet will be seeking a total of $6.5 million in start up 
capital, which will cover continued research and development, clinical trials, legal and 
regulatory costs, patent costs, final prototype development, initial sales and marketing, 
and other business expenses associated with bringing our initial solution to the 
marketplace.  EvIslet’s start up capital fundraising will be done in phases. In the Initial 
phase EvIslet is seeking a first round investment of $3 million. This initial investment 
capital will take EvIslet through Developmental Stage 2.  EvIslet will begin seeking the 
second round investment funding for the Clinical Trial Stage near the end of 
Developmental Stage 2. The desired $3.5 million second investment will carry EvIslet 
through clinical trials and well into the Full Adoption Stage and revenue generation. In 
exchange for these initial capital investments, at each investment phase, EvIslet is willing 





ADDITIONAL NMR DATA 
 
 
A3.a  Stability of the Inorganic Phosphate Peak 
 
 The inorganic phosphate (Pi) peak obtained during 31P NMR acquisitions served 
as a standard to which the β-NTP peak was normalized.  Given that the volume of the 
perfusion medium was much greater than the cell volume, it was assumed that the Pi peak 
was primarily attributed to the phosphates within the medium and that the Pi 
concentration within the medium did not change over time.  Figure A7 plots the integral 
of the Pi over the course of the study performed in CHAPTER 4 (Figure 4.3).  The Pi was 
normalized to the initial integral with the first integral set at 100.  Indeed, the normalized 
Pi integral remained relatively constant over the study with an average value of 99.8 ± 7.1 
(ave. ± std. dev.) over the 55 hours of the experiment.  However, a trend in which the Pi 
integral increased to approximately 110 was noted at the time points associated with the 
lowest DOin (hours 25 to 30), which would lower the β-NTP/Pi ratio.  Nevertheless, this 































































Figure A7  Stability of Pi integral during 
perfusion studies. 
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A3.b  Change in β-NTP/Pi Integral and AIDO at a Constant DOin 
 
 In the data of CHAPTER 5, the β-NTP/Pi integral ratio decreased during the 
initial DOin step decreases.  To determine if these decreases were the result of 
encapsulated cells equilibrating to the perfusion system and not the result of the DOin 
step changes, a study was performed in which the beads were perfused for 23 hours at a 
constant DOin.  Specifically, beads cultured for one week were loaded into a bioreactor 
and perfused for 22 hours at DOin concentration of 0.20 mM.  During this study, the β-
NTP/Pi integral ratio was monitored by 31P NMR and the AIDO concentration was 
monitored by 19F NMR.  Figure A8 demonstrates that there was little change of both of 
these parameters over the course of the study with an average β-NTP/Pi integral ratio of 


























































































Figure A8  Transient changes in the β-NTP/Pi integral ratio 
(♦) and AIDO (◊) at a constant DOin.  The DOin was 
maintained at 0.20 mM for approximately 23 hours while 
perfusing encapsulated βTC-tet cells. 
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